Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Alexander CE, Scullion MMF, Omar MI, Yuan Y, Mamoulakis C, N'Dow JMO, Chen C, Lam TBL

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction.

DOI: 10.1002/14651858.CD009629.pub4.
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction

Cameron Edwin Alexander¹, Malo MF Scullion¹, Muhammad Imran Omar¹,², Yuhong Yuan³, Charalampos Mamoulakis⁴, James MO N'Dow⁵, Changhao Chen⁶, Thomas BL Lam¹

¹Academic Urology Unit, University of Aberdeen, Aberdeen, UK. ²European Association of Urology, Arnhem, Netherlands. ³Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Canada. ⁴Department of Urology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, Crete, Greece. ⁵Urology Department, NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK. ⁶Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

Contact address: Thomas BL Lam, Academic Urology Unit, University of Aberdeen, 2nd Floor, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK. thomasbllam@abdn.ac.uk.

Editorial group: Cochrane Urology Group


Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
Transurethral resection of the prostate (TURP) is a well-established surgical method for treatment of men with lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). This has traditionally been provided as monopolar TURP (MTURP), but morbidity associated with MTURP has led to the introduction of other surgical techniques. In bipolar TURP (BTURP), energy is confined between electrodes at the site of the resectoscope, allowing the use of physiological irrigation medium. There remains uncertainty regarding differences between these surgical methods in terms of patient outcomes.

Objectives
To compare the effects of bipolar and monopolar TURP.

Search methods
A comprehensive systematic electronic literature search was carried out up to 19 March 2019 via CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, PubMed, and WHO ICTRP. Handsearching of abstract proceedings of major urological conferences and of reference lists of included trials, systematic reviews, and health technology assessment reports was undertaken to identify other potentially eligible studies. No language restrictions were applied.

Selection criteria
Randomised controlled trials (RCTs) that compared monopolar and bipolar TURP in men (> 18 years) for management of LUTS secondary to BPO.

Data collection and analysis
Two independent review authors screened the literature, extracted data, and assessed eligible RCTs for risk of bias. Statistical analyses were undertaken according to the statistical guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions. The quality of evidence (QoE) was rated according to the GRADE approach.
Main results
A total of 59 RCTs with 8924 participants were included. The mean age of included participants ranged from 59.0 to 74.1 years. Mean prostate volume ranged from 39 mL to 82.6 mL.

Primary outcomes
BTURP probably results in little to no difference in urological symptoms, as measured by the International Prostate Symptom Score (IPSS) at 12 months on a scale of 0 to 35, with higher scores reflecting worse symptoms (mean difference (MD) -0.24, 95% confidence interval (CI) -0.39 to -0.09; participants = 2531; RCTs = 16; I² = 0%; moderate certainty of evidence (CoE), downgraded for study limitations), compared to MTURP.

BTURP probably results in little to no difference in bother, as measured by health-related quality of life (HRQoL) score at 12 months on a scale of 0 to 6, with higher scores reflecting greater bother (MD -0.12, 95% CI -0.25 to 0.02; participants = 2004; RCTs = 11; I² = 53%; moderate CoE, downgraded for study limitations), compared to MTURP. This corresponds to 20 fewer TUR syndrome events per 1000 participants (95% CI 22 fewer to 17 fewer).

Secondary outcomes
BTURP may carry a similar risk of urinary incontinence at 12 months (RR 0.20, 95% CI 0.01 to 4.06; participants = 751; RCTs = 4; I² = 0%; low CoE, downgraded for study limitations and imprecision), compared to MTURP. This corresponds to four fewer events of urinary incontinence per 1000 participants (95% CI five fewer to 16 more).

BTURP probably slightly reduces blood transfusions (RR 0.42, 95% CI 0.30 to 0.59; participants = 5727; RCTs = 38; I² = 0%; moderate CoE, downgraded for study limitations), compared to MTURP. This corresponds to 28 fewer events of blood transfusion per 1000 participants (95% CI 34 fewer to 20 fewer).

BTURP may result in similar rates of re-TURP (RR 1.02, 95% CI 0.44 to 2.40; participants = 652; RCTs = 6; I² = 0%; low CoE, downgraded for study limitations and imprecision). This corresponds to one more re-TURP per 1000 participants (95% CI 19 fewer to 48 more).

Erectile function as measured by the International Index of Erectile Function score (IIEF-5) at 12 months on a scale from 5 to 25, with higher scores reflecting better erectile function, appears to be similar (MD 0.88, 95% CI -0.56 to 2.32; RCTs = 3; I² = 68%; moderate CoE, downgraded for study limitations) for the two approaches.

Authors’ conclusions
BTURP and MTURP probably improve urological symptoms, both to a similar degree. BTURP probably reduces both TUR syndrome and postoperative blood transfusion slightly compared to MTURP. The impact of both procedures on erectile function is probably similar. The moderate certainty of evidence available for the primary outcomes of this review suggests that there is no need for further RCTs comparing BTURP and MTURP.

Plain language summary
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction

Review question
How does surgery using bipolar technology compare with traditional monopolar technology for men with an enlarged prostate causing difficulty with urination?

Background
People with an enlarged prostate can experience difficulty passing urine. This occurs because the enlarged prostate compresses the urinary tube from which urine leaves the bladder. One option for treatment of this condition is telescopic surgery, which acts to remove prostate tissue and relieve the blockage. This is traditionally performed using a technology called monopolar TURP (short for ‘transurethral resection of the prostate’). In recent times, a technique called bipolar TURP has been developed. This approach uses saline instead of other watery fluids and may put men at lower risk for a problem called TUR syndrome, which is a rare but potentially serious complication caused by fluid absorption, but it is unclear how the two procedures compare overall.

How up-to-date is this review?
The studies included in this review are those that were available via an electronic database search conducted on 19 March 2019.
Study characteristics

We searched the medical literature for clinical trials up to 19 March 2019. We found 59 randomised trials that compared BTURP with MTURP. These studies included a total of 8924 patients. The longest period of follow-up for the outcomes of interest was 12 months after treatment.

Key results

Compared to MTURP, BTURP probably results in similar reduction in urinary symptoms and bother.

It probably slightly reduces both the risk of TUR syndrome and the need for blood transfusion.

Erectile function is probably similar after both procedures, as is the risk of urinary incontinence and the need for a repeat procedure.

Quality of evidence

The quality of evidence for the outcomes of ability to pass urine, patient bother, TUR syndrome, need for blood transfusion, and erectile function was considered to be moderate. The quality of evidence for the outcomes of urinary leakage after the procedure and need for a repeat procedure was low.
# Summary of findings

Summary of findings for the main comparison. BTURP compared to MTURP for lower urinary tract symptoms secondary to benign prostatic obstruction

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>N° of participants (studies) Follow-up</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Relative effect (95% CI)</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Risk with MTURP</th>
<th>Risk difference with BTURP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urological symptoms (IPSS(^a) at 12 months)</td>
<td>2531 (16 RCTs)</td>
<td>⚪⚪⚪⚪ MODERATE(^b)</td>
<td>-</td>
<td>Mean urological symptoms (IPSS at 12 months) was 6.4</td>
<td>MD 0.24 lower (0.39 lower to 0.09 lower)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weighted mean = 6.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bother (HRQoL(^c) at 12 months)</td>
<td>2004 (11 RCTs)</td>
<td>⚪⚪⚪⚪ MODERATE(^b)</td>
<td>-</td>
<td>Mean bother (HRQoL at 12 months) was 1.7</td>
<td>MD 0.12 lower (0.25 lower to 0.02 higher)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weighted mean = 1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUR syndrome</td>
<td>6745 (44 RCTs)</td>
<td>⚪⚪⚪⚪ MODERATE(^b)</td>
<td>RR 0.17 (0.09 to 0.30)</td>
<td>Study population</td>
<td>20 fewer per 1000 (22 fewer to 17 fewer)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weighted mean number of events = 1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary incontinence at 12 months</td>
<td>751 (4 RCTs)</td>
<td>⚪⚪⚪ LOW(^b,d)</td>
<td>RR 0.20 (0.01 to 4.06)</td>
<td>Study population</td>
<td>4 fewer per 1000 (5 fewer to 16 more)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weighted mean number of events = 0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>5727 (38 RCTs)</td>
<td>⚪⚪⚪⚪ MODERATE(^b)</td>
<td>RR 0.42 (0.30 to 0.59)</td>
<td>Study population</td>
<td>28 fewer per 1000 (34 fewer to 20 fewer)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weighted mean number of events = 3.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-TURP</td>
<td>652</td>
<td>⚪⚪⚪⚪</td>
<td>RR 1.02</td>
<td>Study population</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparisons</td>
<td>Events</td>
<td>Weighted Mean Number of Events</td>
<td>Mean Erectile Function (IIEF-5 Score at 12 Months)</td>
<td>Relative Effect</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>--------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bipolar versus Monopolar</td>
<td>321 (3 RCTs)</td>
<td>1.8</td>
<td>19.2</td>
<td>MD 0.88 higher</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6 RCTs)</td>
<td>(0.44 to 2.40)</td>
<td>(19 fewer to 48 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

**Erectile Function (IIEF-5 Score at 12 Months)**

- Weighted mean = 19.2
- Mean erectile function (IIEF-5 score at 12 months) was 19.2
- MD 0.88 higher
  - (0.56 lower to 2.32 higher)

**GRADE Working Group grades of evidence.**

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

---

- **a** IPSS questionnaire scores range from 0 to 35, with higher values signalling more severe lower urinary tract symptoms; the minimum clinically important difference was defined as 4.
- **b** Downgraded by one level for study limitations: blinding of operating surgeon considered unlikely in all trials; method of randomisation, allocation concealment, and blinding of outcome assessment unclear in > 50% of included trials.
- **c** HRQoL questionnaire scores range from 0 to 6, with higher values signalling poorer quality of life.
- **d** Downgraded by one level for imprecision: wide confidence intervals, very small numbers of events for urinary incontinence and re-TURP.
- **e** IIEF-5 questionnaire scores range from 5 to 25, with higher values signalling better erectile function; the minimum clinically important difference was defined as 4.
BACKGROUND

Description of the condition

Benign prostatic hyperplasia (BPH) is a non-malignant condition that is histologically characterised by the cellular proliferation of stromal and epithelial tissues of the prostate (Isaacs 1989). The increase in size of the prostate, which occurs secondary to BPH, is described as benign prostatic enlargement (BPE) and can cause bladder outlet obstruction (BOO) due to compression of the urethra (Abrams 2002). BPE may be diagnosed as the cause for BOO following complete patient medical history, use of self-completed validated symptom questionnaires and bladder diaries, assessment of postvoid residual urine volume, uroflowmetry, digital rectal examination, or pressure flow studies (Abrams 2009; EAU 2018). BOO due to BPE is also described as benign prostatic obstruction (BPO) and is the most common cause of lower urinary tract symptoms (LUTS) in men (CG97 LUTS: NICE guideline, 2010).

LUTS include:

- urinary storage symptoms (frequency, nocturia, urgency, incontinence);
- voiding symptoms (weak or intermittent urinary stream, splitting or spraying, hesitancy, straining);
- postmicturition symptoms (sensation of incomplete emptying, dribbling) (Abrams 2002).

The prevalence and severity of LUTS increase with age. In the Multinational Survey of the Aging Male (MSAM-7), in which 12,815 men in Europe aged 50 to 80 years were surveyed, 31% reported moderate to severe LUTS, and the prevalence of moderate to severe LUTS increased from 22% to 45% when men aged 50 to 59 years were compared with those 70 to 80 years of age, respectively (Rosen 2003; Speakman 2015). LUTS due to BPO have a significant negative impact on men’s quality of life (QoL) and daily activities (Agarwal 2014; Kupelian 2006), and their high prevalence means that medical and surgical management carries major economic implications for healthcare providers. The TRIUMPH study (Trans European Research into the Use of Management Policies for LUTS suggestive of BPH in Primary Health Care) reported a mean annual cost of €658 per patient in 2003 among 5057 European men treated for LUTS due to BPH (van Exel 2006).

Description of the intervention

For most patients presenting with LUTS secondary to BPO, a trial of medical management with drug therapy is indicated (Lepor 1993). However, use of a surgical intervention may be indicated when the patient wants to avoid taking daily medication, when medical therapy fails to sufficiently alleviate bothersome LUTS, and in certain conditions for which a more aggressive approach than medical therapy is required, including acute/chronic renal insufficiency, refractory urinary retention, recurrent urinary tract infections (UTIs), bladder stones, and gross haematuria believed to occur secondary to BPH (AUA 2018; Mebus 1989). Surgery for BPH represents the 10th most common operation performed across the National Health Service (Kirby 2010).

Transurethral resection of the prostate (TURP) via a monopolar electrosurgery unit (ESU), also known as monopolar TURP (MTURP), is a well-established surgical management option for BPO and is widely considered to be the “gold standard” because of its well-documented favourable long-term outcomes (Reich 2006). The European Association of Urology (EAU) Guidelines state that TURP is the current standard surgical procedure for men with prostate sizes of 30 to 80 mL and bothersome to severe LUTS secondary to BPO (EAU 2018).

MTURP employs a single active electrode (the loop) at the site of surgery, which transmits energy into the prostatic tissue through the patient’s body to the return electrode pad on the skin surface. This circuit requires using a non-conductive hypo-osmolar irrigation medium, such as mannitol, sorbitol, or glycine solution. Excessive absorption of such irrigation fluid into the systemic circulation through the prostatic venous sinuses and the peri-prostatic tissues may rarely lead to life-threatening dilutional hypotension, known as transurethral resection (TUR) syndrome, which is associated with longer resection times and larger prostate (Acuña Lope 2010; Hahn 1993; Reich 2008).

The distance between electrodes and the need for electrical current to pass through body tissue as seen with MTURP also require use of higher voltages. MTURP therefore occurs at higher temperatures, leading to thermal damage of surrounding tissues and associated complications, including bleeding and clot retention, erectile dysfunction, urinary incontinence, urethral stricture, and bladder neck contracture (Issa 2008). Although MTURP carries a low risk of mortality (0.1%), such complications mean that it continues to be associated with a high level of patient morbidity (11.1%) (Reich 2008). In light of this, researchers have sought to develop a surgical intervention that can offer effective management of BPO with reduced risk of complications. This has involved incorporation of bipolar technology or bipolar transurethral resection of the prostate (BTURP), which represents a technical modification of standard MTURP.

How the intervention might work

In contrast to MTURP, the bipolar circuit is completed locally with energy confined between an active electrode (resection loop) and a return electrode situated on the resectoscope tip (“true” bipolar), or the sheath (“quasi” systems) (De Sio 2006).

Commercially available bipolar systems were first introduced and assessed in the early 2000s and include:

- Gyrus Plasmakinetic (ACMI, Southborough, MA, USA) (Symons 2002);
- Vista Coblation/Controlled Tissue Resection (CTR) system (ACMI) (Singh 2005; Wendt-Nordhal 2004);
- AUTOCON II 400 ESU (Karl Storz Endoscope, Tuttingen, Germany); and
- TURis (Olympus, Tokyo, Japan) (Abascal Junquera 2006; Komura 2015).

During BTURP, energy is transmitted from the active electrode to the surrounding conductive solution. This results in water evaporation, which creates an interface gas layer surrounding the loop that poses resistance to the energy flow. By adding voltage to the gas layer, a highly energised state of matter (the plasma) is formed around the electrode. Whilst this requires high current initially, maintenance of the plasma requires minimal energy, allowing tissue resection to be performed with a lower voltage. Coagulation is achieved by the dissipation of energy as heat within vessel walls, which creates sealing coagulum from blood and tissue and collagen shrinkage (Issa 2008).
The bipolar circuit allows for use of a conductive and physiological irrigation medium, such as normal saline, and because less tissue resistance is encountered, lower voltages are required (Issa 2008). This has the theoretical advantages of removing the risk of TUR syndrome and allowing TURP to be performed at lower temperatures with reduced thermal damage to surrounding tissues. True bipolar systems, in particular, have the theoretical advantage of negating the passage of electrical current through the urethra and peri-prostatic tissue (Paul 2008; Mamoulakis 2013). The subsequent potential for BTURP to reduce the risk of adverse events, such as bleeding, erectile dysfunction, and urinary incontinence, has been assessed in a large number of randomised controlled trials (RCTs) (Mamoulakis 2009; Omar 2014).

Why it is important to do this review

In spite of the accumulation of evidence comparing MTURP and BTURP over the last decade, there has been ongoing uncertainty regarding the differences between these two surgical methods in terms of patient outcomes. The most recently undertaken systematic reviews and meta-analyses that have examined this question concluded that although BTURP may be associated with fewer adverse events, including TUR syndrome, clot retention, and blood transfusion, further RCTs are required in light of the methodological limitations and limited follow-up of existing RCTs (Cornu 2015; Mamoulakis 2009; Omar 2014). Current American Urological Association (AUA) guidelines state that clinicians may use a monopolar or bipolar approach to TURP, depending on their expertise with these techniques, and EAU guidelines state that BTURP achieves similar short-, mid-, and long-term results comparable with MTURP, but that BTURP has a more favourable perioperative profile (AUA 2018; EAU 2018).

It was important to undertake this review in light of the significant increase in available evidence examining this research question since the most recently published reviews (Cornu 2015; Mamoulakis 2013; Omar 2014). Previous reviews have not consistently adhered to the methodological standards of Cochrane, including publication of a review protocol, implementation of rigorous search strategy, application of GRADE, and use of patient-focused outcomes.

OBJECTIVES

To compare the effects of bipolar and monopolar TURP.

METHODS

Criteria for considering studies for this review

Types of studies

We included only randomised controlled trials (RCTs) because of their ability to provide the most reliable evidence.

Types of participants

Participants (>18 years) with lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO).

BPO will be defined as bladder outlet obstruction secondary to benign prostatic enlargement (BPE).

Types of interventions

We investigated the following comparison of intervention versus comparator.

Intervention

The intervention was bipolar transurethral resection of the prostate (BTURP).

Comparator

The comparator was monopolar transurethral resection of the prostate (MTURP).

If a trial included multiple arms, we included in the review any arms that met the inclusion criteria.

Minimum duration of intervention and follow-up

As our review considered single surgical interventions, the minimum duration of the intervention was not applicable in our review. We did not exclude RCTs based on duration of follow-up.

Types of outcome measures

We did not exclude trials because one or several of our primary or secondary outcome measures were not reported in the publication. When none of our primary or secondary outcomes were reported, we did not include this trial but provided some basic information in an additional table.

Primary outcomes

- Urological symptoms as measured by the International Prostate Symptom Score (IPSS) questionnaire score at 12 months
- Bother as measured by a health-related quality of life (HRQoL) questionnaire score at 12 months
- Transurethral resection (TUR) syndrome

Secondary outcomes

- Urinary incontinence at 12 months
- Postoperative blood transfusion
- Incidence of second transurethral resection of the prostate (TURP) (i.e. re-do TURP)
- Erectile function as measured by the International Index of Erectile Function (IIEF-5) questionnaire score at 12 months

Method and timing of outcome measurement

- Urological symptoms were measured by the International Prostate Symptom Score (IPSS) questionnaire at 12 months postoperatively
- Bother was measured by a validated health-related quality of life (HRQoL) questionnaire at 12 months, as defined by the trialists
- Adverse events such as TUR syndrome, blood transfusion, and the need for re-TURP were measured at any time postoperatively
- Urinary incontinence was measured at 12 months, with the definition of urinary incontinence considered to be that used by the trialists
Search methods for identification of studies

Electronic searches
We searched the following sources from inception of each database to the specified date and placed no restrictions on the language of publication nor on the status of the publication. The search strategy was up-to-date as of 19 March 2019.

- The Cochrane Library databases (Cochrane Reviews and other reviews, CENTRAL, and technology assessments) (Appendix 1).
- MEDLINE (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present) (Appendix 2); also PubMed (http://www.ncbi.nlm.nih.gov/pubmed) before the end of the review, to capture non-MEDLINE records.
- Embase (OvidSP 1974 to Present) (Appendix 3).

Review authors also performed handsearches of the following trial registers.

- ClinicalTrials.gov (https://clinicaltrials.gov/).

Searching other resources
We used the reference lists of included trials, systematic reviews, meta-analyses, and health technology assessment reports to search for other potentially eligible trials or ancillary publications. In addition, we contacted authors of the included trials to request additional information on the retrieved trials. We also searched the abstract proceedings for major urological conferences, including the European Association of Urology (EAU) (https://urosource.uroweb.org/urosource?page=1&search=&types=abstract) and the American Urological Association (AOA), from 2009 to 2018 (https://www.auanet.org/research/annual-meeting-abstracts).

Data collection and analysis

Selection of studies
Two review authors (CEA and MS) independently screened abstracts, titles, or both for records retrieved in the literature searches to determine which trials should be assessed further. We obtained full-text copies of all potentially relevant records. We resolved disagreements through consensus or by recourse to a third review author (MIO). If we were unable to resolve a disagreement, we categorised the trial as a “study awaiting classification” and contacted trial authors for clarification. We prepared an adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram to show the process of trial selection (Liberati 2009).

Data extraction and management
For trials that fulfilled our inclusion criteria, two review authors (CEA and MS) independently extracted key participant and intervention characteristics. We reported data on efficacy outcomes and adverse events using standardised data extraction sheets. We resolved disagreements by discussion or, if required, by consultation with a third review author (MIO).

Duplicate and companion publications
In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximised the information yield by collating all available data and using the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial, and trial documents of the included trials (such as trial registry information) as secondary references under the study ID of the included trial. We also listed duplicate publications, companion documents, multiple reports of a trial, and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial.

Data from clinical trial registers
When data from included trials were available as study results in clinical trial registers such as ClinicalTrials.gov or similar sources, we made use of this information and extracted data. When a full publication of the trial was available, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information was available, we added this trial to the Characteristics of studies awaiting classification table.

Assessment of risk of bias in included studies
Two review authors (CEA and MS) independently assessed the risk of bias of each included trial. We resolved disagreements by consensus or by consultation with a third review author (MIO). When there was disagreement, we consulted the rest of the group and made a judgement based on consensus. When adequate information was not available from trial authors, trial protocols, or both, we contacted trial authors to request missing data on risk of bias items.

We used the Cochrane ‘Risk of bias’ assessment tool and judged risk of bias criteria as having low, high, or unclear risk (Higgins 2011). We evaluated individual bias items as described in the Cochrane Handbook for Systematic Reviews of Interventions, according to the criteria and associated categorisations contained therein (Higgins 2011).

Random sequence generation (selection bias due to inadequate generation of a randomised sequence) - assessment at trial level
For included trials, we described the method used to generate the allocation sequence to allow an assessment of whether it should produce comparable groups.

- Low risk of bias: trial authors achieved sequence generation using computer-generated random numbers or a random numbers table. Drawing lots, tossing a coin, shuffling cards or envelopes, and throwing dice were adequate if this was performed by an independent person who was not otherwise involved in the trial. We considered use of the minimisation technique as equivalent to being random.
- Unclear risk of bias: information about the sequence generation process was insufficient.
- High risk of bias: the sequence generation method was non-random or quasi-random (e.g. sequence generated by odd or even date of birth, sequence generated by some rule based on date (or day) of admission, sequence generated by some rule based on hospital or clinic record number, allocation by judgement of the clinician, allocation by preference of the participant, allocation based on results of a laboratory test or a series of tests, allocation by availability of the intervention).
Allocation concealment (selection bias due to inadequate concealment of allocation before assignment) - assessment at trial level

For included trials, we described the method used to conceal allocation to interventions before assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or could have changed after assignment.

- Low risk of bias: trial authors used central allocation (including telephone, interactive voice recorder, or web-based and pharmacy-controlled randomisation), sequentially numbered drug containers of identical appearance, or sequentially numbered opaque sealed envelopes.
- Unclear risk of bias: information about allocation concealment was insufficient.
- High risk of bias: trial authors used an open random allocation schedule (e.g. a list of random numbers), assignment envelopes without appropriate safeguards, alternation or rotation, date of birth, case record numbers, or any other explicitly unsealed procedure.

We also evaluated trial baseline data to incorporate assessment of baseline imbalance into the risk of bias judgement for selection bias (Corbett 2014). Chance imbalances may also affect judgments on the risk of attrition bias. In the case of unadjusted analyses, we distinguished between studies rated as low risk of bias on the basis of randomisation methods and baseline similarity or baseline similarity alone (Corbett 2014).

Blinding of participants and study personnel (performance bias due to knowledge of allocated interventions by participants and personnel during the trial) - assessment at outcome level

We evaluated the risk of detection bias for all outcomes collectively, as it was considered that all study outcomes in our review were equally susceptible to performance bias. We have noted if outcomes were self-reported, investigator-assessed, or adjudicated outcome measures.

- Low risk of bias: blinding of participants and key study personnel is ensured, and it is unlikely that the blinding could have been broken; there was no blinding or incomplete blinding, but we judge that the outcome is unlikely to have been influenced by lack of blinding.
- Unclear risk of bias: information about blinding of participants and study personnel is insufficient; the trial does not address this outcome.
- High risk of bias: there was no blinding or incomplete blinding, and the outcome is likely to have been influenced by lack of blinding; blinding of trial participants and key personnel was attempted, but it is likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Blinding of outcome assessment (detection bias due to knowledge of allocated interventions by outcome assessors) - assessment at outcome level

We evaluated the risk of detection bias separately for subjective, patient-reported outcomes (urological symptoms, bother, erectile function at 12 months) and for objective, investigator-assessed outcomes (incidence of TUR syndrome, blood transfusion, re-TURP, and urinary incontinence at 12 months).

- Low risk of bias: blinding of outcome assessment is ensured, and it is unlikely that the blinding could have been broken; there was no blinding of outcome assessment, but we judge that the outcome measurement was unlikely to have been influenced by lack of blinding.
- Unclear risk of bias: information about the blinding of outcome assessors is insufficient; the trial did not address this outcome.
- High risk of bias: there was no blinding of outcome assessment, and the outcome measurement is likely to have been influenced by lack of blinding; there was blinding of outcome assessment, but it is likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Incomplete outcome data (attrition bias due to quantity, nature, or handling of incomplete outcome data) - assessment at outcome level

We evaluated the risk of attrition bias separately for immediate postoperative outcomes (TUR syndrome, blood transfusion) and long-term outcomes, including those reported at 12 months (urological symptoms, bother, erectile function and urinary incontinence at 12 months, need for re-TURP).

We stated whether the trial reported attrition and exclusions and the number of participants included in the analysis at each stage (compared with the number of randomised participants per intervention/comparator groups). We also noted whether the trial reported the reasons for attrition or exclusion, and whether missing data were balanced across groups or were related to outcomes. We will consider the implications of missing outcome data per outcome such as high dropout rates (e.g. > 15%) or disparate attrition rates (e.g. difference ≥ 10% between trial arms).

- Low risk of bias: no outcome data are missing; reasons for missing outcome data are unlikely to be related to true outcomes (for survival data, censoring was unlikely to introduce bias); missing outcome data were balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes is not enough to have a clinically relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data.
- Unclear risk of bias: information is insufficient to assess whether missing data in combination with the method used to handle missing data were likely to induce bias; the trial did not address this outcome.
- High risk of bias: the reason for missing outcome data is likely to be related to the true outcome, with imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is enough to induce clinically relevant bias in intervention effect estimates; for continuous outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes is enough.
to induce clinically relevant bias in observed effect size; ‘as-treated’ or similar analysis was done with substantial departure of the intervention received from that assigned at randomisation; application of simple imputation is potentially inappropriate.

Selective reporting (reporting bias due to selective outcome reporting) - assessment at trial level
We prepared a ‘Risk of bias’ graph and a ‘Risk of bias’ summary figure.

We distinguished between self-reported, investigator-assessed, and adjudicated outcome measures.

We considered the following outcomes as self-reported: urological symptoms, bother, erectile function at 12 months as reported by participants.

We considered the following outcomes as investigator-assessed: TUR syndrome, blood transfusion, urinary incontinence at 12 months, re-TURP.

Summary assessment of risk of bias
Risk of bias for a trial across outcomes
Some risk of bias domains such as selection bias (sequence generation and allocation sequence concealment) affect the risk of bias across all outcome measures in a trial. In any trials with high risk of selection bias, all endpoints investigated in the associated trial were marked as high risk.

Risk of bias for an outcome within a trial and across domains
We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial-level entries and outcome-specific entries). We considered low risk of bias to denote low risk of bias for all key domains, unclear risk to denote unclear risk of bias for one or more key domains, and high risk to denote high risk of bias for one or more key domains.

Risk of bias for an outcome across trials and across domains
These are our main summary assessments that are incorporated into our judgements about the quality of evidence in the ‘Summary of finding’ tables. We defined outcomes as having low risk of bias when most information comes from trials at low risk of bias, unclear risk when most information comes from trials at low or unclear risk of bias, and high risk when a sufficient proportion of information comes from trials at high risk of bias.

Measures of treatment effect
When at least two included trials are available for a comparison and a given outcome, we have expressed dichotomous data as a risk ratio (RR) or an odds ratio (OR) with 95% confidence interval (CI). For continuous outcomes measured on the same scale (e.g. weight loss in kilogram), we estimated the intervention effect using the mean difference with 95% CI. For continuous outcomes measuring the same underlying concept but using different measurement scales, we calculated the standardised mean difference (SMD).

For outcomes of urological symptoms as measured by IPSS at 12 months and erectile function as measured by IIEF-5 score, the minimum clinically important difference (MCID) was considered to be 4. For other primary and secondary outcomes, the MCID was considered to be arbitrary or too subjective to define.

Unit of analysis issues
This review took into account the level at which randomisation occurred such as cross-over trials, cluster-randomised controlled trials, and multiple observations for the same outcome. When more than one comparison from the same trial was eligible for inclusion in the same meta-analysis, we combined groups to create a single pair-wise comparison. This review does not include any trials with cross-over or cluster design.

Dealing with missing data
When possible, we contacted authors of the included trials with the aim of obtaining missing data.

We carefully evaluated important numerical data such as screened, randomly assigned participants, as well as intention-to-treat and as-treated and per-protocol populations. When required, we investigated attrition rates (e.g. dropouts, losses to follow-up, withdrawals) and critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward).

For trials where the standard deviation of the outcome is not available at follow-up or cannot be re-created, we standardised by using the average of the pooled baseline standard deviation from trials in which this information was reported.

When included trials did not report means and standard deviations (SDs) for outcomes, and we did not receive the needed information from trial authors, we aimed to input these values by estimating mean and variance from median, range, and size of the sample (Hozo 2005).

Assessment of heterogeneity
We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1. In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta-analysis (Higgins 2003), noting that an I² statistic ≥ 75% indicates a considerable level of heterogeneity (Higgins 2011).

When there was evidence of heterogeneity, we attempted to determine possible reasons for this by examining individual trial and subgroup characteristics.

Assessment of reporting biases
For those outcomes for which more than 10 trials are included, we used funnel plots to assess small-trial effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias. Therefore these results require careful interpretation (Egger 1997; Sterne 2011).

Data synthesis
We undertook meta-analysis only if participants, interventions, comparisons, and outcomes were judged to be sufficiently similar to ensure an answer that is clinically meaningful. Unless we found
good evidence of homogenous effects across trials, we primarily used a random-effects model to summarise low risk of bias data. In addition, we performed statistical analyses according to the statistical guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

Quality of evidence and 'Summary of findings' table
We presented the overall certainty of evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results (Guyatt 2008; Guyatt 2011a; Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e; Guyatt 2011f; Guyatt 2011g; Guyatt 2011h). Two review authors (CEA and MIO) independently rated the certainty of evidence for each outcome. We presented a summary of the evidence in Summary of findings for the main comparison. This provides key information about the best estimate of the magnitude of effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and rating of overall confidence in effect estimates for each outcome. We created Summary of findings for the main comparison based on the methods described in the Cochrane Handbook for Systematic Reviews of Interventions by using the table editor in Review Manager (RevMan) (Higgins 2011). We used the GRADEpro Guideline Development Tool (GDT) software to help with standardisation of Summary of findings for the main comparison. We justified all decisions to downgrade the certainty of evidence by using footnotes, and we provided comments to aid the reader’s understanding of the Cochrane Review when necessary.

We presented Summary of findings for the main comparison to report the following outcomes, listed according to priority.

- Urological symptoms as measured by the International Prostate Symptom Score (IPSS) questionnaire at 12 months.
- Bother as measured by a health-related quality of life (HRQoL) questionnaire at 12 months.
- Transurethral resection (TUR) syndrome.
- Postoperative blood transfusion.
- Postoperative urinary incontinence at 12 months.
- Incidence of second TURP (i.e. re-do TURP).
- Erectile function at 12 months as measured by IIEF-5.

Subgroup analysis and investigation of heterogeneity
We expected the following characteristics to introduce clinical heterogeneity, and we planned on carrying out the following subgroup analyses including investigations of interactions.

- Prostate volume: large versus small prostate volume, with specific categories for these to be defined by the primary authors.
- Patient age: older versus younger patients, with specific categories for these to be defined by the primary authors.

In light of the anticipated heterogeneity of thresholds for specific categories of prostate volume and patient age, we did not apply our own specific values.

Sensitivity analysis
We undertook sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following.

- Taking into account risk of bias, as specified in the Assessment of risk of bias in included studies section.
- Very long or large trials, to establish the extent to which they dominate the overall results.

RESULTS
Description of studies
Results of the search
We identified 1249 records through an electronic database search. We identified 40 records through handsearching of other sources. After removing 432 duplicates, we screened the titles and abstracts of 857 records, and we excluded 647 records. We screened 210 full-text records and excluded 81 records that did not meet the inclusion criteria. We included a total of 59 RCTs (129 records). We did not identify studies awaiting classification nor ongoing RCTs. The flow of literature through the assessment process is shown in the PRISMA flowchart (Figure 1). Baseline characteristics of the included studies are detailed in Table 1.
Included studies
Details of included studies are presented in the Characteristics of included studies table.

Source of data
Of the 59 included RCTs, seven were published in Chinese (He 2010; Mei 2010; Qian 2014; Wang 2007; Wu 2005; Xin 2009; Xue 2008), one in Korean (Kim 2006), one in German (Rose 2007), one in French (Ghozzi 2014), one in Spanish (Rojo 2018), and the other 48 in English.

Of the 59 included RCTs, full-text publications were available for 46 RCTs, and only abstract proceedings were identified for the 13 remaining RCTs (Bahadzor 2006; Bertolotto 2007; Choi 2006; D’Elia 2004; Eaton 2004; Egui Rojo 2017; Goh 2009; Kadyan 2014; Nasution 2017; Shaik 2017; Symons 2002; Terrone 2006; Xin 2007).

Study design and settings
All studies were RCTs that compared BTURP to MTURP. Four studies were multi-institutional (Bertolotto 2007; Choi 2006; Mamoulakis 2013; Méndez-Probst 2011), and 55 were single-institution trials. The included studies were performed between 2002 and 2016. The follow-up duration varied from only the immediate postoperative period to 48 months - De Sio 2006 - and 60 months postoperatively - Xie 2012.

Participants
The included trials enrolled participants aged > 18 years with lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). BPO was to be defined as bladder outlet obstruction secondary to benign prostatic enlargement (BPE). We included 8924 randomised participants. Of these, 6745 contributed data to the primary and secondary outcomes. The mean age of included participants ranged from 59.0 (BTURP) and 61.0 (MTURP) - De Sio 2006 - to 74.1 (BTURP) and 73.8 (MTURP) - Wu 2005. The mean prostate volume ranged from 39 mL (BTURP and MTURP) - Egui Rojo 2017 - to 82.4 mL (BTURP) and 82.6 mL (MTURP) - Bhansali 2009.

Intervention and comparator
A total of 50 studies reported the specific BTURP technology used in their intervention group, as described in the 'Description of interventions' table (Table 2). In all, 31 studies used Gyrus Plasmakinetic (ACMI, Southborough, MA, USA), 14 used TURis (Olympus, Tokyo, Japan), four used the Vista Coblation/Controlled Tissue Resection (CTR) system (ACMI), and one used AUTOCON II 400 ESU (Karl Storz Endoscope, Tuttinglen, Germany). A total of 46 studies reported the specific irrigation fluid that was used with MTURP, as detailed in the

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
'Description of interventions' table (Table 2); 24 used glycine; seven used mannitol; three used mannitol/ethanol; three used mannitol/sorbitol; three used sterile distilled water; two used glucose solution; one used Urion liquid; and one multi-centre trial varied irrigation fluid by centre (glycine, sorbitol, mannitol/sorbitol, water).

**Outcomes**

The number of studies that reported each of the respective primary and secondary outcomes is described in Summary of findings for the main comparison. Urological symptoms as measured by IPSS at 12 months were reported by 16 studies. Bother as reported by HRQoL at 12 months was reported by 11 studies. The incidence of TUR syndrome was reported by 44 studies; the incidence of post-operative urinary incontinence at 12 months by four studies; the incidence of postoperative blood transfusion by 38 studies; and the incidence of re-TURP by six studies. Erectile function as measured by IIEF-5 score at 12 months was reported by three RCTs.

**Funding sources and conflicts of interest**

Four studies reported sources of funding. Chen 2010 reported support from Shanghai Shenkang Hospital Development Centre and Science and Technology Fund of Shanghai Jiao Tong University School of Medicine, Mamoulakis 2013 from Karl Storz Endoscope, Méndez-Probst 2011 from Olympus and ACMI, and Singhania 2010 from BYL Nair Hospital.

**Excluded studies**

We excluded a total of 81 studies (83 records) on full-text screening as they did not meet inclusion criteria. Details of the excluded studies are presented in the Characteristics of excluded studies table.

**Risk of bias in included studies**

A summary of risk of bias judgements for the included studies is presented in the 'Risk of bias' graph (Figure 2) and in the 'Risk of bias' summary (Figure 3) (Characteristics of included studies).

---

**Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.**
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
Figure 3. (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants</th>
<th>Blinding of outcome assessment</th>
<th>Incomplete outcome data</th>
<th>Incomplete outcome data</th>
<th>Selective reporting (repo)</th>
</tr>
</thead>
</table>
Figure 3. (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>+</th>
<th>-</th>
<th>+</th>
<th>-</th>
<th>+</th>
<th>-</th>
<th>+</th>
<th>-</th>
<th>+</th>
<th>-</th>
<th>+</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ertruhan 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fagerström 2011</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Geavlete 2011</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Ghozzi 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giuliani 2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goh 2009</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>He 2010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ho 2007</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Iori 2008</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Kadyan 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim 2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Komura 2015</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Lin 2006</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Mammoulakis 2013</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Me 2010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Méndez–Probst 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michelsen 2007</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Nasution 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuhoğlu 2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patankar 2006</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Qian 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rojo 2018</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>
Figure 3. (Continued)

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation

Random sequence generation

The sequence generation for participation allocation was adequate in 24 studies and was rated at low risk of bias. In the remaining trials, the method of sequence generation was unclear or was not specified (Figure 2, Figure 3).

Allocation concealment

Six studies had adequate allocation concealment and were rated to be at low risk of bias. In the remaining trials, treatment allocation was unclear (Figure 2, Figure 3).

Blinding

Blinding of participants and personnel

All studies were considered to be at high risk of bias, as it was considered unlikely that any of the operating surgeon(s) of included studies were blinded. No studies reported blinding of operating surgeon(s) to the interventions (Figure 2, Figure 3).

Blinding of outcome assessment

Subjective outcomes (urological symptoms at 12 months, bother at 12 months, erectile function at 12 months, urinary incontinence at 12 months, TUR syndrome)

Five studies reported adequate blinding of outcome assessment and were rated at low risk of bias; three studies reported that blinding of outcome assessment was not undertaken and were rated at high risk of bias; and the remaining studies did not report blinding of outcome assessment and did not report the objective outcomes of interest; these were rated at unclear risk (Figure 2, Figure 3).

Objective outcomes (blood transfusion and re-TURP)

A total of 38 studies were rated at low risk of bias, and the remaining studies were rated at unclear risk, as they did not report the objective outcomes of interest (Figure 2, Figure 3).

Incomplete outcome data

Immediate postoperative outcomes (blood transfusion, TUR syndrome)

In all, 18 studies were rated at low risk of bias for these outcomes. One study was rated at high risk of bias due to loss to follow-up or missing data resulting in significant differential loss to follow-up between trial arms (Demirdag 2016). In the other studies, risk of bias due to incomplete outcome data was unclear (Figure 2, Figure 3).

Long-term outcomes (urological symptoms at 12 months, bother at 12 months, erectile function at 12 months, urinary incontinence, re-TURP)

Four studies were rated at low risk of bias for these outcomes. Two studies were rated at high risk of bias due to significant loss to follow-up (Demirdag 2016; Stucki 2014). The other studies were considered to be at unclear risk of bias (Figure 2, Figure 3).

Selective reporting

We identified published protocols for three included studies and rated the risk of reporting bias for these studies as low (El-Assmy 2018; Komura 2015; Mamoulakis 2013). We judged the risk of selective reporting bias as unclear for the remaining studies, with no identifiable published protocols available (Figure 2, Figure 3).

Other potential sources of bias

No other potential sources of bias were assessed.

Effects of interventions

See: Summary of findings for the main comparison BTURP compared to MTURP for lower urinary tract symptoms secondary to benign prostatic obstruction

A summary of results for the comparison of BTURP versus MTURP for LUTS due to BPO is provided in Summary of findings for the main comparison.

BTURP versus MTURP

Primary outcomes

Urological symptoms as measured by IPSS at 12 months

BTURP probably results in similar improvements in urological symptoms, as measured by the International Prostate Symptom Score (IPSS) at 12 months (mean difference (MD) -0.24, 95% confidence interval (CI) -0.39 to -0.09; participants = 2531; RCTs = 16; I² = 0%), compared to MTURP (Analysis 1.1). The MD of -0.24 (95% CI -0.39 to -0.09) was less than the predefined minimum clinically important difference for IPSS of 4.

We rated the certainty of evidence as moderate, downgrading by one level for study limitations, including concerns over selection bias (method of randomisation and allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), detection bias (blinding of outcomes assessment was unclear in > 50% of included RCTs), and reporting bias (selective reporting was unclear in > 50% of included RCTs) (Summary of findings for the main comparison; Figure 4).
Bother as measured by HRQoL score at 12 months

BTURP probably results in similar improvements in bother, as measured by health-related quality of life (HRQoL) scores at 12 months (MD -0.12, 95% CI -0.25 to 0.02; participants = 2004; RCTs = 11; I² = 53%), compared to MTURP (Analysis 1.2).

We rated the certainty of evidence as moderate, downgrading by one level for study limitations, including concerns over selection bias (method of randomisation and allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), detection bias (blinding of outcome assessment was unclear in > 50% of included RCTs), and reporting bias (selective reporting was unclear in > 50% of included RCTs) (Summary of findings for the main comparison; Figure 5).
**TUR syndrome**

BTURP probably slightly reduces TUR syndrome events (risk ratio (RR) 0.17, 95% CI 0.09 to 0.30; participants = 6745; RCTs = 44; $I^2 = 0\%$) compared to MTURP. This corresponds to 20 fewer TUR syndrome events per 1000 participants (95% CI 22 fewer to 17 fewer; *Analysis 1.3*).

We rated the certainty of evidence as moderate, downgrading by one level for study limitations, including concerns over selection bias (method of randomisation and allocation concealment was unclear in $>50\%$ of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), and reporting bias (selective reporting was unclear in $>50\%$ of included RCTs) (*Summary of findings for the main comparison; Figure 6*).
Secondary outcomes

Urinary incontinence at 12 months

BTURP may result in similar rates of urinary incontinence at 12 months (RR 0.20, 95% CI 0.01 to 4.06; participants = 751; RCTs = 4) compared to MTURP. This corresponds to four fewer events of urinary incontinence per 1000 participants (95% CI 5 fewer to 16 more) (Analysis 1.4).

We rated the certainty of evidence as low, downgrading by one level for study limitations, with concerns over selection bias (method of randomisation and allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), detection bias (blinding of outcome assessment was unclear in > 50% of included RCTs), and reporting bias (selective reporting was unclear in > 50% of included RCTs), as well as by one level for imprecision (wide confidence intervals and small numbers of events; Summary of findings for the main comparison).

Blood transfusion

BTURP probably slightly reduces blood transfusions (RR 0.42, 95% CI 0.30 to 0.59; participants = 5727; RCTs = 38; I² = 0%) compared to MTURP. This corresponds to 28 fewer blood transfusions per 1000 participants (95% CI 34 fewer to 20 fewer; Analysis 1.5).

We rated the certainty of evidence as moderate, downgrading by one level for study limitations, including concerns over selection bias (method of randomisation and allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), and reporting bias (selective reporting was unclear in > 50% of included RCTs) (Summary of findings for the main comparison; Figure 7).
Re-TURP

BTURP may result in similar rates of re-TURP (RR 1.02, 95% CI 0.44 to 2.40; participants = 652; RCTs = 6; I² = 0%) compared to MTURP. This corresponds to one more event of re-TURP per 1000 participants (95% CI 19 fewer to 48 more) (Analysis 1.6).

We rated the certainty of evidence as low, downgrading by one level for imprecision (wide confidence intervals and small numbers of events) and by one level for study limitations, with concerns over selection bias (method of allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), and reporting bias (selective reporting was unclear in > 50% of included RCTs) (Summary of findings for the main comparison).

Erectile function as measured by IIEF-5 score at 12 months

BTURP probably results in similar erectile function as measured by the International Index of Erectile Function score (IIEF-5) at 12 months (MD 0.88, 95% CI -0.56 to 2.32; RCTs = 3; I² = 68%) compared to MTURP (Analysis 1.7). The MD of 0.88 (95% CI -0.56 to 2.32) was less than the predefined minimum clinically important difference of 4 for IIEF-5 at 12 months.

We rated the certainty of evidence as moderate, downgrading by one level for study limitations, including concerns over selection bias (method of allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), and reporting bias (selective reporting was unclear in > 50% of included RCTs) (Summary of findings for the main comparison).

Subgroup analysis

Prostate volume

Of the included RCTs, Kumar 2013 was the only study to include specific subgroup analyses by prostate volume. Researchers defined small prostates as > 20 mL to < 50 mL and large prostates as 50 to 80 mL. They compared monopolar TURP, bipolar TURP, and photo-selective vaporisation of the prostate (PVP) by prostate volume and observed no significant difference in effect for urological symptoms (IPSS at 12 months), bother (HRQoL at 12 months), TUR syndrome, or erectile function (IIEF-5 at 12 months). They did, however observe a significant difference in effect for blood transfusion in men with large prostates. The number of events of postoperative blood transfusion in men with large prostates who had undergone MTURP was six (n = 31) compared to one blood transfusion for BTURP (n = 27) and no blood transfusions for PVP (n = 31) (P = 0.009).

Patient age

We did not identify any analysis or data within the included RCTs that would allow for subgroup analysis by patient age.
**Sensitivity analysis**

In light of the judged high risk of attrition bias seen in Demirdag 2016, with 37 patients excluded due to loss to follow-up or missing data and the significant differential loss to follow-up (23/59 participants lost to follow-up for BTURP vs 14/59 for MTURP), we performed sensitivity analysis while excluding this study from the meta-analysis for outcomes assessed. The exclusion of Demirdag 2016 from the meta-analysis did not result in any significant change in effect size that would impact the overall conclusions of the analysis; for blood transfusion, effect size changed from RR 0.42 (95% CI 0.30 to 0.59) (study included) to RR 0.40 (95% CI 0.28 to 0.57) (study excluded), and for TUR syndrome, effect size and 95% CIs remained identical (RR 0.17, 95% CI 0.09 to 0.30), regardless of its inclusion or exclusion from the meta-analysis.

In light of the size of the largest included RCT (Al-Rawashdah 2017), with 497 included participants, we performed sensitivity analysis while excluding this study from the meta-analysis for outcomes assessed. The exclusion of Al-Rawashdah 2017 from the meta-analysis did not result in any significant change in effect size that would impact the overall conclusions of the analysis; for urological symptoms (IPSS at 12 months), effect size changed from MD -0.24 (95% CI -0.39 to -0.09) (study included) to MD -0.28 (95% CI -0.45 to -0.10) (study excluded); for bother (HRQol at 12 months), effect size changed from MD -0.12 (95% CI -0.25 to 0.02) (study included) to -0.13 (95% CI -0.30 to 0.03) (study excluded); for TUR syndrome, effect size changed from RR 0.17 (95% CI 0.09 to 0.30) (study included) to RR 0.18 (95% CI 0.10 to 0.32) (study excluded); and for blood transfusion, effect size changed from RR 0.42 (95% CI 0.30 to 0.59) (study included) to RR 0.43 (95% CI 0.30 to 0.60) (study excluded).

**DISCUSSION**

**Summary of main results**

Bilateral transurethral resection of the prostate (BTURP) and monopolar transurethral resection of the prostate (MTURP) probably result in similar improvement in urological symptoms and bother. BTURP probably slightly reduces transurethral resection (TUR) syndrome and postoperative blood transfusion compared to MTURP. BTURP and MTURP probably do not differ in terms of erectile function. The moderate certainty of evidence available for urological symptoms, bother, TUR syndrome, blood transfusion, and erectile function suggests that there is no need for further randomised controlled trials (RCTs) comparing BTURP and MTURP for these outcomes. Observed differences between BTURP and MTURP for International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) score at 12 months were less than the predefined minimum clinically important differences for these outcomes and therefore are unlikely to be of clinical relevance to patients or care providers.

BTURP and MTURP may also have similar effects on postoperative urinary incontinence and the need for re-TURP, but low-certainty evidence for these outcomes means that they deserve further study in the form of prospective RCTs that incorporate standardised and clinically meaningful definitions, as well as sufficient duration of follow-up.

**Overall completeness and applicability of evidence**

We believe that evidence is generalisable in addressing the question of how BTURP compares with MTURP for men with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO). All studies recruited men with significant LUTS secondary to BPO requiring surgery, although some heterogeneity is evident in terms of prostate size and patient age.

In terms of the index intervention of BTURP, significant clinical heterogeneity is apparent in terms of the different types of BTURP used. Data were insufficient for sensitivity or subgroup analysis on how the different types of BTURP compared to each other. All studies compared BTURP versus the control intervention of MTURP, which was glycine-based in most studies. For outcomes, we noted heterogeneity of outcome measurement and reporting, with some studies not specifying how outcomes were measured. In particular, the primary outcome of TUR syndrome was inconsistently defined, with some studies failing to provide a clear definition. Accordingly, the incidence of TUR syndrome varied across studies. It should be noted that 20% of participants who developed TUR syndrome were derived from a single study (Yousef 2010). The higher incidence of TUR syndrome in some selected trials may be due to learning curve effects, different hospital settings and hospital protocols, or large size of the prostate as in the Yousef 2010 RCT. In that study, the average resection weight of the prostate was significantly higher than that in other included RCTs, at a mean (standard deviation (SD)) of 82.5 grams (15.5) (BTURP) and 89.2 grams (18.3) (MTURP). This large resection weight should be considered in the context of more widespread urological practice. Furthermore, it is possible that inconsistencies in the definition/method of measuring the presence of TUR syndrome across different RCTs could explain the different rates reported. Nevertheless, the evidence overall appears to be sufficiently complete for us to present conclusions regarding the clinical effectiveness of BTURP compared with MTURP, in terms of reducing TUR syndrome.

**Quality of the evidence**

The certainty of evidence (GRADE) was moderate for the primary outcomes of urological symptoms, bother, and TUR syndrome, and for the secondary outcomes of blood transfusion and erectile function. Certainty of evidence for these outcomes was Downgraded by one level due to methodological limitations, including concerns regarding selection bias (method of randomisation and allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), detection bias (blinding of outcomes assessment for subjective outcomes was unclear in > 50% of included RCTs), and reporting bias (selective reporting was unclear in > 50% of included RCTs). Certainty of evidence (GRADE) was low for the secondary outcomes of urinary incontinence and re-TURP and was downgraded by one level for imprecision (small numbers of events and wide confidence intervals) and by one level for methodological limitations, with concerns regarding selection bias (method of allocation concealment was unclear in > 50% of included RCTs), performance bias (blinding of operating surgeons was considered unlikely in all trials), and reporting bias (selective reporting was unclear in > 50% of included RCTs).

Another potential source of bias is clinical heterogeneity across subgroups of interventions. For instance, BTURP represents a diverse range of interventions, with differences in equipment, magnitude of energy, and techniques. The various bipolar systems represent distinct technological advancements based on different electrophysiological principles regarding current flow. The various bipolar systems (Vista Coblation/Controlled Tissue Resection (CTR))...
system (ACMI, Southborough, MA, USA); Gyrus (ACMI); TURis (Olympus, Tokyo, Japan); S(aline) Resectoscope (Richard Wolf GmbH, Knittlingen, Germany); Tekno Tom (Tekno-Medical, Tuttinglen, Germany); and AUTOCON II 400 ESU (Karl Storz Endoscope, Tuttinglen, Germany)) share a common feature, namely, the ability to perform in normal saline (Issa 2008; Rassweiler 2007). However, some are considered “quasi-” rather than “true” bipolar systems because they do not meet the definition that requires both electrodes be attached to a single port (International Electrotechnical Commission 1998; www.iec.ch). Therefore, each system follows distinct electrophysiological principles regarding current flow due to the different configuration-arrangement of the active and neutral electrodes (mainly the position and shape of the latter) at the resectoscope, which may result in significant clinical effects (Faul 2008). Consequently, efficacy and principally safety should be cautiously and separately evaluated for each system (Faul 2008). In this systematic review, subgroup analyses were not performed to check for differences among the three systems evaluated in RCTs, as in previous meta-analyses (CG97 LUTS: NICE guideline, 2010; Cornu 2015; Mammoulakis 2009a), which may have introduced bias.

Potential biases in the review process

In spite of our stringent inclusion criteria and comprehensive search strategy, it is possible that not all eligible RCTs were included in the databases searched. For some older reports of RCTs, usable data were limited and contacting study authors was challenging. To reduce the risk of bias, we carefully performed the method described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). There was no deviation from the original protocol, but this was updated when required to meet updated Cochrane requirements.

One author of this review (CM) was directly involved in a large international multi-centre RCT comparing BTURP versus MTURP that is included in the present review (Mammoulakis 2013), as well as in the first focused meta-analysis published in the field (Mammoulakis 2009a). To minimise bias, the risk of bias assessment of all RCTs including Mammoulakis 2013 and GRADE certainty of evidence assessments were performed by other review authors, who were not involved in the RCTs nor in the pivotal meta-analysis (CA, MS and CA, MS, MO, respectively). On the other hand, some authors of this review (CA, MO, CM, J ND, TL) were directly involved in a previously published similar meta-analysis in the field (Omar 2014). In this meta-analysis, the same seven outcomes were considered critical to clinical decision-making and therefore were selected for GRADE assessment in evaluating the certainty of evidence, which may have resulted in bias.

For the 11 studies not published in English (Ghozzi 2014; He 2010; Kim 2006; Mei 2010; Qian 2014; Rojo 2018; Rose 2007; Wang 2007; Wu 2005; Xin 2009; Xue 2008), study authors were able to identify other suitably trained individuals who could offer translation to allow assessment of eligibility for inclusion, data extraction, and risk of bias. To identify all potentially eligible studies, a comprehensive electronic search was undertaken in concordance with guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), along with handsearching of trial registers including ClinicalTrials.gov (https://clinicaltrials.gov/) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP, http://www.who.int/ictrp/en) and major urological conference proceedings.

Last but not least, the number of studies was insufficient to generate funnel plots per comparison for three out of the seven outcomes of this review (i.e. urinary incontinence at 12 months, erectile dysfunction at 12 months, and repeat TURP). Consequently, risk of reporting bias cannot be ruled out.

Agreements and disagreements with other studies or reviews

We identified the following relevant systematic reviews.

- An early systematic review compared the effectiveness and safety of ablative methods (including BTURP) against MTURP for treating patients with LUTS secondary to BPO (Lourenco 2008); it included six RCTs (De Sio 2006; Kim 2006; Nuhoglu 2006; Seckiner 2006; Singh 2005; Tefekli 2005). These are all included in the present review, with the exception of Tefekli 2005, which was excluded as it examined the use of a hybrid bipolar technique utilising vapourisation as well as resection. Urological symptoms as measured by IPSS was the primary outcome; others included maximum urinary flow rate ($Q_{\text{max}}$), duration of operation, length of hospital stay, reoperation, and adverse events. It was concluded that data were too few to provide precise estimates, and that statistically significant differences could not be detected. Duration of the operation was the only exception, favouring BTURP, which bore significant heterogeneity and was of doubtful clinical or economic importance (Lourenco 2008).

- A subsequent focused meta-analysis - Mammoulakis 2009a - included 16 RCTs (Abascal Junquera 2006; Ackaoyze 2006; Bhansali 2009; De Sio 2006; Erurthun 2007; Ho 2007; Iori 2008; Kim 2006; Lin 2006; Michielsen 2007; Nuhoglu 2006; Patankar 2006; Rose 2007; Seckiner 2006; Singh 2005; Yang 2004), all of which are also included in the present review. Review authors concluded that no clinically relevant differences exist in short-term (up to 12 months) effectiveness (urological symptoms as measured by IPSS, bother as measured by HRQoL score, and $Q_{\text{max}}$); no differences exist in operation duration and incidence of acute urine retention after postoperative catheter removal; and no differences exist in short-term urethral stricture/bladder neck contracture rates, but that BTURP is preferable due to a more favourable perioperative safety profile (elimination of TUR syndrome, lower incidence of clot retention, lower incidence of blood transfusion - achieved with the Gyrus system (ACMI Southborough, MA, USA) - and shorter irrigation, catheterisation, and possibly hospitalisation times). Data on the TURis system (Olympus, Tokyo, Japan) were not mature at that time to permit safe conclusions. That meta-analysis did not consider the incidence of urinary incontinence or erectile dysfunction, nor did it implement the GRADE system. However, it was noted that the quality of RCTs was relatively poor, and that limited follow-up might result in under-reporting of complications such as urethral stricture/bladder neck contracture rates.

- Two subsequent meta-analyses - Ahmed 2015; Burke 2010 - that included nine RCTs (De Sio 2006; Ho 2007; Iori 2008; Michielsen 2007; Nuhoglu 2006; Patankar 2006; Seckiner 2006; Singh 2005; Yang 2004) and 12 RCTs (Abascal Junquera 2006; De Sio 2006; Erurthun 2007; Ho 2007; Iori 2008; Lin 2006; Michielsen 2007; Nuhoglu 2006; Patankar 2006; Seckiner 2006; Singh 2005; Yang 2004), respectively, out of the 16 RCTs included in the above-mentioned pivotal meta-analysis did not provide any additional information (Mammoulakis 2009a).
• A subsequent focused meta-analysis of high quality was conducted by some of the authors of the present review (Omar 2014). This meta-analysis included 24 RCTs (Abascal Junquera 2006; Açıkgöz 2006; Bhansali 2009; Chen 2009; De Sio 2006; Erturban 2007; Fagerström 2011; Geavlete 2011; Ho 2007; Iori 2008; Kim 2006; Kong 2009; Lin 2006; Mamoulakis 2013; Méndez-Probst 2011; Michielsen 2007; Nuhoğlu 2006; Patankar 2006; Rose 2007; Seckiner 2006; Singh 2005; Singhania 2010; Yang 2004; Youssef 2010), all of which are also included in the present review. Review authors concluded that no clinically relevant differences exist in short-term (up to 12 months) effectiveness (urological symptoms as measured by IPSS, bother as measured by HRQoL score, and Qmax), no differences exist in the short-term incidence of adverse events (acute urine retention after postoperative catheter removal, urinary incontinence, urethral strictures, urinary tract infections, and need for reoperation), and results on erectile dysfunction are inconclusive, but that BTURP is preferable due to a more favourable safety profile (lower incidence of TUR syndrome, lower incidence of blood transfusion, and lower incidence of clot retention).

• One of the major strengths of this meta-analysis is that GRADE was applied for the first time for evaluating the certainty of evidence. The same seven outcomes as in the present review were selected. Application of GRADE showed evidence for assessed outcomes to be of moderate certainty, except for HRQoL score and erectile function (low certainty of evidence). Several major methodological limitations were identified in the included RCTs, the vast majority of which had short-term follow-up. Review authors stressed that these results should be interpreted with caution, and that larger, well-designed RCTs that adhere to the recommendations set out in the Consolidated Standards Of Reporting Trials (CONSORT) statement are needed, which include clinically important outcome measures.

• A subsequent meta-analysis - Cornu 2015 - included 23 RCTs (Akman 2013; Bhansali 2009; Chen 2010; De Sio 2006; Erturban 2007; Fagerström 2011; Geavlete 2011; Giulianelli 2013; Ho 2007; Huang 2012; Iori 2008; Kim 2006; Kong 2009; Mamoulakis 2013; Méndez-Probst 2011; Michielsen 2007; Nuhoğlu 2006; Patankar 2006; Seckiner 2006; Singh 2005; Singhania 2010; Xie 2012; Yang 2004), all of which are also included in the present review. Review authors concluded that no clinically relevant differences exist in short-term (up to 12 months) effectiveness (urological symptoms as measured by IPSS, bother as measured by HRQoL score, and Qmax), catheterisation, and hospitalisation times; that no differences exist in operation duration, in the incidence of urinary tract infections, or in the short-term incidence of urethral strictures/bladder neck contractures, incontinence, and need for reoperation; and that results on erectile dysfunction are inconclusive, but BTURP is preferable due to a more favourable safety profile (elimination of TUR syndrome, lower incidence of blood transfusions, lower incidence of clot retention, lower incidence of acute urine retention after postoperative catheter removal, lower incidence of need for immediate reoperation). Neither the risk of bias tool nor GRADE was implemented in this meta-analysis.

Compared to all relevant previous meta-analyses, our present systematic review and meta-analysis represents the largest body of evidence by far, including 59 RCTs. One of the major strengths of the present meta-analysis is that the strict methods described in the

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

The lack of clinically important differences in urological symptoms and bother at 12 months when MTURP and BTURP are compared suggests that these surgical interventions can offer comparable clinical effectiveness in the management of LUTS secondary to BPO. This remains true for several other important short-term adverse events, including urinary incontinence, need for re-TURP, and erectile function. This has important implications for surgeons and patients for whom these surgical interventions are considered in the surgical management of BPO.

The ability of BTURP to potentially reduce TUR syndrome events and the need for blood transfusion suggest that it offers a favourable perioperative safety profile compared to MTURP. These benefits have potential implications in reducing morbidity and mortality associated with surgical treatment of BPO, especially in light of a reported incidence of TUR syndrome of up to 2.1% in some series (Reich 2008). This may allow for longer resection times and resection of larger prostates without risk of TUR syndrome. The allowance for longer resections may also permit further time to ensure sufficient coagulation time to secure haemostasis, thereby reducing risks of bleeding. These features may be particularly beneficial for urologists in training. However, it should be borne in mind that bipolar technology does not prevent fluid absorption (Rassweiler 2007; Starkman 2007), which may still result in fluid over-load.

**Implications for research**

The low certainty of evidence for how BTURP and MTURP compare in terms of urinary incontinence and need for re-TURP means that these outcomes deserve further study in the form of prospective RCTs that incorporate clinically meaningful definitions and sufficient duration of follow-up (e.g. at 12 months). The potentially attenuated benefits of BTURP in patients with larger prostates, compared to MTURP, deserve further study, with potential implications for TUR syndrome and blood transfusion events. In addition, it remains unknown whether there are any differences in clinical effectiveness among the different types of BTURP as a technology, in terms of equipment, energy, and techniques, as well as the relative cost-effectiveness of BTURP technology compared to MTURP.
ACKNOWLEDGEMENTS

We thank Professor Philipp Dahm, Co-ordinating Editor, Cochrane Urology, for advice and guidance provided with regards to Cochrane Review methods.

We are grateful to the following individuals for their kind efforts in assisting with study translation, assessment of eligibility, and data extraction for foreign language articles: Lena Lantsova, Euan Fisher, Christopher Carroll, Sergio Fdez-Pello Montes, Jae Hung, and Professor Philipp Dahm.
References to studies included in this review

Abascal Junquera 2006 [published data only]

Acuña Lopez 2010 [published data only]

Ahmad 2016 [published data only]

Akçayöz 2006 [published data only]

Akman 2013 [published data only]


Al-Rawashdah 2017 [published data only]


Bahadzor 2006 [published data only]

Bertolotto 2007 [published data only]


Bhansali 2009 [published data only]

Chen 2009 [published data only]

Chen 2010 [published data only]

Choi 2006 [published data only]
* Choi SH, Lee JH, Seo JH, Yoon CJ, Moon KH, Park YI, Cho SR. The comparison of PK tissue management system TURP with

D’Elia 2004 {published data only}

Demirdag 2016 {published data only}

De Sio 2006 {published data only}


Eaton 2004 {published data only}


Egui Rojo 2017 {published data only}

El-Assmy 2018 {published data only}

Erturhan 2007 {published data only}

Fagerström 2011 {published data only}


Geavlete 2011 {published data only}


Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


Huang 2012 [published data only]


Iori 2008 [published data only]


Kaday 2014 [published data only]


Kim 2006 [published data only]


Komura 2015 [published data only]


Kong 2009 [published data only]


Kumar 2013 [published data only]


Lin 2006 [published data only]


Mamoulakis 2013 [published data only]


Ho CC, Eng HS, Das S. Results from an international multi-centre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate. British Journal of Urology International 2012;109(7):E22; author reply E22-4. [PUBMED: 22414177]


Mei 2010 (published data only)


Méndez-Probst 2011 (published data only)


Michielsen 2007 (published data only)


Ho H, Lim KB. Re: Bipolar transurethral resection in saline - an alternative surgical treatment for bladder outlet obstruction?
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


** Nasution 2017 (published data only)**


** Nuhoğlu 2006 (published data only)**


** Patankar 2006 (published data only)**


** Qian 2014 (published data only)**


** Rojo 2018 (published data only)**


** Rose 2007 (published data only)**


** Seckiner 2006 (published data only)**


** Shaik 2017 (published data only)**


** Singh 2005 (published data only)**


** Singhania 2010 (published data only)**


** Stucki 2014 (published data only)**


** Symons 2002 (published data only)**

* Symons S, Browning A, Chahal R. A comparative study of the Gyrus plasmakinetic electrosurgical system versus conventional loop electrosurgery (TURP) for the treatment of bladder

**References to studies excluded from this review**

**Demir 2015** *(published data only)*


**El Saied Hafez 2013** *(published data only)*


**Engeler 2010** *(published data only)*


**Fung 2005** *(published data only)*


**Inzuna 2017** *(published data only)*


**Kwon 2011** *(published data only)*


**Liangyu 2006** *(published data only)*


**Lv 2012** *(published data only)*


**Michielsen 2010b** *(published data only)*

* Michielsen DP, Coomans D, Peeters I, Braeckman JG. Conventional monopolar resection or bipolar resection in saline for the management of large (>60 g) benign prostatic hyperplasia: an evaluation of morbidity. Minimally Invasive
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


**Michielsen 2011** (published data only)


**Muslumanoglu 2012** (published data only)


**Neyer 2011** (published data only)


**Tefekli 2005** (published data only)


**Treharne 2018** (published data only)


**Valdivia Uría 2005** (published data only)


**Vasudeva 2019** (published data only)


**Yoon 2006** (published data only)


**Zhang 2013** (published data only)


### Additional references

**Abras 2002**


**Abras 2009**


**Agarwal 2014**


**Ahyai 2010**


**AUA 2018**

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Guyatt 2011c

Guyatt 2011d

Guyatt 2011e

Guyatt 2011f

Guyatt 2011g

Guyatt 2011h

Hahn 1993

Higgins 2003

Higgins 2011

Hozo 2005

Isaacs 1989


**References to other published versions of this review**

**Mamoulakis 2014**


* Indicates the major publication for the study

**CHARACTERISTICS OF STUDIES**

**Characteristics of included studies [ordered by study ID]**

**Abascal Junquera 2006**

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Spain

**Participants**
- **Total participants enrolled:** 45; (A) = 24, (B) = 21
- **Inclusion criteria:** clinical diagnosis of symptomatic BPH with USS prostate volume between 30 and 70 grams
- **Exclusion criteria:** anticoagulant therapy, neurogenic bladder, de-obstructive surgery for prostate adenocarcinoma or suspected adenocarcinoma, indwelling bladder catheter

**Baseline characteristics:**
- No significant differences between arms reported
- Age, years (SD): (A) = 69.5 (9.5), (B) = 67.3 (9.2)
- Mean preoperative prostate volume, grams (SD): (A) = 39.5 (9.8), (B) = 42.5 (11.6)
- Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Olympus SurgMaster)
- **Intervention B:** monopolar TURP (Storz, irrigation fluid = glycine)

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): not reported
  - HRQoL (12 months): not reported
  - TUR syndrome: (A) = 0 (n = 24), (B) = 0 (n = 21)
- **Secondary outcomes:**
  - Blood transfusion: (A) = 0 (n = 24), (B) = 0 (n = 21)
  - Urinary incontinence (12 months): not reported
  - Erectile dysfunction (IIEF-5) (12 months): not reported
  - Need for repeat TURP (i.e. re-TURP): not reported
- **Other reported outcomes:**
  - Acute urinary retention
  - Mean duration of resection time
  - Mean duration of catheterisation
  - Mean duration of hospital stay
Abascal Junquera 2006 (Continued)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean duration of irrigation</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Mean reduction in serum sodium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean reduction in haematocrit</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source of funding

None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded to interventions</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>These objective outcomes are not likely affected by blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not assessed by this trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full judgement on selective reporting</td>
</tr>
</tbody>
</table>

Methods

- Study type: single-centre randomised controlled trial (1:1)

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Setting:** Mexico

### Participants

- **Total participants enrolled:** 30; (A) = 15, (B) = 15
- **Inclusion criteria:** diagnosis of BPH, presenting with ultrasound prostate volume between 20 and 80 mL
- **Exclusion criteria:** anticoagulant therapy with neurogenic bladder suspected or diagnosed prostate adenocarcinoma

**Baseline characteristics:**

No significant differences between arms reported

- Age, years: (A) = 68.1, (B) = 67.4
- Mean preoperative prostate volume, grams (SD): (A) = 49.6 (17.1), (B) = 58.8 (14.6)
- Preoperative catheterisation state: not reported

### Interventions

- **Intervention A:** bipolar TURP (Gyrus ACMI Bipolar Resector)
- **Intervention B:** monopolar TURP; monopolar resector, irrigation fluid = glycine

### Outcomes

**Primary outcomes:**

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 15), (B) = 0 (n = 15)

**Secondary outcomes:**

- Blood transfusion: (A) = 0 (n = 15), (B) = 0 (n = 15)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

- Clot retention
- Acute urinary retention
- Mean duration of resection
- Mean duration of catheterisation
- Mean duration of hospital stay
- Mean duration of irrigation
- Mean decrease in serum sodium
- % change in haematocrit
- Incidence of postoperative clot evacuation
- Trial also provided subjective assessment of cutting capacity, intraoperative visibility, degree of fragment adherence to blade, bleeding during cutting

### Source of funding

None reported
### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded to interventions</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>These objective outcomes are not likely affected by blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not assessed by this trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full judgement on selective reporting</td>
</tr>
</tbody>
</table>

### Methods

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Pakistan

### Participants

- **Total participants enrolled:** 220; (A) = 110, (B) = 110
- **Inclusion criteria:** symptomatic enlarged prostate based on IPSS
- **Exclusion criteria:** bladder stone, urethral stricture, previous prostatic surgery, neurogenic bladder, any urological malignancy
### Ahmad 2016 (Continued)

**Baseline characteristics:**

- Mean age, years (SD): (A) = 69.5 (10.93), n = 110, (B) = 69.1 (11.72), n = 110
- Mean preoperative prostate volume, mL (SD): (A) = 50.4 (26.34), n = 110, (B) = 48.9 (18.6), n = 110
- Preoperative catheterisation state: not reported

**Interventions**

- **Intervention A:** bipolar TURP (specific technology not reported)
- **Intervention B:** monopolar TURP (specific technology not reported, irrigation fluid = glycine 1.5%)

**Outcomes**

**Primary outcomes:**

- IPSS at 12 months: not reported
- HRQoL at 12 months: not reported
- TUR syndrome: (A) = 0 (n = 110), (B) = 0 (n = 110)

**Secondary outcomes:**

- Blood transfusion: (A) = 1 (n = 110), (B) = 0 (n = 110)
- Urinary incontinence at 12 months: not reported
- IIEF-5 at 12 months: not reported
- Need for re-TURP: not reported

**Other reported outcomes:**

- $Q_{\text{max}}$ (mL/s)
- Duration of resection (minutes)
- Amount of tissue resected (grams)
- Hospital stay (days)
- Duration of catheterisation (days)

**Source of funding**

Not reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded to interventions</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias):</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
Ahmad 2016 (Continued)

Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment</th>
<th>Low risk</th>
<th>Not reported but these objective outcomes are not likely affected by blinding of outcome assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Objective outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>This study reports that all participants (n = 220) were included in the analyses for these outcomes: &quot;at follow-up 110 patients appeared in the bipolar group and 110 patients appeared in the monopolar group&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not assessed by this trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full judgement on selective reporting</td>
</tr>
</tbody>
</table>

Akman 2013

Methods
- **Study type**: single-centre randomised controlled trial (1:1)
- **Setting**: Turkey

Participants
- **Total participants enrolled**: 286; (A) = 143, (B) = 143
- **Inclusion criteria**: moderate or severe LUTS (IPSS > 16) with failed medical therapy (at least 2 weeks), recurrent urinary retention, able to give fully informed consent
- **Exclusion criteria**: neurogenic bladder dysfunction, previous prostatic or urethral surgery, prostate cancer, bladder calculus, bladder tumour and coagulopathy, suspicion of prostate cancer (abnormal DRE findings, higher serum PSA levels), urethral stricture

Baseline characteristics:
No significant differences between arms reported
Mean age, years (SD): (A) = 67.4 (9.3), (B) = 67.7 (7.7)
Mean preoperative prostate volume, mL (SD): (A) = 59.7 (24.9), (B) = 55.9 (23.9)
Preoperative catheterisation state: not reported

Interventions
- **Intervention A**: bipolar TURP (Olympus UES 40 SurgMasterSystem)
- **Intervention B**: monopolar TURP (Martine ME 411 Elecsurgical Generator, irrigation fluid = glycine)

Outcomes
- **Primary outcomes**:
  - IPSS (12 months): mean IPSS (SD) (12 months): (A) = 10.3 (3.0) (n = 127), (B) = 10.8 (2.9) (n = 130)
  - HRQoL (12 months): not reported
  - TUR syndrome: (A) = 0 (n = 143), (B) = 2 (n = 143)
Secondary outcomes:

Blood transfusion: (A) = 3 (n = 143), (B) = 8 (n = 143)

Urinary incontinence (12 months): (A) = 0 (n = 127), (B) = 0 (n = 130)

Erectile dysfunction (IIEF-5) (12 months): results represented only in graphical format with no specific data reported

Need for repeat TURP (i.e. re-TURP): (A) = 6 (n = 34), (B) = 4 (n = 33) (2012 BJUI paper)

Other reported outcomes:

\( Q_{\text{max}} \)

Clot retention

Urethral stricture

Bladder neck contracture

Operation duration

Catheterisation duration

Hospitalisation duration

Postoperative haemoglobin drop

Postoperative serum sodium drop

Source of funding
None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded to interventions</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but these objective outcomes are not likely affected by blinding of outcome assessment</td>
</tr>
</tbody>
</table>

Akman 2013 (Continued)
### Akman 2013 (Continued)

| Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion) | Unclear risk | This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes |
| Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP) | Unclear risk | Study states: "in the monopolar TURP group 130/143 (90.1%) were followed for at least one year, and in the bipolar TURP group, 127/143 were followed for the same period" This study provides specific reasons for all patient dropouts and losses to follow-up for these outcomes. It is considered unclear how such incomplete outcome data would impact observed differences in reported outcomes |
| Selective reporting (reporting bias): All outcomes | Unclear risk | RCT protocol could not be identified to allow for full judgement on selective reporting |

### Akçayöz 2006

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Turkey

**Participants**
- **Total participants enrolled:** 42; (A) = 21, (B) = 21
- **Inclusion criteria:** clinical BPH
- **Exclusion criteria:** suspicion of prostatic adenocarcinoma, urethral stricture, bladder stones, neurological disorders, respiratory problems, previous prostatic urethral or bladder surgery

**Baseline characteristics:**

No statistically significant differences between arms reported

Mean age, years (SD): (A) = 67 (7), (B) = 66 (9)

Mean preoperative prostate volume, mL (SD): (A) = 40 (13), (B) = 47 (15)

Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Gyrus Plasmakinetic)
- **Intervention B:** monopolar TURP, irrigation fluid = 1.5% glycine

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): not reported
  - HRQoL (12 months): not reported
  - TUR syndrome: (A) = 0 (n = 21), (B) = 0 (n = 21)

- **Secondary outcomes:**
  - Blood transfusion: (A) = 0 (n = 21), (B) = 0 (n = 21)
  - Urinary incontinence (12 months): not reported
  - Erectile dysfunction (IIEF-5) (12 months): not reported
  - Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded to interventions</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but these objective outcomes are not likely affected by blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not assessed by this trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full decision on selective reporting</td>
</tr>
</tbody>
</table>
Methods

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Italy

Participants

- **Total participants enrolled:** 497; (A) = 246, (B) = 251
- **Inclusion criteria:** BPH scheduled to undergo TURP
- **Exclusion criteria:** bleeding disorders, prostate cancer, neurogenic bladder, previous urethral or prostatic surgery

**Baseline characteristics:**

Mean age, years (SD): (A) = 67.7 (0.6) (n = 246), (B) = 67.0 (0.7) (n = 251)

Mean preoperative prostate volume, mL (SD): (A) = 53.95 (0.16), (B) = 54.11 (0.17)

Preoperative catheterisation state: not reported

Interventions

- **Intervention A:** bipolar TURP (specific technology = Gyrus PK Super-Pulse Olympus)
- **Intervention B:** monopolar TURP (specific technology = Karl Storz and ERBE Generator, irrigation fluid = sorbitol/mannitol irrigation fluid)

Outcomes

**Primary outcomes:**

- IPSS at 12 months: (A) = 7.75 (0.10) (n = 251), (B) = 7.89 (0.10) (n = 246)
- HRQoL at 12 months: (A) = 0.81 (0.05) (n = 251), (B) = 0.84 (0.05) (n = 246)
- TUR syndrome: (A) = 0 (n = 251), (B) = 7 (n = 246)

**Secondary outcomes:**

- Blood transfusion: (A) = 0 (n = 251), (B) = 5 (n = 246)
- Urinary incontinence at 12 months: not reported
- IIEF-5 at 12 months: not reported
- Need for re-TURP: not reported

**Other reported outcomes:**

- $Q_{\text{max}}$
- PVR
- Operative time
- PSA level drop
- Length of hospitalisation
- Time of catheterisation
- Urinary retention
- Postoperative haemoglobin drop
- Postoperative sodium drop
- Urethral stricture
- Bladder neck contracture

Source of funding

None
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>&quot;All 497 patients enrolled in this study were computer randomized (simple randomization 1:1)&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific method used to conceal allocation sequence not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected by blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Low risk</td>
<td>Study states: &quot;all patients completed the follow-up visits at 3, 12, 24, and 36 months&quot;</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified for full judgement on selective reporting</td>
</tr>
</tbody>
</table>

### Methods
- **Study type:** single-centre randomised controlled trial (1:1); **conference abstract only available for data extraction**
- **Setting:** Malaysia

### Participants
- **Total number enrolled:** 103; (A) = 52, (B) = 51
- **Included:** benign prostatic hyperplasia (BPH)
- **Exclusion criteria:** not reported
- **Age:** not reported
### Baseline characteristics

- **Interventions**
  - Intervention A: bipolar TURP (Plasma Kinetic Resection of Prostate)
  - Intervention B: monopolar TURP, irrigation fluid = not reported

### Outcomes

- **Primary outcomes:**
  - IPSS (12 months): not reported
  - HRQoL (12 months): not reported
  - TUR syndrome: not reported

- **Secondary outcomes:**
  - Blood transfusion: not reported
  - Urinary incontinence (12 months): not reported
  - Erectile dysfunction (IIEF-5) (12 months): not reported
  - Need for repeat TURP (i.e. re-TURP): not reported

- **Other reported outcomes:**
  - Acute urinary retention

  Abstract states that data recorded for mean operative time, haemoglobin drop, serum sodium level, duration of catheterisation, hospital stay, IPSS, QoL, and PVR at 1 month but no specific data reported in abstract

### Source of funding

- None reported

### Notes

- This is a conference abstract with limited information

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
</tbody>
</table>
### Bahadzor 2006 (Continued)

**Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)**
- Risk: Unclear
- Outcome: These outcomes were not reported

**Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)**
- Risk: Unclear
- Outcome: These outcomes were not reported

**Selective reporting (reporting bias): All outcomes**
- Risk: Unclear
- Outcome: RCT protocol not available to allow for full judgement

### Bertolotto 2007

**Methods**
- **Study type:** multi-centre (3-centre) randomised controlled trial (1:1); only published abstract available for data extraction
- **Setting:** Italy

**Participants**
- **Total number enrolled:** 100; (A) = 52, (B) = 48
- **Inclusion criteria:** candidates for surgery for obstructive symptoms, prostate estimated volume < 100 mL, $Q_{\text{max}} \leq 15 \text{ mL/s}$, IPSS $\geq 13$, PSA $\leq 4 \text{ ng/L}$
- **Exclusion criteria:** not reported

**Baseline characteristics:** reported only for overall cohort and not individual arms

- **Age, years:** not reported for both arms (median age overall = 71)

**Interventions**
- **Intervention A:** bipolar TURP (TURis; Olympus Surgmaster)
- **Intervention B:** monopolar TURP, irrigation fluid = glycine

**Outcomes**

**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 52), (B) = 0 (n = 48)

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- Urethral stricture
<table>
<thead>
<tr>
<th>Source of funding</th>
<th>None reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notes</td>
<td>This is a conference abstract with limited information. Patient population identical to that reported in a previously published abstract by the same authors (Bertolotto 2006)</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unlcear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not assessed by this trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full judgement</td>
</tr>
</tbody>
</table>
### Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** India

### Participants
- **Total participants enrolled:** 70; data on number of participants allocated to each arm unclear at baseline
- **Inclusion criteria:** BPH-related LUTS requiring surgical intervention, prostate gland > 60 grams on 3D transrectal USS
- **Exclusion criteria:** AUASS Score (AUASS) < 18, $Q_{\text{max}} > 12 \text{ mL/s}$, gland < 60 g (3D-TRUS), neurological illness, renal insufficiency, bladder stone, urethral stricture, evidence of prostate carcinoma, patients receiving 5-a reductase inhibitors

**Baseline characteristics:**
No significant differences between groups for reported characteristics
- Age: not reported
- Mean preoperative prostate gland size, grams (SD): (A) = 82.38 (17.965), (B) = 82.61 (19.157)
- Preoperative catheterisation state: not reported

### Interventions
- **Intervention A:** bipolar TURP (Plasmakinetic Superpulse System – 24 Gyrus)
- **Intervention B:** monopolar TURP (ValleyLab, irrigation fluid = glycine)

### Outcomes
**Primary outcomes:**
- IPSS (12 months): not reported specifically, only AUASS scores
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 34), (B) = 4 (n = 33)

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- $Q_{\text{max}}$ (3, 9, 12 months)
- Urethral stricture
- Bladder neck contracture
- Mean blood loss (mL)
- Hospitalisation duration
- Catheterisation duration

### Source of funding
Study states “no financial conflict of interest” but does not report funding for study specifically

### Notes
Study authors contacted regarding absence of specific data on postoperative AUASS and QoL scores

### Risk of bias

---

**Bhansali 2009**

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Bhansali 2009 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;patients were randomised 1:1 using envelopes into two groups&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Unclear whether the envelopes were sequentially numbered, opaque, and sealed</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Participants were blinded but considered unlikely that operating surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Low risk</td>
<td>&quot;In the study, participants were blinded regarding the treatment modality they were receiving, as were the staff members who had done the outcome assessment of the patient’s treatment, including decision to remove the catheter in post-operative period&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment of selective reporting. However, no outcome data on the incidence of blood transfusion or QoL were reported even though the study reports capturing these data elsewhere in the manuscript</td>
</tr>
</tbody>
</table>

### Chen 2009

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

**Participants**
- **Total participants enrolled:** 40; (A) = 21, (B) = 19
- **Inclusion criteria:** older than 55 years and fit for anaesthesia, symptomatic BPH, prostate volume > 50 mL, IPSS ≥ 18, Qmax < 15 mL/s, failed medical therapy with alpha blockers or 5-alpha reductase inhibitors
- **Exclusion criteria:** suspected prostate cancer, bladder calculus, neurogenic bladder, previous prostate surgery, previous urethral stricture
### Baseline characteristics:

- No significant differences between arms reported
- Mean age, years (SD): \( (A) = 72.6 (6.5), (B) = 71.8 (6.3) \)
- Mean preoperative prostate volume, mL (SD): \( (A) = 78.4 (16.4), (B) = 76.8 (17.5) \)
- Preoperative catheterisation state: not reported

### Interventions

- **Intervention A:** bipolar TURP (TURIS, Olympus)
- **Intervention B:** monopolar TURP (Olympus, irrigation fluid = mannitol 4%)

### Outcomes

#### Primary outcomes:

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: \( (A) = 0 (n = 21), (B) = 1 (n = 19) \)

#### Secondary outcomes:

- Blood transfusion: \( (A) = 1 (n = 21), (B) = 3 (n = 19) \)
- Urinary Incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

#### Other reported outcomes:

- IPSS at 3 months and 6 months
- \( Q_{\text{max}} \) at 3 months and 6 months
- Acute urinary retention
- Duration of operation
- Duration of catheterisation
- Duration of hospital stay
- Decrease in postop serum sodium
- Decrease in postop haemoglobin

### Source of funding

None reported

### Notes

This RCT is based on a different population than a subsequent publication by the authors (Chen 2010) - this has been confirmed by study authors

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation concealment (selection bias): All outcomes  
- Unclear risk  
- Not reported

Blinding of participants and personnel (performance bias): All outcomes  
- High risk  
- "In our study, patients were blinded to the operation equipment, but not to surgeons"

Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)  
- Unclear risk  
- Not reported for outcome assessors, but patients were blinded as per above: "in our study, patients were blinded to the operation equipment, but not to surgeons"

Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)  
- Low risk  
- Not reported but objective outcomes unlikely to have been affected

Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)  
- Unclear risk  
- This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically

Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)  
- Unclear risk  
- These outcomes were not reported by the trial

Selective reporting (reporting bias): All outcomes  
- Unclear risk  
- RCT protocol not available to allow for full assessment of selective reporting
  
  However, study seems to suggest that data on complications such as urinary incontinence were recorded, but no data were reported within the manuscript

Chen 2010

Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

Participants
- **Total number enrolled:** 100; (A) = 50, (B) = 50
- **Inclusion criteria:** failure of medical therapy, all indications for surgical treatment of BPH
- **Exclusion criteria:** severe pulmonary disease, allergic response to alcohol, prostate cancer, bladder calculus, neurogenic bladder dysfunction, previous prostate surgery, urethral stricture, coagulopathy

**Baseline characteristics:**
- No significant differences between groups reported
- Mean age, years (SD): (A) = 69.7 (7.6), (B) = 71.2 (6.3)
- Mean preoperative prostate volume, mL (SD): (A) = 60.2 (18.7), (B) = 59.1 (17.3)
- Preoperative catheterisation state: not reported
### Interventions

- **Intervention A:** bipolar TURP; TURis Olympus SurgMasterSystem
- **Intervention B:** monopolar TURP; irrigation fluid = 4% mannitol, 1% ethanol

### Outcomes

#### Primary outcomes:
- **IPSS (12 months):** (A) = 4.2 (2.6) (n = 50), (B) = 4.1 (2.3) (n = 50)
- **HRQoL (12 months):** not reported
- **TUR syndrome:** (A) = 0 (n = 50), (B) = 0 (n = 50)

#### Secondary outcomes:
- **Blood transfusion:** (A) = 1 (n = 50), (B) = 3 (n = 50)
- **Urinary incontinence (12 months):** (A) = 0 (n = 50), (B) = 2 (n = 50)
- **Erectile dysfunction (IIEF-5) (12 months), mean IIEF-5 (SD):** (A) = 19.5 (6.1) (n = 24), (B) = 19.3 (4.0) (n = 28)

#### Other reported outcomes:
- **IPSS at 6, 24 months**
- **Q_{max} at 6, 12, and 24 months**
- **IIEF-5 at 6 and 24 months**
- **Urethral stricture**
- **Bladder neck contracture**
- **Acute urinary retention**
- **Duration of operation**
- **Mean operation duration**
- **Mean resected weight**
- **Mean serum sodium decrease**
- **Mean Hb decrease**
- **Frequency of retrograde ejaculation**

#### Source of funding

"Supported by Shanghai Shenkang Hospital Development Centre and Science and Technology Fund of Shanghai JiaoTong University School of Medicine"

#### Notes

This RCT is based on a different population than a previous publication by the study authors (Chen 2009) - this has been confirmed by the authors

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>&quot;The stratified permuted randomization algorithm was performed to implement the randomisation&quot;</td>
</tr>
</tbody>
</table>
### Chen 2010 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment</td>
<td>Unclear</td>
<td>Specific method used to conceal allocation sequence not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>High</td>
<td>Study states: &quot;only patients were blinded to the different treatments while the surgeons and supervisors were not&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detecion bias): Subjective outcomes</td>
<td>High</td>
<td>Study states: &quot;only patients were blinded to the different treatments while the surgeons and supervisors were not&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (objective outcomes):</td>
<td>Low</td>
<td>These objective outcomes are unlikely to have been affected by blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Unclear</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes</td>
<td>Unclear</td>
<td>Study states: &quot;all 100 patients completed the two year follow-up&quot;, but unclear if this also applies to the 12-month time point</td>
</tr>
<tr>
<td>Selective reporting</td>
<td>Unclear</td>
<td>RCT protocol not available to allow for judgement</td>
</tr>
</tbody>
</table>

### Choi 2006

#### Methods

- **Study type**: multi-centre randomised controlled trial; only published abstract available for data extraction. Note number of involved centres not reported in abstract
- **Setting**: South Korea

#### Participants

- **Total number enrolled**: 200; number of patients in each arm of the trial not reported
- **Inclusion criteria**: "BPH patients"
- **Exclusion criteria**: not reported
- **Baseline characteristics**: not reported

#### Interventions

- **Intervention A**: bipolar TURP; Plasma Kinetic (PK) Tissue Management System (Gyrus)
- **Intervention B**: monopolar TURP; irrigation fluid = not reported

#### Outcomes

**Primary outcomes**:

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
Secondary outcomes:

Blood transfusion: not reported

Urinary Incontinence (12 months): not reported (no time of follow-up provided for urinary incontinence data)

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:

Acute urinary retention

Postoperative drop in serum sodium

Postoperative drop in haemoglobin

Abstract states data collected for resected tissue amount, operative time, changes in haemoglobin, hospital stay, duration of catheter, IPSS, $Q_{max}$, but no specific data provided

Source of funding

None reported

Notes

This is a conference abstract with limited information

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
</tbody>
</table>
### Choi 2006 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment of selective reporting</td>
</tr>
</tbody>
</table>

### D'Elia 2004

**Methods**
- **Study type**: single-centre randomised controlled trial (1:1)
- **Setting**: Italy

**Participants**
- **Total participants enrolled**: 85; (A) = 43, (B) = 42
- **Inclusion criteria**: not reported
- **Exclusion criteria**: not reported
- **Baseline characteristics**: no specific data reported

**Interventions**
- **Intervention A**: bipolar TURP (Gyrus)
- **Intervention B**: monopolar TURP (irrigation fluid = not reported)

**Outcomes**

**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: not reported

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- Catheterisation time
- Hospitalisation time

Abstract states data collected on operative time, resected weight, blood loss and irrigation fluid absorption, IPSS, peak flow rates, and postvoid residual volumes, but no specific data provided

**Source of funding**
- None reported

**Notes**
- This is a conference abstract with limited information

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
### D’Elia 2004 (Continued)

<table>
<thead>
<tr>
<th>Risk of Bias</th>
<th>Unclear</th>
<th>Not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full judgement; however abstract states that data were collected on operative time, resected weight, blood loss, irrigation fluid absorption, IPSS, peak flow rates, and postvoid residual volumes, but no specific data outcome data were provided</td>
</tr>
</tbody>
</table>

### De Sio 2006

**Methods**

- **Study type**: single-centre randomised controlled trial (1:1)
- **Setting**: Italy

**Participants**

- **Total participants enrolled**: 70; (A) = 35, (B) = 35
- **Inclusion criteria**: symptomatic BPH, age > 50 years, good performance status, acute urinary retention if catheter removal failed after therapy with alpha-blockers or chronic urinary retention unresponsive to medical treatment, IPSS ≥18, maximal flow rate \(Q_{\text{max}}\) < 15 mL/s
- **Exclusion criteria**: prostate volume < 30 cm³, documented or suspected prostate cancer, neurogenic bladder, bladder stone or diverticula, urethral stricture, maximal bladder capacity > 500 mL

**Baseline characteristics:**
No significant differences between arms reported

Mean age, years (SD): (A) = 59 (5.9), (B) = 61 (5.9)

Mean preoperative prostate volume, cm³ (SD): (A) = 51.6 (3.9), (B) = 47.5 (5.1)

Preoperative catheterisation status: not reported

**Interventions**

- **Intervention A:** bipolar TURP (Gyrus Plasmakinetic System)
- **Intervention B:** monopolar TURP (ValleyLab Force FX); irrigation fluid = not reported

**Outcomes**

**Primary outcomes:**

IPSS (12 months): (A) = 3.9 (n = 35), (B) = 3.8 (n = 35)

HRQoL (12 months): (A) = 1.0 (n = 35), (B) = 0.8 (n = 35)

TUR syndrome: (A) = 0 (n = 35), (B) = 0 (n = 35)

**Secondary outcomes:**

Blood transfusion: (A) = 1 (n = 35), (B) = 0 (n = 35)

Urinary incontinence (12 months): not reported

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): (A) = 1 (n = 32), (B) = 1 (n = 31)

**Other reported outcomes:**

IPSS at 3, 6, and > 12 months

HRQoL at 24/36/48 months

Q_{max} (mL/s) (12 months)

Urethral stricture

Bladder neck contracture (48 months)

Mean duration of operation (minutes)

Mean decrease in postoperative haemoglobin

Mean decrease in postoperative sodium

Mean duration of catheterisation

Mean duration of hospital stay

Clot retention

Acute urinary retention

Death

**Source of funding**

Study reports that no financial support was received

**Notes**

Patient population identical to that reported in 2 abstracts (De Sio 2005; Autorino 2007) and another paper (Autorino 2009) published by the same authors

Four relevant commentaries have been detected and taken into account for potential inclusion of additional information (Autorino 2007a; Kaplan 2010; Rassweiler 2009; Seitz 2009)
### De Sio 2006 (Continued)

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;randomisation was performed using a stratified permuted randomisation algorithm&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific method of allocation concealment not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Study states: &quot;outcome assessors were blinded to treatments patients had received&quot; (Autorino 2009). However, not reported explicitly if patients involved in recording self-assessed outcomes were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>These objective outcomes are unlikely to have been affected by blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>Study accounts for all patients in analyses: “ninety percent of the patients completed the 4-yr assessments: 32 (of 35) in the PK group and 31 (of 35) in the standard TURP group. There was no statistically significant difference in the number of dropouts in the two groups (p = 0.2). Reasons for dropout were the following: refused follow-up (3 patients), moved away (2 patients), and death from other causes (2 patients)” (Autorino 2009)</td>
</tr>
<tr>
<td>Impact of incomplete outcome data on reported differences in outcomes between intervention arms considered unclear</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>Study accounts for all patients in analyses: “ninety percent of the patients completed the 4-yr assessments: 32 (of 35) in the PK group and 31 (of 35) in the standard TURP group. There was no statistically significant difference in the number of dropouts in the two groups (p = 0.2). Reasons for dropout were the following: refused follow-up (3 patients), moved away (2 patients), and death from other causes (2 patients)” (Autorino 2009)</td>
</tr>
<tr>
<td>Impact of incomplete outcome data on reported differences in outcomes between intervention arms considered unclear</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full judgement of selective reporting</td>
</tr>
</tbody>
</table>

### Demirdag 2016

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Turkey

**Participants**
- **Total participants enrolled:** 118; (A) = 59, (B) = 59
Demirdag 2016 (Continued)

- **Inclusion criteria**: prostate glands larger than 60 mL, moderate to severe lower urinary tract symptoms and significant postmicturition residual (PMR) urine volume (> 100 mL) in spite of medical treatment with alpha blockers and 5-alpha reductase inhibitors
- **Exclusion criteria**: history or suspicion of prostate cancer, bladder stone, neurogenic bladder, previous prostatic surgery, previous urethral stricture

**Baseline characteristics:**
Mean age, years (SD): (A) = 65 (9.0), n = 36, (B) = 66.87 (10.1), n = 45
Mean preoperative prostate volume, mL (SD): (A) = 71.8 (12.93), n = 36, (B) = 73.9 (14.13), n = 45
Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A**: bipolar TURP (Olympus Gyrus PK SuperPulse Generator)
- **Intervention B**: monopolar TURP (ValleyLab Force FX Electrocautery, irrigation fluid = glycine 5%)

**Outcomes**

- **Primary outcomes**:
  - IPSS (12 months): not reported at 12 months
  - HRQoL (12 months): not reported at 12 months
  - TUR syndrome: (A) = 0 (n = 36), (B) = 2 (n = 45)

- **Secondary outcomes**:
  - Blood transfusion: (A) = 4 (n = 36), (B) = 8 (n = 45)
  - Urinary incontinence (12 months): not reported
  - Erectile dysfunction (IIEF-5) (12 months): not reported at 12 months
  - Need for repeat TURP (i.e. re-TURP): not reported

- **Other reported outcomes**:
  - Operation duration
  - Postoperative haemoglobin
  - Postoperative sodium
  - Catheterisation time
  - Clot retention
  - Postoperative IIEF-5 (not explicitly at 12 months)

**Source of funding**
None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study states: &quot;randomised into MTURP or BTURP arms via software program with a 1:1 ratio&quot;; limited detail reported regarding specific randomisation sequence</td>
</tr>
<tr>
<td><strong>Demirdag 2016</strong> (Continued)</td>
<td><strong>Allocation concealment (selection bias): All outcomes</strong></td>
<td>Unclear risk</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td><strong>Blinding of participants and personnel (performance bias): All outcomes</strong></td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) blinded</td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</strong></td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</strong></td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td><strong>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</strong></td>
<td>High risk</td>
<td>Study states: “total of 37 patients have been excluded because of loss of follow-up or missing data” This resulted in significant differential loss to follow-up between arms: n = 23/59 in BTURP vs 14/59. No specific details provided to explain loss to follow-up or missing data</td>
</tr>
<tr>
<td><strong>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</strong></td>
<td>High risk</td>
<td>Study states: “total of 37 patients have been excluded because of loss of follow-up or missing data” This resulted in significant differential loss to follow-up between arms: n = 23/59 in BTURP vs 14/59. No specific details provided to explain loss to follow-up or missing data</td>
</tr>
<tr>
<td><strong>Selective reporting (reporting bias): All outcomes</strong></td>
<td>Unclear risk</td>
<td>No RCT protocol available to allow for full judgement on selective reporting</td>
</tr>
</tbody>
</table>

**Eaton 2004**

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1); only published abstract available for data extraction
- **Setting:** United Kingdom

**Participants**
- **Total participants enrolled:** 100; (A) = 50, (B) = 50
- **Inclusion criteria:** urodynamically obstructed men
- **Exclusion criteria:** not reported

**Baseline characteristics:**
All were ASA 1/2
Preoperative catheterisation, n: (A) = 15, (B) = 15

**Interventions**
- **Intervention A:** bipolar TURP; technology reported as both Plasmakinetic and Karl Storz (unclear if both Gyrus and Karl Storz instruments were used)
- **Intervention B:** monopolar TURP; irrigation fluid = glycine
Outcomes

**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: not reported

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary Incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- Urethral stricture
- Bladder neck contracture
- UTI
- Bladder neck contracture
- Acute urinary retention
- Mean duration of catheterisation
- Mean duration of hospital stay
- Secondary haemorrhage requiring re-admission
- PVR change

Source of funding
- None reported

Notes
- This is a conference abstract with limited information

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
### Eaton 2004 (Continued)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</th>
<th>Unclear risk</th>
<th>These outcomes were not reported by the trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment on selective reporting. However, study states that IPSS at 12 months was recorded, but no specific outcome data provided - abstract only with no full manuscript identified</td>
</tr>
</tbody>
</table>

### Egui Rojo 2017

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Spain

**Participants**
- **Total participants enrolled:** 77; (A) = 35, (B) = 42
- **Inclusion criteria:** not reported
- **Exclusion criteria:** not reported

**Baseline characteristics:**
- Mean age, years (SD): not reported for individual arms, for both arms: 66 (50 to 82)
- Mean preoperative prostate volume, mL (SD): not reported for individual arms, for both arms: 39 (10 to 69)
- Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (specific technology = not reported)
- **Intervention B:** monopolar TURP (specific technology = not reported, irrigation fluid = not reported)

**Outcomes**
- **Primary outcomes:**
  - IPSS at 12 months: not reported
  - HRQoL at 12 months: not reported
  - TUR syndrome: not reported

**Secondary outcomes:**
- Blood transfusion: not reported
Urinary incontinence at 12 months: not reported
IIEF-5 at 12 months: not reported
Need for re-TURP: not reported

Other reported outcomes:
Retrograde ejaculation
IPSS at IIEF-5 at 1 and 3 months

Source of funding
None reported

Notes
Only abstract available

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment of selective reporting</td>
</tr>
</tbody>
</table>
**El-Assmy 2018**

### Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Egypt

### Participants
- **Total participants enrolled:** 294; (A) = 145, (B) = 149
- **Inclusion criteria:** presenting for BPH surgery; 50 years or older at the time of intervention; married, sexually interested, and having a continuous relationship with the same partner
- **Exclusion criteria:** indwelling catheter for longer than 1 month before intervention to avoid recall bias in filling out questionnaires

#### Baseline characteristics:
- Mean age, years (SD): (A) = 62 (6.3), (B) = 64 (7.7)
- Mean preoperative prostate volume, mL (SD): (A) = 68 (22), (B) = 63 (23)
- Preoperative catheterisation state: not reported explicitly, although patients were excluded if catheterised for > 1 month before intervention

### Interventions
- **Intervention A:** bipolar TURP (specific technology = TUR in Saline-TURis, Olympus SurgMaster UES-40 Bipolar Generator)
- **Intervention B:** monopolar TURP (specific technology = ValleyLab Force FX Electrosurgical Unit, irrigation fluid = glycine)

### Outcomes
- **Primary outcomes:**
  - IPSS at 12 months: appears to be reported but data not clearly attributable to 1 arm of the trial
  - HRQoL at 12 months: appears to be reported but data not clearly attributable to 1 arm of the trial
  - TUR syndrome: not reported

#### Secondary outcomes:
- Blood transfusion: not reported
- Urinary incontinence at 12 months: not reported
- IIEF-5 at 12 months: not reported
- Need for re-TURP: not reported

#### Other reported outcomes:
- IIEF-5 (erectile function) scores
- Orgasmic function
- Mean operation time
- Mean resection weight
- Capsular perforation
- Mean catheter time
- Intercourse satisfaction
- Ejaculatory function (Ej-MSHQ score)

### Source of funding
- None reported

---

**Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)**

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;randomization process was carried out using a computer based software in a 1:1 ratio&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Method of allocation concealment not reported specifically</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded. Study reports blinding of patients</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Reported data for IPSS and QoL could not be attributed to 1 individual arm of the trial; therefore judgement cannot clearly be made</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>Reported data for IPSS and QoL could not be attributed to 1 individual arm of the trial; therefore judgement cannot clearly be made</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Low risk</td>
<td>This study was registered with ClinicalTrials.gov (NCT01810068), with no clear discrepancies between outcomes in protocol and reported study</td>
</tr>
</tbody>
</table>

### Erturhan 2007

**Methods**

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Turkey

**Participants**

- **Total number enrolled:** 240; (A) = 120, (B) = 120
- **Inclusion criteria:** BPE with moderate or severe LUTS (IPSS ≥ 18), significant postvoid residual volume (> 50 mL)
- **Exclusion criteria:** documented/suspected prostate cancer, previous prostatic surgery, urethral stricture, neurogenic bladder disorder
Baseline characteristics:
Unclear if significant differences between arms at baseline (no P values provided)
Mean age, years (range): (A) = 68.5 (52 to 90), (B) = 67.4 (68 to 74)
Mean prostate volume, mL (SD): (A) = 43 (9), (B) = 42 (11)
Preoperative catheterisation state: not reported

Interventions
• Intervention A: bipolar TURP (Gyrus Plasmakinetic Resection, Medicalm UK)
• Intervention B: monopolar TURP (ValleyLab Force EX, glycine 5%)

Outcomes
Primary outcomes:
IPSS (12 months): (A) = 4 (2) (n = 120), (B) = 4 (2) (n = 120)
HRQoL (12 months): (A) = 2 (1) (n = 120), (B) = 2 (1) (n = 120)
TUR syndrome: (A) = 0 (n = 120), (B) = 2 (n = 120)
Secondary outcomes:
Blood transfusion: (A) = 1 (0.83) (n = 120), (B) = 7 (5.83) (n = 120)
Urinary incontinence (12 months): (A) = 0 (n = 120), (B) = 0 (n = 120)
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported
Other reported outcomes:
IPPSS at 1 month
HRQoL at 1 and 12 months
Q\textsubscript{max} (mL/s) at 1, 12 months
Clot retention
Urethral stricture
Bladder neck contracture
Acute urinary retention
Death due to TURP
Mean duration of operation (minutes)
Mean duration of catheterisation (days)
Mean duration of hospital stay (days)
Duration of operation
Perioperative and postoperative irrigation volume
Irrigation duration
Catheterisation duration
Hospitalisation duration

Source of funding
None reported
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment of selective reporting. However, no data were reported for erectile dysfunction outcomes although this is described in the methods section as captured data</td>
</tr>
</tbody>
</table>

### Fagerström 2011

#### Methods
- **Study type:** randomised controlled trial (ratio of randomisation not reported)
- **Setting:** Sweden

#### Participants
- **Total number enrolled:** not specifically reported: 185; (A) = 98, (B) = 87
- **Inclusion criteria:** symptomatic BPH requiring surgery due to failed medical therapy or urinary retention, TRUS estimated prostatic volume 30 to 100 mL
Exclusion criteria: evident prostate or bladder cancer, core biopsy of prostate within 3 months before scheduled surgery, neurogenic bladder dysfunction, urethral stricture

Baseline characteristics:
Not all characteristics comparable at baseline: MTURP patients significantly older (P = 0.007)
Mean age, years (SD): (A) = 69.5 (7.2), (B) = 72.7 (8.4)
Mean preoperative prostate volume, mL (SD); (A) = 55.6 (18.2), (B) = 58.2 (17.6)
Preoperative catheterisation state: (A) = 33, (B) = 34

Interventions
- Intervention A: bipolar TURP (Olympus TURis, Tokyo, Japan)
- Intervention B: monopolar TURP (irrigation fluid = mannitol 3% and ethanol 1%)

Outcomes
Primary outcomes:
IPSS (3, 6, 12, > 12 months): no specific data available – graphical format only
HRQoL (validated questionnaire): not reported
TUR syndrome: (A) = 0 (n = 98), (B) = 3 (n = 87)

Secondary outcomes:
Blood transfusion: (A) = 4 (n = 98), (B) = 10 (n = 87)
Urinary incontinence 12 months: not reported
IIEF-5 at 12 months: not reported
Need for re-TURP: (A) = 0 (n = 98), (B) = 3 (n = 87)

Other reported outcomes:
Urethral stricture
Bladder neck contracture
UTI
Acute urinary retention
Mean duration of operation
Mean Hb decrease (%)
Mean duration of catheterisation (hours)
Mean duration of hospital stay (hours)
Re-admission rate

Source of funding
None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Fagerström 2011 (Continued)

<table>
<thead>
<tr>
<th>Random sequence generation (selection bias): All outcomes</th>
<th>Low risk</th>
<th>Study states: &quot;202 patients were allocated, using a random numbers table, to either TURP using a bipolar system or conventional monopolar technique&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Method of allocation concealment not reported specifically</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) was blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>The number of patients that underwent analysis in each arm is not clearly reported to allow for this assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>The number of patients that underwent analysis in each arm is not clearly reported to allow for this assessment</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full judgement on selective reporting</td>
</tr>
</tbody>
</table>

### Geavlete 2011

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1:1)
- **Setting:** Romania

**Participants**
- **Total number enrolled:** 340; (A) = 170, (B) = 170
- **Inclusion criteria:** BPH and severe LUTS; inclusion criteria consisted of $Q_{max} < 10 \text{ mL/s}$, IPSS > 19, prostate volume between 30 and 80 mL
- **Exclusion criteria:** severe comorbidities, previous prostate surgery, history of prostate cancer, abnormal DRE, increased PSA

**Baseline characteristics:**
- No statistically significant differences between arms reported
- Age: not reported
Mean preoperative prostate volume (mL) (range): (A) = 53.7 (30 to 79), (B) = 54.8 (32 to 80)
Preoperative catheterisation state: not reported

Interventions

- **Intervention A**: bipolar TURP (TURis Olympus SurgMaster, saline)
- **Intervention B**: MTURP (sterile water for irrigation)
- **Intervention C**: Plasmakinetic Vaporisation of the Prostate (no data collected)

Outcomes

**Primary outcomes:**

IPSS (12 months): (A) = 7.5 (2 to 15) (n = 170), (B) = 8.0 (3 to 16) (n = 170)

HRQoL (12 months): not reported

TUR syndrome: (A) = 0 (n = 170), (B) = 3 (n = 170)

**Secondary outcomes:**

Blood transfusion: (A) = 3 (n = 170), (B) = 11 (n = 170)

Urinary incontinence (12 months): data not reported explicitly at 12 months

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): incidence of re-TURP not reported explicitly, only overall re-treatment rates

**Other reported outcomes:**

IPSS at 1, 3, 6, 18 months

Q\textsubscript{max}

Clot retention

Urinary incontinence (unclear timing of assessment)

Urethral stricture

Bladder neck contracture

UTI

Acute urinary retention

Mean duration of operation (minutes)

Mean duration of catheterisation period (hours)

Mean duration of hospital stay (days)

Mean haemoglobin drop (g/dL)

Capsular perforation rate

Rehospitalisation rate

Source of funding

None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Geavlete 2011

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low</td>
<td>Study states: &quot;randomised by means of sealed envelopes&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear</td>
<td>Unclear whether the sealed envelopes were sequentially numbered and opaque</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes</td>
<td>Low</td>
<td>Study states: &quot;during follow-up, both patients as well as the urologists performing the investigations were unaware of treatment modality&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low</td>
<td>Study states: &quot;during follow-up, both patients as well as the urologists performing the investigations were unaware of treatment modality&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear</td>
<td>RCT protocol not available to allow for full assessment on selective reporting</td>
</tr>
</tbody>
</table>

### Ghozzi 2014

**Methods**

- **Study type:** prospective randomised controlled trial
- **Setting:** hospital, France

**Participants**

- **Total number enrolled:** 60; (A) = 31, (B) = 29
- **Inclusion criteria:** benign prostatic hyperplasia, age over 50 years, PSA < 4 ng/mL, no suspicious finding on DRE
- **Exclusion criteria:** documented prostate cancer, bladder tumour, urethral stricture, bladder stone, neurogenic bladder, previous TURP

**Baseline characteristics:**

No statistically significant differences between arms reported
Mean age, years (SD): (A) = 70.25 (7.23), (B) = 68.71 (7.63)
Mean preoperative prostate volume, mL (SD): (A) = 49.5 (6.33), (B) = 49.5 (5.48)

Preoperative catheterisation state: not reported

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Intervention A: bipolar TURP using 0.9% saline irrigation. 27 Fr OLYMPUS Active Bipolar Resectoscope utilising TURis technology</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>• Intervention B: monopolar TURP (1.5% glycine irrigation). 27 Fr OLYMPUS Active Monopolar Resectoscope</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Outcomes

**Primary outcomes:**

IPSS (12 months) (SD): (A) = 2.6 (0.59) (n = 31), 3.1 (1.06) (n = 29)

HRQoL (12 months): not reported

TUR syndrome: (A) = 0 (n = 31), (B) = 2 (n = 29)

**Secondary outcomes:**

Blood transfusion: (A) = 1 (n = 31), (B) = 2 (n = 29)

Urinary incontinence (12 months): not reported

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

Operation duration

Resected tissue amount

Serum sodium change

Haemoglobin change

Haematocrit change

$Q_{\text{max}}$ change

Irrigation duration

Catheterisation duration

Hospitalisation duration

Urethral stricture rate

Bladder contracture

### Source of funding

None reported

### Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
### Ghozzi 2014 (Continued)

<table>
<thead>
<tr>
<th>Source of Bias</th>
<th>Risk of Bias</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported, but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>All participants in bipolar (n = 31/31) and monopolar (29/29) arms appear to be accounted for in analyses</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Low risk</td>
<td>All participants in bipolar (n = 31/31) and monopolar (29/29) arms appear to be accounted for in analyses</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>No RCT protocol available to allow for full assessment of selective reporting</td>
</tr>
</tbody>
</table>

### Giulianelli 2013

**Methods**

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Italy

**Participants**

- **Total number enrolled:** 160; (A) = 80, (B) = 80
- **Inclusion criteria:** LUTS of BPH
- **Exclusion criteria:** documented or suspected prostate surgery, renal impairment, associated hydronephrosis and urethral stricture

**Baseline characteristics:**

- No significant differences between arms reported
  - Mean age, years (SD): (A) = 62.5 (6.9), (B) = 64.18 (7.2)
  - Mean prostate volume, mL (SD): (A) = 47.8 (14.6), (B) = 50 (9.8)

**Interventions**

- **Intervention A:** bipolar TURP; Gyrus Plasmakinetic (PKTURP)
- **Intervention B:** monopolar TURP; irrigation fluid = mannitol/sorbitol solution
Primary outcomes:

IPSS (12 months): (A) = 4.5 (n = 80), (B) = 5.3 (n = 80)
HRQoL (12 months): (A) = 0.9 (n = 80), (B) = 1.5 (n = 80)
TUR syndrome: (A) = 0 (n = 80), (B) = 2 (n = 80)

Secondary outcomes:

Blood transfusion: (A) = 0 (n = 80), (B) = 3 (n = 80)
Urinary incontinence (12 months): (A) = 0 (n = 79), (B) = 0 (n = 75)
Erectile dysfunction (IIEF-5) (12 months): (A) = 24 (n = 80), (B) = 22 (n = 80)
Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:

IPSS at 1, 3, 6, 18, 24, 30, 36 months
HRQoL at 1, 3, 6, 18, 24, 30, 36 months
Q_max
Clot retention
IIEF-5 at 1, 3, 6, 18, 24, 30, 36 months
Bladder neck contracture
UTI
Re-treatment rate (not explicitly re-TURP)
Acute urinary retention
Median duration of operation (minutes)
Median duration of catheterisation (hours)
Median duration of hospital stay (hours)

Source of funding
None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific method of randomisation not clearly reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific method of allocation concealment not clearly reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
</tbody>
</table>
Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)  
**Unclear risk**  
Not reported

Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)  
**Low risk**  
Not reported but objective outcomes unlikely to have been affected

Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)  
**Unclear risk**  
This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically

Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)  
**Unclear risk**  
Study states: "one year after TURP, 154 patients (75 in the monopolar and 79 in the bipolar group) were assessed for urinary continence and number of retreatments"  
This suggests that 6 patients were lost to follow-up with no reported reason for loss to follow-up. Impact of incomplete outcome data on reported differences in outcomes between intervention arms considered unclear

Selective reporting (reporting bias): All outcomes  
**Unclear risk**  
RCT protocol not available to allow for full assessment

**Giulianelli 2013 (Continued)**

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** United Kingdom

**Participants**
- **Total participants enrolled:** 210; (A) = 110, (B) = 100
- **Inclusion criteria:** not reported
- **Exclusion criteria:** not reported

**Baseline characteristics:**
- No significant differences between arms reported
- Mean age, years (SD): (A) = 72, (B) = 73
- Mean preoperative prostate volume, mL: (A) = 68.9, (B) = 69.8
- Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP; Olympus SurgMaster TURis, irrigation fluid = saline
- **Intervention B:** monopolar TURP (glycine), irrigation fluid = glycine

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): not reported
  - HRQoL (12 months): not reported
  - TUR syndrome: (A) = 0 (n = 110), (B) = 3 (n = 100)
### Secondary outcomes:

- Blood transfusion: not reported
- Urinary Incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

### Other reported outcomes:

- Mean duration of resection (minutes)
- Mean postoperative sodium
- Capsular perforation rate

Comparison of resectoscopes in terms of 15 parameters scored by the operating surgeon on a scale of 1 to 10, with higher scores indicating better performance

### Source of funding

None reported

### Notes

This is a conference abstract with limited information. Data for many outcomes are reported as significant or not significant without numerical values. Protocol is available at [http://www.isrctn.com(ISRCTN49628875?q=bipolar%20AND%20prostate%20AND%20Goh&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search](http://www.isrctn.com(ISRCTN49628875?q=bipolar%20AND%20prostate%20AND%20Goh&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search)

"A comparison between the use of transurethral resection of the prostate (TURP) with bipolar cutting loop diathermy for the treatment of benign prostatic hypertrophy (Goh; Southmead Hospital, Bristol, UK)"

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this study</td>
</tr>
</tbody>
</table>
### Goh 2009 (Continued)

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</th>
<th>Unclear risk</th>
<th>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment. However, abstract states that IPSS was recorded at 12 months, but these data are not reported, and it does not appear that they have been published</td>
</tr>
</tbody>
</table>

### He 2010

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

**Participants**
- **Total participants enrolled:** 300; (A) = 150, (B) = 150
- **Inclusion criteria:** symptomatic BPH that required surgery owing to urinary retention or failed medical therapy
- **Exclusion criteria:** severe medical disease, previous prostatic or urethral surgery, prostate cancer, acontractile detrusor

**Baseline characteristics:**
- No significant differences between arms reported
- Mean age, years (SD): (A) = 72.5 (4.0), (B) = 71.9 (3.1)
- Mean preoperative prostate volume, mL (SD): (A) = 45.0 (5.5), (B) = 46.1 (6.3)
- Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Gyrus Transurethral Bipolar Electrosurgical System)
- **Intervention B:** monopolar TURP (Wolf 26 F Storz Electrosurgical Generator), irrigation fluid = 5% mannitol

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): not reported
  - HRQoL (12 months): not reported
  - TUR syndrome: (A) = 0 (n = 142), (B) = 5 (n = 139)
- **Secondary outcomes:**
  - Blood transfusion: (A) = 1 (n = 142), (B) = 3 (n = 139)
  - Urinary incontinence (12 months): not reported (only data at 3 months available)
  - Erectile dysfunction (IIEF-5) (12 months): not reported
  - Need for repeat TURP (i.e. re-TURP): Not reported
Other reported outcomes:

- IPSS at 3 months, no specific data available for 6 and 12 months
- Mean QoL at 3 months
- $Q_{\text{max}}$ (mL/s)
- Clot retention
- Incontinence (3 months)
- Urethral stricture
- Bladder neck contracture
- Duration of operation (minutes)
- Duration of catheterisation (days)
- Duration of hospital stay (days)
- Change in postoperative serum sodium (Na+)

Source of funding

None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>All participants in bipolar (n = 142/142) and monopolar (139/139) arms appear to be accounted for in analyses, with no reported loss to follow-up for these outcomes</td>
</tr>
</tbody>
</table>
Incomplete outcome data 
(attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)

Unclear risk

These outcomes were not reported by trial authors

Selective reporting (reporting bias): All outcomes

Unclear risk

RCT protocol not available to allow for full assessment

**He 2007**

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Singapore

**Participants**
- **Total number enrolled:** 100; (A) = 48, (B) = 52
- **Inclusion criteria:** > 50 years, fit for anaesthesia, failed medical therapy with alpha-blockers or 5-alpha reductase inhibitors, IPSS > 18, Q\textsubscript{max} < 15 mL/s, acute urinary retention, failed trial of void without urinary catheter
- **Exclusion criteria:** documented or suspected prostate cancer, bladder calculus, neurogenic bladder, previous prostate surgery, renal impairment, associated hydronephrosis, urethral stricture

**Baseline characteristics**

No significant differences between arms reported

Mean age, years (SD): (A) = 66.6 (6.8), (B) = 66.5 (7.2)

Mean preoperative prostate volume, mL: (A) = 56.5 (17.9), (B) = 54.8 (19.2)

Preoperative catheterisation status: (A) = 24 (n = 48), (B) = 21 (n = 52)

**Interventions**
- **Intervention A:** bipolar TURP (Olympus TURIS System)
- **Intervention B:** monopolar TURP (irrigation fluid = glycine 5%)

**Outcomes**

**Primary outcomes:**

- IPSS (12 months): specific data not provided, in graphical format only
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 48), (B) = 2 (n = 52)

**Secondary outcomes:**

- Blood transfusion: (A) = 1 (n = 48), (B) = 1 (n = 52)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

- Q\textsubscript{max}
- Clot retention
- Urethral stricture
## UTI

### Acute urinary retention

- Mean resection time
- Mean reduction in postoperative serum Na+
- Mean reduction in postoperative haemoglobin

### Source of funding

None reported

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;patients included in the study were computer randomized in a 1:1 ratio into two groups&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific methods to ensure allocation concealment not clearly reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study states: &quot;all patients had at least one year follow-up&quot;; all patients (n = 48 for bipolar, n = 52 for monopolar TURP) appear to have been included in the final analyses for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>Study states: &quot;all patients had at least one year follow-up&quot;; however, data for IPSS at 12 months are provided only in graphical format with no specific data provided; therefore, full interpretation of data is not possible</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>
### Methods
- **Study type:** single-centre, RCT (1:1)
- **Setting:** China

### Participants
- **Total number enrolled:** 136; (A) = 71, (B) = 65
- **Inclusion criteria:** symptomatic BPH, > 50 years, medication failure, International Prostate Symptom Score (IPSS) > 16, maximum flow rate ($Q_{\text{max}}$) < 15 mL/s, prostate volume of 30 to 80 mL estimated on transrectal ultrasound (TRUS)
- **Exclusion criteria:** documented or suspected prostate cancer, neurogenic bladder, bladder calculus or tumour, previous prostate surgery, urethral stricture, parafunction of blood coagulability

**Baseline characteristics:**
- No significant differences between arms reported.
  - Mean age, years (SD): (A) 65.08 (4.19) (n = 71), (B) 64.55 (3.67) (n = 65) ($P = 0.613$)
  - Mean preoperative prostate volume, mL (SD): (A) = 52.92 (10.60), (B) = 50.08 (10.84) ($P = 0.101$)
  - Preoperative catheterisation state: not reported

### Interventions
- **Intervention A:** bipolar TURP (Gyrus), irrigation fluid = 0.9% saline
- **Intervention B:** monopolar TURP (Storz), irrigation fluid = mannitol 5% solution

### Outcomes
**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: not reported

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- Clot retention
- Drop in sodium (mmol/L)
- Drop in haemoglobin (g/dL)
- Duration of operation (minutes)
- Operation duration
- Capsular perforation
- Postoperative bleeding

### Source of funding
None reported

### Notes

---

**Huang 2012**

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Huang 2012 (Continued)

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;randomization was done by the opaque envelope method&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study reports use of opaque envelopes to ensure allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for assessment</td>
</tr>
</tbody>
</table>

### Iori 2008

#### Methods

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Italy

#### Participants

- **Total number enrolled:** 53; (A) = 27, (B) = 26
- **Included:** LUTS secondary to BPO
- **Exclusion criteria:** neurological illness, renal insufficiency, bladder stone, urethral stricture, taking finasteride

**Baseline characteristics**
Iori 2008 (Continued)

No significant differences between arms reported

Mean age, years (SD): (A) = 65 (5), (B) = 63 (5)
Mean prostate volume, cm³ (SD): (A) = 49 (11), (B) = 48 (9)

**Interventions**

- **Intervention A**: bipolar TURP (Gyrus PlasmaKinetic); irrigation fluid = 0.9% saline
- **Intervention B**: monopolar TURP; irrigation fluid = mannitol

**Outcomes**

**Primary outcomes:**

- IPSS (12 months): mean IPSS at 12 months (SD): (A) = 7.0 (1.7) (n = 27), (B) = 6.7 (4) (n = 26)
- HRQoL (12 months): (A) = 1 (1) (n = 27), (B) = 1 (1) (n = 26)
- TUR syndrome: (A) = 0 (n = 27), (B) = 0 (n = 26)

**Secondary outcomes:**

- Blood transfusion: (A) = 0 (n = 27), (B) = 0 (n = 26)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

- Mean $Q_{max}$ (mL/s)
- Clot retention
- Acute urinary retention
- Mean resection time (minutes)
- Mean catheterisation time (hours)
- Mean postoperative hospital stay (hours)
- Mean reduction in Hb at 24 hours postop (g/dL)

**Source of funding** None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: “the patients were randomized 1:1, using envelopes, into two groups”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study states: “the patients were randomized 1:1, using envelopes, into two groups”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unclear whether the envelopes were sealed, sequentially numbered, and opaque</td>
</tr>
</tbody>
</table>
Iori 2008 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes specifically</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

Kadyan 2014

Methods

- **Study type:** single-centre randomised controlled trial (1:1); only published abstract available for data extraction
- **Setting:** India

Participants

- **Total participants enrolled:** 110; (A) = not reported, (B) = not reported
- **Inclusion criteria:** > 50 years, DRE benign gland, gland volume > 50 mL, PSA < 4 ng/mL, LUTS with BEP, urine culture -ve
- **Exclusion criteria:** suspected prostate cancer, neurogenic bladder, bladder malignancy, previous prostate surgery, stricture urethra, vesical calculus, renal impairment

  **Baseline characteristics:** specific data not provided in abstract

  **Preoperative catheterisation, n:** (A) = and (B) = not reported

Interventions

- **Intervention A:** bipolar TURP; specific technology used not reported
- **Intervention B:** monopolar TURP; irrigation fluid not reported

Outcomes

Primary outcomes:

IPSS (12 months): not reported
Kaday 2014 (Continued)

HRQoL (12 months): not reported
TUR syndrome: not reported

Secondary outcomes:
Blood transfusion: not reported
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:
Resection duration
Serum sodium level change
IPSS change
Q_max change

Source of funding
None reported

Notes
This is a conference abstract with limited information

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeons were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
</tbody>
</table>
**Kadyan 2014** (Continued)

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</th>
<th>Unclear risk</th>
<th>These outcomes were not reported by the trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

**Kim 2006**

**Methods**
- **Study type:** parallel RCT
- **Setting:** inpatient/single centre/South Korea
- **Ethnicity:** not reported
- **Study duration:** August 2003 to October 2004

**Participants**
- **Total participants enrolled:** 50 (Intervention A = 25/Intervention B = 25)
- **Inclusion criteria:** aged 50 or over with IPSS score higher than 8, Q\textsubscript{max} lower than 15 mL/s, prostate volume 30 to 120 mL on the basis of the TRUS test
- **Exclusion criteria:** younger than 50 years of age, neurogenic bladder disorder, bladder cancer, prostate cancer, history of prostate surgery, medications taken that may have influenced functioning of the bladder, suspected to have a bladder abnormality and a disease in the lower part of the ureter without BPH in urodynamical study

**Baseline characteristics:** no significant differences between interventions in IPSS, Q\textsubscript{max}, and prostate volume, but no report on differences in age

Mean age, years (SD): (A) = 68.1 (8.9), (B) = 70.6 (7.5)

Mean prostate volume, mL: (A) = 53.2 (14.9), (B) = 51.7 (19.1)

**Interventions**
- **Intervention A:** bipolar TURP; Gyrus Plasma Kinetic Resectoscope
- **Intervention B:** monopolar TURP; for irrigating fluid, Urion liquid was used

**Outcomes**

**Primary outcomes:**
- IPSS (12 months): not reported (only at 1 and 6 months)
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 25), (B) = 0 (n = 25)

**Secondary outcomes:**
- Blood transfusion: (A) = 0 (n = 25), (B) = 2 (n = 25)
- Urinary incontinence (12 months): not reported explicitly at 12 months
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- Resection duration
- Serum sodium level change
Kim 2006 (Continued)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin level change</td>
<td>None reported</td>
<td></td>
</tr>
<tr>
<td>Catheterisation duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalisation duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPSS change</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resection volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q_max change</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source of funding None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to be affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>
Komura 2015

Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Japan

Participants
- **Total number enrolled:** 136; (A) = 69, (B) = 67
- **Inclusion criteria:** age > 50 years, Eastern Cooperative Oncology Group performance status ≤ 2; acute urinary retention if catheter removal failed after therapy with alpha-blockers, chronic urinary retention unresponsive to medical therapies, IPSS ≥ 15
- **Exclusion criteria:** suspected prostate cancer, bladder calculus, previous prostate surgery, men taking 5-alpha reductase inhibitor preoperative medication

Baseline characteristics
No significant differences between arms reported
- Mean age, years (SD): (A) = 69.8 (5.8), (B) = 68.0 (5.4)
- Mean preoperative prostate volume, mL (SD): (A) = 50.9 (17.2), (B) = 53.0 (20.1)
- Preoperative indwelling catheter: (A) = 6, (B) = 7

Interventions
- **Intervention A:** bipolar TURP; TURIs (Olympus, Tokyo, Japan); irrigation fluid = 0.9% saline
- **Intervention B:** monopolar TURP; irrigation fluid = 4% mannitol solution, 1% ethanol

Outcomes

Primary outcomes:
- IPSS (12 months): (A) = 7.6 (3.5) (n = 52), (B) = 8.3 (2.3) (n = 58)
- HRQoL (12 months): 12 months: (A) = 4.4 (3.9) (n = 52), (B) = 4.1 (5.4) (n = 58)
- TUR syndrome: (A) = 0 (n = 63), (B) = 0 (n = 61)

Secondary outcomes:
- Blood transfusion: (A) = 1 (n = 63), (B) = 4 (n = 61)
- Urinary incontinence (12 months): not reported (data available only at 3 months)
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:
- IPSS at 24 and 36 months
- HRQoL at 24 and 36 months
- Mean Q\text{max}
- Clot retention
- Urinary incontinence at 3 months
- Urethral stricture and bladder neck contracture
- UTI
- Acute urinary retention
- Mean reduction in postoperative Na (mEq/L)
- Mean reduction in postoperative Hb (g/dL)
Komura 2015 (Continued)

Incidence of epididymitis
Mean duration of catheterisation time (hours)
Mean hospitalisation duration (days)
Mean duration of operation (minutes)

Source of funding
None reported

Notes
Protocol is available at https://upload.umin.ac.jp/cgi-open-bin/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000012628&language=E

"Multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate" (UMIN000010801)

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: “randomisation was performed using a stratified permuted randomisation algorithm (1:1)”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study states: “randomisation was performed using a stratified permuted randomisation algorithm (1:1)”</td>
</tr>
<tr>
<td>Any specific measures to ensure allocation concealment not reported explicitly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>&quot;The nature of the intervention made blinding of the treatment providers impossible and thus the surgeon was not blinded; however, both the outcome assessors and the patients were blinded with regard to the intervention type (double-blind RCT)&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Low risk</td>
<td>&quot;The nature of the intervention made blinding of the treatment providers impossible and thus the surgeon was not blinded; however, both the outcome assessors and the patients were blinded with regard to the intervention type (double-blind RCT)&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>&quot;The nature of the intervention made blinding of the treatment providers impossible and thus the surgeon was not blinded; however, both the outcome assessors and the patients were blinded with regard to the intervention type (double-blind RCT)&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports loss of follow-up at n = 1 for MTURP and n = 0 for BTURP for these perioperative outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>All patients (n = 58 for MTURP and n = 52 for BTURP), including those lost to follow-up (n = 9 for MTURP, n = 17 for BTURP), were accounted for in the reported analyses. Considered unclear how loss to follow-up may have impacted observed differences in outcomes between arms</td>
</tr>
</tbody>
</table>
Komura 2015 (Continued)

Selective reporting (reporting bias): All outcomes

The study protocol is available. The report includes all expected outcomes, including those that were prespecified.

Kong 2009

Methods

- Study type: single-centre randomised controlled trial (1:1)
- Setting: Malaysia

Participants

- Total number enrolled: 102; (A) = 51, (B) = 51
- Inclusion criteria: moderate to severe LUTS that failed medical treatment, complications of BOO or catheter dependency
- Exclusion criteria: American Society of Anesthesiologists Score > 2, pacemaker, suspected or known prostate cancer, concurrent bladder stone, previous bladder neck surgery

Baseline characteristics:

No significant differences between treatment arms reported

Mean age, years (SD): (A) = 68.44 (7.33), (B) = 68.53 (6.69)

Mean preoperative prostate volumes, mL: (A) = 41.8 (9.8), (B) = 43.1 (10.94)

Interventions

- Intervention A: bipolar TURP; Gyrus Plasmakinetic Resection (PKRP); irrigation fluid = saline
- Intervention B: monopolar TURP; Pfizer Electrosurgical Instrument System; irrigation fluid = glycine

Outcomes

Primary outcomes:

IPSS (12 months): not reported
HRQoL (12 months): not reported
TUR syndrome: (A) = 0 (n = 51), (B) = 0 (n = 51)

Secondary outcomes:

Blood transfusion: (A) = 0 (n = 51), (B) = 2 (n = 51)
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:

IPSS at 1 month
HRQoL at 1 month
Q_{max}
Acute urinary retention
Mean reduction in haemoglobin (g/dL)
Mean reduction in serum sodium (mmol/l)
Mean duration of catheterisation (hours)
Mean duration of hospital stay (days)
## Kong 2009 (Continued)

### Duration of operation

| Source of funding | None reported |

### Notes

<table>
<thead>
<tr>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bias</strong></td>
</tr>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
</tr>
</tbody>
</table>

## Kumar 2013

### Methods

- **Study type:** single-centre randomised controlled trial (1:1:1)
- **Setting:** India

### Participants

- **Total number enrolled:** 117; (A) = 57, (B) = 60

---

**Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)**

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Inclusion criteria: LUTS secondary to BPE, age ≥ 50, IPSS > 7, prostate volume measured by transrectal ultrasound (TRUS): > 20 and < 80 mL, Qmax < 15 mL/s

Exclusion criteria: history of prostate, bladder, or urethral surgery; spinal surgery or spinal trauma; neurological disease; postvoid residual urine (PVRU) > 300 mL; indwelling Foley catheter where indication for catheterisation was chronic retention (PVRU > 300 mL); diagnosis of carcinoma of the prostate; carcinoma of the bladder; urethral stricture; those receiving antiplatelet drugs for whom drugs could not be safely stopped perioperatively; not giving written informed consent

Baseline characteristics:

No significant differences between arms reported

Mean age, years (SD): (A) = 62.31 (6.36), (B) = 63.68 (6.57)

Mean preoperative prostate volume, mL (SD): (A) = 50.26 (16.50), (B) = 52.20 (15.93)

Interventions

- Intervention A: bipolar TURP; Gyrus ACM Plasmakinetic System; irrigation fluid = 0.9% saline
- Intervention B: monopolar TURP, irrigation fluid = glycine
- Intervention C: third arm of RCT included Photoselective Vaporisation of the Prostate (PVP) with green light laser; no data were collected as not an intervention of interest

Outcomes

Primary outcomes:

- IPSS (12 months): (A) = 6.94 (1.22) (n = 52), (B) = 7.07 (1.22) (n = 57)
- HRQoL (12 months): (A) = 1.67 (0.61) (n = 52), (B) = 1.59 (0.65) (n = 57)
- TUR syndrome: (A) = 0 (n = 57), (B) = 1 (1.66) (n = 60)

Secondary outcomes:

- Blood transfusion: (A) = 3 (n = 57), (B) = 7 (n = 60)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): (A) = 16.30 (2.59) (n = 52), (B) = 16.17 (2.36) (n = 57)

Need for repeat TURP (i.e. re-TURP): data provided for “re-operation” but not specifically for re-TURP

Other reported outcomes:

- IPSS at 1, 3, 6, > 12 months
- HRQoL at 1, 3, 6, > 12 months
- Qmax
- IIEF-5 at 1, 3, 6, > 12 months
- Clot retention
- Urethral stricture and bladder neck contracture
- UTI
- Acute urinary retention
- Mean duration of operation
- Mean duration of catheterisation
- Duration and volume of irrigation fluid used postoperatively
- Haemoglobin level change
Kumar 2013 (Continued)

Incidence of transient dysuria

Source of funding
None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;eligible patients were randomized into three groups using a computer generated randomization table of equal numbers&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific measures to ensure allocation concealment during randomisation process not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports that all patients (n = 60 for MTURP, n = 57 for BTURP) were included in analyses for these perioperative outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>Study reports loss to follow-up of n = 3 for MTURP and n = 5 for BTURP for these outcomes. Considered unclear how this loss to follow-up may have impacted observed differences in outcomes between arms</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

Lin 2006

Methods
- Study type: single-centre RCT (1:1)
- Setting: Taiwan

Participants
- Total number enrolled: 40; (A) = 22, (B) = 18
Lin 2006 (Continued)

- **Inclusion criteria:** LUTS due to BPH
- **Exclusion criteria:** evidence of suspicion of prostate or bladder malignancy, bladder stones and/or bladder diverticulum, urethral stricture, IPSS < 15, $Q_{\text{max}} > 15$, neurogenic bladder disorder, previous surgical treatments for BPH

**Baseline characteristics:**

No significant differences between arms reported.

Mean age, years (SD): (A) = 69.0 (no SD) (n = 22), (B) = 69.0 (no SD) (n = 24) (P = 0.891)

Mean preoperative prostate volume (grams) (SD): not reported.

Preoperative catheterisation state: not reported.

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Primary outcomes:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention A (bipolar):</strong> Vista CTR; irrigation fluid = saline</td>
<td><strong>IPSS (12 months):</strong> values provided only for median (rather than mean) IPSS at 12 months: (A) = 15.5 (no SD) (n = 22), (B) = 18.5 (no SD) (n = 18)</td>
</tr>
<tr>
<td><strong>Intervention B (monopolar):</strong> Vista CTR; irrigation fluid = distilled water</td>
<td><strong>HRQoL (12 months):</strong> not reported</td>
</tr>
</tbody>
</table>

**Secondary outcomes:**

Blood transfusion: not reported

Urinary incontinence (12 months): not reported

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

IPSS at 6 months

$Q_{\text{max}}$

Clot retention and evacuation

Bladder neck contracture

Resection time (minutes) (SD): (A) = 50.0 (no SD) (n = 22), (B) = 47.5 (no SD) (n = 18)

Change in serum sodium levels, mEq/L (SD): (A) = -0.91 (3.56), (B) = -7.94 (5.12)

Change in haemoglobin, g/dL (SD): (A) = -0.62 (0.59), (B) = -0.64 (0.41)

**Source of funding**

None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Lin 2006 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;patients were randomized using opaque envelopes&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study reports use of &quot;opaque envelopes&quot; to ensure allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the study</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the study</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Low risk</td>
<td>Study states: &quot;none of the patients were lost to follow-up&quot;</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Mamoulakis 2013

**Methods**
- **Study type:** multi-centre RCT (1:1)
- **Settings:** Netherlands, Greece, Italy, Germany

**Participants**
- **Total number enrolled:** 279; (A) = 141, (B) = 139
- **Inclusion criteria:** benign prostatic obstruction, $Q_{\text{max}} < 15$, IPSS $> 13$, voided volume $> 125$ mL, indwelling/intermittent catheterisation
- **Exclusion criteria:** suspected malignant disease of the lower urinary tract, including prostate cancer, impaired detrusor function (neurogenic bladder, postvoid residual urine volume $> 400$ mL), active UTI, 5-alpha reductase inhibitor or alpha blocker consumption within the last 3 months or 2 weeks before surgery, cardiovascular disease necessitating anticoagulation continuation that might jeopardise outcome, immunosuppression

**Baseline characteristics:**
Mamoulakis 2013 (Continued)

No significant differences between arms reported

Mean age, years (SD): (A) 69.3 (8.5) (n = 135), (B) 68.4 (8.2) (n = 120) (P = 0.525)

Mean preoperative prostate volume, grams (SD): (A) = 63.8 (29.4) (n = 135), (B) = 63.5 (30.8) (n = 120) (P = 0.939)

Preoperative catheterisation state: (A) = 47 (n = 135), (B) = 47 (n = 120)

Interventions

- **Intervention A**: bipolar TURP (Autocon II 400 ESU Karl Storz)
- **Intervention B**: monopolar TURP (Karl Storz), irrigation fluid = hypotonic solution as irrigation fluid (multi-centre): Centre 1 (Netherlands) sorbitol 5%, Centre 2 (Germany) sorbitol-mannitol, Centre 3 (Greece) water for injection, Centre 4 (Italy) glycine

Outcomes

**Primary outcomes:**

IPSS (12 months) (SD): not catheterised preop: (A) = 7.7 (4.0) (n = 88), (B) = 7.5 (4.8) (n = 73)*; catheterised preop: (A) = 7.1 (4.5) (n = 47), (B) = 5.5 (4.8) (n = 47)

HRQoL (12 months) (SD): not catheterised preop: (A) = 1.1 (1.0) (n = 88), (B) = 1.1 (1.2) (n = 73)*; catheterised preop (A) = 1.3 (0.8) (n = 47), (B) = 0.9 (1.1) (n = 47)

*Non-catheterised patients were included in the meta-analyses

TUR syndrome: (A) = 0 (n = 141), (B) = 1 (n = 138)

**Secondary outcomes:**

Blood transfusion: (A) = 9 (n = 141), (B) = 4 (n = 138)

Urinary incontinence (12 months): not reported

Erectile dysfunction (IIEF-5) (12 months): data provided for IIEF-15 scores only

Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

IPSS at 24 to 36 months

QoL at 24 to 36 months

$Q_{\text{max}}$

Clot retention

Urethral stricture/Bladder neck contracture

Acute urinary retention

Hospitalisation time

Sodium drop (mmol/L)

Haemoglobin drop (mmol/L)

Duration of operation (minutes)

Catheterisation time (days)

Capsular perforation rate

Hospitalisation duration

Source of funding

"We acknowledge the support of Karl Storz Endoscope"
**Mamoulakis 2013 (Continued)**

Notes  
Protocol is available at http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=703

"A prospective, randomized, double-blinded study to compare bipolar trans urethral resection of the prostate (bipolar TURP) versus monopolar trans urethral resection of the prostate (monopolar TURP) in terms of safety and efficacy" (NTR 703)

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;randomization numbers were assigned using a stratified permuted computer algorithm after completing eligibility screening&quot; (Mamoulakis 2012)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;randomization was performed within 24 h prior to treatment application, which was done blindly among centres through the central electronic system to minimize potential selection bias and guarantee allocation concealment&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Study reports that surgeons were not blinded due to the nature of interventions</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Low risk</td>
<td>Study states: &quot;outcome assessors and patients were both blinded for the intervention type (double-blind RCT)&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Study states: &quot;outcome assessors and patients were both blinded for the intervention type (double-blind RCT)&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study states that all participants were included in analysis for these outcomes, except n = 1/139 in the MTURP arm was excluded because of incidental bladder cancer</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>At 12 months, differential loss to follow-up between arms; at 12 months, n = 121 analysed in MTURP arm (n = 139 received intervention) and n = 135 analysed in BTURP arm (n = 141 received intervention). The subsequent impact of loss to follow-up on observed differences in outcomes between arms was considered unclear</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Low risk</td>
<td>The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way</td>
</tr>
</tbody>
</table>

**Mei 2010**

Methods  
- **Study type:** single-centre randomised controlled trial (1:1)  
- **Setting:** China
Participants

- **Total participants enrolled:** 146; (A) = 73, (B) = 73
- **Inclusion criteria:** symptomatic BPH that required surgery owing to urinary retention or failed medical therapy
- **Exclusion criteria:** neurogenic bladder dysfunction, previous prostatic or urethral surgery, prostate cancer, bladder cancer, severe medical disease

**Baseline characteristics:**

- No significant differences between arms reported
- Mean age (SD): (A) = 72.1 (4.4), (B) = 71.6 (5.1)
- Mean preoperative prostate volume, mL (SD): (A) = 55.5 (6.3), (B) = 53.6 (5.2)
- Preoperative catheterisation state: not reported

Interventions

- **Intervention A:** bipolar TURP (Gyrus Electrosurgical System)
- **Intervention B:** monopolar TURP (WOLF Electrosurgical System, irrigation fluid = 5% mannitol)

Outcomes

**Primary outcomes:**

- IPSS (12 months): data available only at 3 and 6 months
- HRQoL (12 months): data available only at 3 and 6 months
- TUR syndrome: (A) = 0 (n = 73), (B) = 2 (n = 73)

**Secondary outcomes:**

- Blood transfusion: (A) = 1 (n = 73), (B) = 4 (n = 73)
- Urinary incontinence (12 months): reported only at 6 months
- Erectile dysfunction (IIEF-5) (12 months): no specific data provided
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

- Mean $Q_{\text{max}}$
- Urethral stricture
- Mean duration of operation (minutes)
- Mean duration of catheterisation (days)
- Mean change in postoperative serum sodium ($Na^+$)
- Mean reduction in postoperative haemoglobin (Hb)

**Source of funding**

None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
Mei 2010 (Continued)

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias): All outcomes</th>
<th>Unclear risk</th>
<th>Not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>All included participants (n = 73 in monopolar and n = 73 in bipolar arms) included in analyses for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

Michielsen 2007

**Methods**
- **Study type:** single-centre RCT (1:1)
- **Setting:** Belgium

**Participants**
- **Total number enrolled:** 518; (A) = 263, (B) = 255
- **Inclusion criteria:** bladder obstruction due to BPH, IPSS ≥ 13, QoL ≥ 3, Qmax < 15 mL/s
- **Exclusion criteria:** neurogenic bladder, prostate cancer, previous prostatic or urethral surgery, bladder stones, receiving anticoagulant therapy

**Baseline characteristics**
- No significant differences between arms reported
- Mean age, years (SD): (A) = 72.5 (9.2), (B) = 72.4 (9.0)
- Mean preoperative prostate volume, mL (SD): (A) = 45.0 (18.3), (B) = 53.9 (23.6)
- Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Olympus SurgMaster), irrigation fluid = saline
Michielsen 2007 (Continued)

- **Intervention B:** monopolar TURP (Olympus), irrigation fluid = glycine 1.5%

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Primary outcomes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IPSS (12 months): not reported</td>
</tr>
<tr>
<td></td>
<td>HRQoL (12 months): not reported</td>
</tr>
<tr>
<td></td>
<td>TUR syndrome: (A) = 0 (n = 285), (B) = 2 (n = 265)</td>
</tr>
</tbody>
</table>

**Secondary outcomes:**
- Blood transfusion: (A) = 4 (n = 118), (B) = 1 (n = 120)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported; only treatment rates for urethral stricture as postoperative complication reported

**Other reported outcomes:**
- Clot retention
- Urethral stricture
- Acute urinary retention
- Drop in sodium level
- Drop in haemoglobin
- Duration of operation (minutes)
- Duration of catheterisation (days)
- Hospitalisation time (days)

**Source of funding**
- None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>&quot;After initial cystoscopy and examination with the patient under anesthesia the patient was randomized to monopolar TURP or bipolar TURIS by drawing a closed envelope&quot; (Michielsen 2007; Michielsen 2010; Michielsen 2010b)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported if envelopes were opaque, or if other measures were taken to ensure allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Study reported as &quot;unblinded study&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR</td>
<td>High risk</td>
<td>Study reported as &quot;unblinded study&quot;</td>
</tr>
</tbody>
</table>
### Michielsen 2007 (Continued)

**syndrome, Urinary Incontinence**

<table>
<thead>
<tr>
<th>Source:</th>
<th>Low risk</th>
<th>Study reported as “unblinded study” but objective outcomes unlikely to have been affected</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</strong></td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td><strong>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</strong></td>
<td>Unclear risk</td>
<td>These outcomes were not reported by this trial</td>
</tr>
<tr>
<td><strong>Selective reporting (reporting bias): All outcomes</strong></td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>

---

### Méndez-Probst 2011

**Methods**

- **Study type:** multi-centre, randomised controlled trial (1:1)
- **Setting:** 5 Canadian centres, Canada

**Participants**

- **Total number enrolled:** 43; (A) = 22, (B) = 21
- **Inclusion criteria:** LUTS suggestive of BPH, peak urinary flow rates < 12 mL/s, American Urological Association (AUA) symptom scores > 12, acute urinary retention
- **Exclusion criteria:** previous prostatic surgery (open or transurethral), urethral stricture, failure to discontinue alpha-adrenergic blocking agents for at least 14 days before surgery, failure to discontinue 5-alpha reductase inhibitor for at least 1 month before surgery, interest in future fertility, known neurogenic bladder dysfunction, untreated urinary tract infection, American Society of Anesthesiology (ASA) class > III, requiring anticoagulation, unwilling or unable to comply with the follow-up schedule

**Baseline characteristics:**

- No significant differences between arms reported
- Mean age years: (A) = 68 (7), (B) = 67 (7)
- Mean preoperative prostate volume, grams (SD): (A) = 57.92 (25.56), (B) = 50.23 (20.74)
- Preoperative catheterisation state: (A) = 6 (n = 22), (B) = 6 (n = 21)

**Interventions**

- **Intervention A:** bipolar TURP (VISTA, ACM), irrigation fluid = not explicitly stated. Assumed normal saline
- **Intervention B:** monopolar TURP (ERBE, Marietta, GA, or ValleyLab, Tyco Healthcare Group LP), irrigation fluid = not explicitly stated

**Outcomes**

**Primary outcomes:**

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
TUR syndrome: (A) = 0 (n = 22), (B) = 0 (n = 21)

**Secondary outcomes:**

Blood transfusion: (A) = 0 (n = 22), (B) = 0 (n = 21)

Urinary incontinence (12 months): not reported explicitly at 12 months

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

AUA QoL not reported explicitly at 12 months

\( Q_{\text{max}} \) (mL/s)

Urethral stricture

Bladder neck contracture

UTI

Acute urinary retention

Duration of operation (minutes)

Duration of bladder irrigation (minutes)

Duration of postop catheterisation (days)

Duration of hospital stay (days)

Haemoglobin change

Serum sodium change

Incidence of haematuria requiring intervention

Incidence of dysuria/overactive bladder symptoms

**Source of funding**

Study authors received funding from Olympus/ACMI. This investigator-initiated study was supported by ACMI Canada. All sites received financial support and investigative product

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported; considered unlikely that operating surgeon(s) were blinded</td>
</tr>
</tbody>
</table>
### Méndez-Probst 2011 (Continued)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</th>
<th>Unclear risk</th>
<th>Not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>Not reported; objective outcomes unlikely to have been affected</td>
<td></td>
</tr>
<tr>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
<td></td>
</tr>
<tr>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
<td></td>
</tr>
<tr>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
<td></td>
</tr>
</tbody>
</table>

### Nasution 2017

#### Methods
- **Study type:** multi-centre randomised controlled trial (1:1:1)
- **Setting:** 3 Indonesian centres

#### Participants
- **Total number enrolled:** 220; (A) = 80, (B) = 76, (C) = 64
- **Inclusion criteria:** BPH and urinary retention planning for surgery
- **Exclusion criteria:** not reported

**Baseline characteristics:**

No significant differences between arms reported

Mean age, years: not reported

Mean preoperative prostate volume, grams (SD): 46.63 (12.33) (both arms)

Preoperative catheterisation state: not reported

#### Interventions
- **Intervention A:** bipolar TURP, irrigation fluid = not explicitly stated. Assumed normal saline
- **Intervention B:** monopolar TURP, irrigation fluid = not explicitly stated
- **Intervention C:** Thulium Laser Vaporesection

#### Outcomes
**Primary outcomes:**

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR Syndrome: not reported
Secondary outcomes:
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:
- Mean operation time
- Catheterisation time
- Hospital stay
- Mean change in haemoglobin
- Mean change in sodium level

Source of funding

Notes
Only abstract proceedings available

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias):</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation concealment (selection bias):</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>High risk</td>
<td>Not reported; considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>(performance bias): All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias):</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>outcomes (Blood transfusion, Re-TURP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias):</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)

Unclear risk  These outcomes were not reported

Selective reporting (reporting bias): All outcomes

Unclear risk  RCT protocol not available to allow for full assessment

Nasution 2017 (Continued)

Methods

- Study type: single-centre randomised controlled trial (1:1)
- Setting: Turkey

Participants

- Total number enrolled: 57; (A) = 27, (B) = 30
- Inclusion criteria: diagnosis of BPH, LUTS, I-PSS > 15, Qmax < 10 mL/s
- Exclusion criteria: prostate/urethra surgery, suspicion of prostate cancer, neurogenic bladder

Baseline characteristics:

No significant differences between arms reported

Mean age, years (SD): (A) = 65.2 (9.3) (B) = 64.6 (8.8)

Mean preoperative prostate volume, grams (SD): (A) = 47 (7.7), (B) = 49 (8.1)

Interventions

- Intervention A: bipolar (Gyrus), irrigation fluid = saline
- Intervention B: monopolar (Storz), irrigation fluid = glycine

Outcomes

Primary outcomes:

IPSS (12 months): (A) = 5.4 ± 3.7 (n = 24), (B) = 5.2 ± 3.2 (n = 26)

HRQoL (12 months): not reported

TUR syndrome: (A) = 0 (n = 27), (B) = 0 (n = 30)

Secondary outcomes:

Blood transfusion: (A) = 1 (n = 27), (B) = 2 (n = 30)

Urinary incontinence (12 months): not reported

Erectile dysfunction (IIEF-5) (12 months): not reported

Need for repeat TURP (i.e. re-TURP): (A) = 0 (n = 27), (B) = 0 (n = 30)

Other reported outcomes:

IPSS at 1 month

Qmax (mL/s)

Acute urinary retention

Urethral stricture

Duration operation (minutes)
Nuhoglu 2006 (Continued)

- Duration of catheter (hours)
- Haemoglobin level change
- Serum sodium level change

Source of funding

None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study states: &quot;patients randomly divided into two groups&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No description of how randomisation was undertaken</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study states: &quot;patients randomly divided into two groups&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unclear if steps undertaken to ensure allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported; considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study states that all participants were included in all analyses up to 1-month follow-up</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>Study reports loss to follow-up of n = 4/30 for MTURP and 3/27 for BTURP with specific reasons provided. Considered unclear how loss to follow-up may have impacted observed differences between arms</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

Patankar 2006

Methods

- **Study type:** single-centre randomised controlled trial (1:1)
• Setting: India

Participants
• Total participants enrolled: 512; (A) = 261, (B) = 251
• Inclusion criteria: men older than 45 years, AUA score ≥ 18, prostate volume 35 to 70 mL, $Q_{\text{max}} \leq 10$ mL/s
• Exclusion criteria: previous prostate surgery or prostate cancer

Baseline characteristics:
No statistically significant differences between arms reported
Mean age, years (SD): (A) = and (B)=; not clear which data refer to which intervention arm
Mean preoperative prostate volume, mL (SD): (A) = 51.3 (12.44), (B) = 52.26 (10.71)
Preoperative catheterisation status: not reported

Interventions
• Intervention A: bipolar TURP (PK Superpulse)
• Intervention B: monopolar TURP (irrigation fluid = glycine)

Outcomes
Primary outcomes:
IPSS (12 months): not reported
HRQoL (12 months): not reported
TUR syndrome: (A) = 0 (n = 52), (B) = 2 (n = 51)

Secondary outcomes:
Blood transfusion: (A) = 0 (n = 52), (B) = 1 (n = 51)
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:
UTI
Duration of operation
Catheterisation duration
Change in serum sodium level
Clot retention rate
Urethral stricture

Source of funding
None reported

Notes

Risk of bias

Bias  Authors' judgement  Support for judgement
Random sequence generation (selection bias): All outcomes  Low risk  Study states: "randomization was done by the opaque envelope method"
### Patankar 2006 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allocation concealment</strong></td>
<td>Low</td>
<td>Study states: &quot;opaque envelopes&quot; were used for allocation concealment</td>
</tr>
<tr>
<td><strong>Blinding of participants and personnel</strong></td>
<td>High</td>
<td>Not reported if operating surgeon(s) were blinded but considered unlikely; study reports that participants were blinded</td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment</strong></td>
<td>Low</td>
<td>Study states: &quot;participants were blinded regarding the treatment modality they were undergoing, as was the staff that did the outcome assessment and decided when to remove the catheter&quot;</td>
</tr>
<tr>
<td><strong>Incomplete outcome data</strong></td>
<td>Low</td>
<td>Study states: n = 1/53 patients were lost to follow-up in the BTURP arm, with no patients in the MTURP arm lost to follow-up</td>
</tr>
<tr>
<td><strong>Incomplete outcome data</strong></td>
<td>Unclear</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td><strong>Selective reporting</strong></td>
<td>Unclear</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Qian 2014

<table>
<thead>
<tr>
<th>Methods</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study type</strong></td>
<td>Study type: single-centre randomised controlled trial (1:1)</td>
<td></td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Setting: China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total participants enrolled</strong></td>
<td>Total participants enrolled: 150; (A) = 75, (B) = 75</td>
<td></td>
</tr>
<tr>
<td><strong>Inclusion criteria</strong></td>
<td>Inclusion criteria: symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
<td></td>
</tr>
<tr>
<td><strong>Exclusion criteria</strong></td>
<td>Exclusion criteria: neurogenic bladder dysfunction, previous prostatic or urethral surgery, prostate cancer, bladder cancer, severe medical disease</td>
<td></td>
</tr>
<tr>
<td><strong>Baseline characteristics:</strong></td>
<td>Baseline characteristics: No significant differences between arms reported</td>
<td></td>
</tr>
<tr>
<td>Mean age, years (SD)</td>
<td>Mean age, years (SD): (A) = 61.1 (10.9), (B) = 60.4 (11.3)</td>
<td></td>
</tr>
<tr>
<td>Mean preoperative prostate volume, mL (SD)</td>
<td>Mean preoperative prostate volume, mL (SD): (A) = 59.1 (8.2), (B) = 59.5 (8.6)</td>
<td></td>
</tr>
</tbody>
</table>
Qian 2014 (Continued)

Preoperative catheterisation state: not reported

Interventions

- **Intervention A**: bipolar TURP (technology not reported)
- **Intervention B**: monopolar TURP (irrigation fluid not reported)

Outcomes

**Primary outcomes:**

IPSS (12 months): not reported explicitly at 12 months
HRQoL (12 months): not reported explicitly at 12 months
TUR syndrome: not reported

**Secondary outcomes:**

Blood transfusion: not reported
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): reported only for 8-month follow-up
Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

Mean Q$_{\text{max}}$
Erectile dysfunction (IIEF-5 at 8 months)
Mean duration of operation (minutes)
Mean duration of catheterisation (days)
Mean duration of hospital stay (days)

Source of funding

None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Describes use of random number tables - no specific quotation available due to Chinese translation</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Describes use of random number tables; unclear if additional measures were used to ensure allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported; considered unlikely that blinding surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
</tbody>
</table>
### Qian 2014 (Continued)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</th>
<th>Unclear risk</th>
<th>These outcomes were not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Rojo 2018

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Spain

**Participants**
- **Total participants enrolled:** 100; (A) = 42, (B) = 58
- **Inclusion criteria:** refractory BPH (no response to oral treatment), acute urine retention, repetitive urinary tract infection
- **Exclusion criteria:** prostate cancer, previous pelvis surgery, previous pelvic radiotherapy, cognitive problems to follow study instructions

**Baseline characteristics:**
- No significant differences between arms reported
  - Mean age, years (SD): (A) = 66.3 (6.8), (B) = 66.32 (7.5)
  - Mean preoperative prostate volume, mL (SD): (A) = 41.35 (17.1), (B) = 37.02 (16.7)
  - Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (technology not reported)
- **Intervention B:** monopolar TURP (irrigation fluid = glycine)

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): not reported explicitly at 12 months
  - HRQoL (12 months): not reported
  - TUR syndrome: not reported
- **Secondary outcomes:**
  - Blood transfusion: not reported
  - Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): not reported at 12 months

Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:

Retrograde ejaculation

Source of funding

None reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>In methods section, study authors state: ”randomization under a cross sequence of numbers 1:1”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Describes use of cross-section of numbers for randomisation; unclear if additional measures were used to ensure allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Study reported blinding of participants; blinding of surgeons not reported but considered unlikely that this was undertaken</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study authors state that IIEF-5 tool was used to measure erectile function outcomes. However, specific data are not provided, but rather only use of the phrase &quot;erec tile problems&quot; when referring to data. Considered unclear how this may have impacted overall findings</td>
</tr>
</tbody>
</table>
### Rose 2007

#### Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Germany

#### Participants
- **Total participants enrolled:** 72 (A) = 38, (B) = 34
- **Inclusion criteria:** not reported

**Baseline characteristics:**
- No significant differences between arms reported
- Mean age, years (SD): not reported specifically for BTURP and MTURP arms
- Mean preoperative prostate volume, mL (SD): not reported
- Preoperative catheterisation state: not reported

#### Interventions
- **Intervention A:** bipolar TURP (TURIS Olympus)
- **Intervention B:** monopolar TURP (irrigation fluid = mannitol)

#### Outcomes

**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 38), (B) = 0 (n = 34)

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- Duration of operation
- Catheterisation duration
- Hospitalisation duration
- Serum sodium level drop
- Haemoglobin level drop

#### Source of funding
- No clear source reported from translation

#### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Specific method used for randomisation not completely clear: &quot;the distribution in each surgical procedure took randomly place in two operating theaters, in one of which a conventional resectoscope was installed, in the other a TURis resectoscope was installed&quot;</td>
</tr>
</tbody>
</table>
### Rose 2007 (Continued)

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias): All outcomes</th>
<th>Unclear risk</th>
<th>Specific method used for randomisation not completely clear: “the distribution in each surgical procedure took randomly place in two operating theaters, in one of which a conventional resectoscope was installed, in the other a TURis resectoscope was installed”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>All participants (n = 38 for BTURP and n = 34 for MTURP) were included in the analyses for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Seckiner 2006

#### Methods
- **Study type**: single-centre RCT (1:1)
- **Setting**: Turkey

#### Participants
- **Total number enrolled**: 48, (A) = 24, (B) = 24
- **Inclusion criteria**: IPSS > 8, Qmax = 15 mL/s, prostate volume 30 to 70 g on transrectal ultrasonography
- **Exclusion criteria**: < 50 years of age; those with a known neurogenic bladder, cancer of the prostate or bladder, history of prostate surgery, currently on medication known to affect voiding function

**Baseline characteristics:**

No significant differences between arms reported

Mean age, years (SD): (A) = 61.2 (9.3) (n = 24), (B) = 63.9 (10.9) (n = 24)

Mean preoperative prostate volume, grams (SD): (A) = 49.4 (18.9) (n = 24), (B) = 41.4 (14.5) (n = 24)

Preoperative catheterisation state: not reported
### Interventions
- **Intervention A**: bipolar TURP (Gyrus), irrigation fluid = saline
- **Intervention B**: monopolar (Karl Storz), irrigation fluid = glycine

### Outcomes

#### Primary outcomes:
- IPSS (12 months) (SD): (A) = 8.7 (4.1) (n = 23), (B) = 8.3 (2.9) (n = 21)
- HRQoL (12 months) (SD): (A) = 1.8 (0.8) (n = 23), (B) = 2.0 (0.8) (n = 21)
- TUR syndrome: (A) = 0 (n = 24), (B) = 0 (n = 24)

#### Secondary outcomes:
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

#### Other reported outcomes:
- $Q_{\text{max}}$ (1, 3, 6, 12 months)
- Urethral stricture rate
- Mean duration of operation
- Mean duration of catheterisation
- Haemoglobin level change
- Serum sodium level change

### Source of funding
None reported

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Study states: &quot;patients were randomized 1:1&quot;, but no information on method of randomisation reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
**Seckiner 2006 (Continued)**

<table>
<thead>
<tr>
<th>Outcome Assessment</th>
<th>Bias Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports inclusion of all participants (n = 24/24 for MTURP and n = 24/24 for BTURP) for analysis of these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>12-month data are not reported for 3 patients in MTURP arm and for 1 patient in BTURP arm. No reasons for missing data provided; considered unclear how missing data may have impacted observed differences between arms</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>

**Shaik 2017**

**Methods**
- **Study type:** single-centre RCT (1:1)
- **Setting:** India

**Participants**
- **Total number enrolled:** 60; (A) = 32 (B) = 28
- **Inclusion criteria:** not reported
- **Exclusion criteria:** not reported

**Baseline characteristics:**
No significant differences between arms reported
- Mean age, years (SD): not reported for individual arms, mean age for both arms: 72 years (3)
- Mean preoperative prostate volume, mL (SD): not reported for individual arms, mean volume for both arms: 71 (5)
- Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (specific technology not reported), irrigation fluid/specific technology not reported
- **Intervention B:** monopolar (specific technology not reported), irrigation fluid/specific technology not reported

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): no specific data reported, although study reports this outcome as recorded
  - HRQoL (12 months): not reported
  - TUR syndrome: not reported
- **Secondary outcomes:**
  - Blood transfusion: not reported
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:
Resection time
Postoperative catheterisation duration
Duration of hospital stay

Source of funding
None reported

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported by the trial</td>
</tr>
</tbody>
</table>
Shaik 2017 (Continued)

Selective reporting (reporting bias): All outcomes Unclear risk

RCT protocol not available to allow for full assessment of selective reporting. However, this study reports IPSS at 12 months as recorded but no specific data provided within published abstract.

Singh 2005

Methods
- **Study type:** single-centre, RCT (1:1)
- **Setting:** India

Participants
- **Total number enrolled:** 60, (A) = 30, (B) = 30
- **Inclusion criteria:** symptomatic benign prostatic hyperplasia (BPH) requiring surgical intervention, chronic retention with Schäfer obstruction grade 2
- **Exclusion criteria:** IPSS < 7, Qmax > 12 mL/s, PCAR < 0.75 on transrectal ultrasonography, neurological illness, renal insufficiency, bladder stone, urethral stricture, taking finasteride

**Baseline characteristics:**
Not reported whether baseline characteristics significantly different. No P values
Mean age, years (SD): (A) 68.9 (7.6) (n = 30), (B) 67.9 (9.8) (n = 30). P not reported
Mean preoperative prostate volume: not reported
Preoperative catheterisation state: not reported

Interventions
- **Intervention A:** bipolar TURP (ACMI Corp), irrigation fluid = saline with 1% ethanol
- **Intervention B:** monopolar TURP (Valley Laboratory), irrigation fluid = not stated

Outcomes

**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 30), (B) = 0 (n = 30)

**Secondary outcomes:**
- Blood transfusion: (A) = 0 (n = 30), (B) = 1 (n = 30)
- Urinary incontinence (12 months): reported only at 4 weeks
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- IPSS at 1, 3 months
- HRQoL at 1, 3 months
- Qmax at 1, 3 months
- Urinary incontinence at 4 weeks
- Urethral stricture
- Bladder neck contracture
- UTI
Singh 2005 (Continued)

<table>
<thead>
<tr>
<th>Source of funding</th>
<th>None reported</th>
</tr>
</thead>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>“Patients were randomized 1:1 using envelopes into two groups...”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>“Patients were randomized 1:1 using envelopes into two groups...”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unclear whether the envelopes were sealed, sequentially numbered, and opaque</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>
Singhania 2010

Methods

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** India

Participants

- **Total number enrolled:** 60; (A) = 30, (B) = 30
- **Inclusion criteria:** failed medical therapy, acute urinary retention with failed voiding trial, recurrent urinary tract infection and haematuria, documented or suspected prostate cancer, neurogenic bladder, previous prostate surgery, urethral stricture, bladder stones, renal impairment
- **Exclusion criteria:** documented or suspected prostate cancer, neurogenic bladder, previous prostate cancer, neurogenic bladder, previous prostate surgery, urethral stricture, associated bladder stones, renal impairment

**Baseline characteristics:**

Only limited data for baseline characteristics provided for comparison

Mean age (SD): (A) = 63.86 (6.1), (B) = 65.96 (6.6)

Mean preoperative prostate volume: not reported

Preoperative catheterisation status: not reported

Interventions

- **Intervention A:** bipolar TURP (Gyrus PK Bipolar Resection System), irrigation fluid = normal saline
- **Intervention B:** monopolar TURP (Erbee); 1.5%, irrigation fluid = glycine

Outcomes

**Primary outcomes:**

- IPSS (12 months): (A) = 6.13 (0.94), (B) = 6.23 (0.94)
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 30), (B) = 0 (n = 30)

**Secondary outcomes:**

- Blood transfusion: (A) = 0 (n = 30), (B) = 0 (n = 30)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): (A) = 0 (n = 30), (B) = 0 (n = 30)

**Other reported outcomes:**

- Mean IPSS at 1, 3, 6 months
- Mean Q$_{max}$ at 1, 3, 6, 12 months
- Clot retention
- Urethral stricture
- Bladder neck contracture
- UTI
- Mean duration of operation (minutes)
- Mean decline in serum sodium (mEq/L)
- Mean decline in haemoglobin (g %)
Singhania 2010 (Continued)

Postoperative incidence of epididymitis

Source of funding
From the research society, BYL Nair Hospital

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;they were divided into two groups using standard randomization codes&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Any steps taken to ensure allocation concealment were not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

Stucki 2014

Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** Switzerland

Participants
- **Total number enrolled:** 137; (A) = 70, (B) = 67
• **Included**: presence of LUTS and relevant reduction in IPSS QoL and/or significant PVR > 100 mL refractory to medical therapy with alpha-blockers and/or 5 alpha-reductase inhibitors, BPH with acute urinary retention, failed TWOC

• **Exclusion criteria**: neurogenic bladder, prostate cancer, previous prostatic/urethral surgery, bleeding disorders

**Baseline characteristics:**

No significant differences between arms reported

Mean age, years (SD): (A) = 67 (none), (B) = 66 (none)

Median preoperative prostate volume (cm³) (SD): (A) = 34 (none) (n = 67), (B) = 35 (none) (n = 66)

Preoperative catheterisation state: not reported

**Interventions**

• **Intervention A**: bipolar TURP (Gyrus), irrigation fluid = 0.9% saline

• **Intervention B**: monopolar TURP (Karl Storz), irrigation fluid = sorbitol/mannitol

**Outcomes**

**Primary outcomes:**

- IPSS (12 months): no numerical values reported
- HRQoL (12 months): no numerical values reported
- TUR syndrome: (A) = 0 (n = 70), (B) = 1 (n = 67)

**Secondary outcomes:**

- Blood transfusion: (A) = 1 (n = 70), (B) = 1 (n = 67)
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

- Clot retention
- Urethral stricture
- Bladder neck stricture
- Need for reoperation for procedures (other than re-TURP)
- Duration of operation (median minutes)
- Duration of catheterisation (median days)
- Duration of hospital stay (median days)
- Haemoglobin level change
- Clot retention rate

**Source of funding**

None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)
### Stucki 2014 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;were computer randomized at a 1:1 ratio&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>High risk</td>
<td>Study reports that n = 46/67 and n = 43/70 of participants in monopolar and bipolar arms, respectively, were included in 12-month IPSS follow-up analysis. No reasons for incomplete data are reported. This was considered to represent significant loss to follow-up not accounted for in the analyses</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Symons 2002

**Methods**
- **Study type:** single-centre randomised controlled trial (2:1)
- **Setting:** United Kingdom

**Participants**
- **Total number enrolled:** 45; (A) = 32, (B) = 13
- **Inclusion criteria:** clinical diagnosis of BPH with bladder outflow obstruction
- **Exclusion criteria:** not reported

**Baseline characteristics:**
- No significant differences between arms reported
- Mean age (SD): not reported
- Mean preoperative prostate volume: not reported
Preoperative catheterisation status: not reported

Interventions

- **Intervention A**: bipolar TURP; Gyrus Plasmakinetic Electrosurgical System, irrigation fluid = saline
- **Intervention B**: monopolar TURP, irrigation fluid = 1.5% glycine

Outcomes

**Primary outcomes:**
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: not reported

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

Source of funding

None reported

Notes

This is a conference abstract with limited information

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
</tbody>
</table>
### Symons 2002 (Continued)

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</th>
<th>Unclear risk</th>
<th>These outcomes were not reported; only abstract available with limited reported data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Terrone 2006

**Methods**
- **Study type:** single-centre RCT; randomisation ratio not reported
- **Setting:** Italy

**Participants**
- **Total number enrolled:** 50; (A) = not reported, (B) = not reported
- **Inclusion criteria:** bothersome LUTS
- **Exclusion criteria:** not reported

**Baseline characteristics**
- Study reports no significant differences between arms but specific data not available
- Mean age (SD): not reported
- Mean preoperative prostate volume: not reported
- Preoperative catheterisation status: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Vista CTR Bipolar Resection System, ACMI)
- **Intervention B:** monopolar TURP; specific irrigation fluid not reported

**Outcomes**

**Primary outcomes:**
- IPSS (12 months): unclear which values refer to specific arms of the trial
- HRQoL (12 months): unclear which values refer to specific arms of the trial
- TUR syndrome: not reported

**Secondary outcomes:**
- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
- $Q_{max}$: data provided only for range of improvement; not possible to determine which values refer to specific arms of the trial
- Mean duration of catheterisation
- Mean duration of procedure (minutes)
- Mean postoperative haemoglobin (g/dL)
## Terrone 2006 (Continued)

**Mean postoperative sodium (mmol/L)**

**Source of funding**  
None reported

**Notes**  
This is a conference abstract with limited information

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>No evidence that these outcomes were recorded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>It is unclear which data refer to which arms of the trial; therefore presented data cannot be fully interpreted to allow for full judgement</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

## Wang 2007

**Methods**

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

**Participants**

- **Total participants enrolled:** 164; (A) = 82, (B) = 82
Wang 2007 (Continued)

- **Inclusion criteria:** symptomatic BPH that required surgery owing to urinary retention or failed medical therapy
- **Exclusion criteria:** neurogenic bladder dysfunction, previous prostatic or urethral surgery, prostate cancer, bladder cancer, severe medical disease

**Baseline characteristics:**
No significant differences between arms reported
Mean age (SD): (A) = 70.0 (4.2), (B) = 70.5 (4.6)
Mean preoperative prostate volume, mL (SD): (A) = 57.9 (5.8), (B) = 58.6 (5.6)
Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Gyrus F27 Electrosurgical System)
- **Intervention B:** monopolar TURP (WOLF Electrosurgical System), irrigation fluid = 5% mannitol

**Outcomes**

<table>
<thead>
<tr>
<th>Primary outcomes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPSS (12 months): not reported</td>
</tr>
<tr>
<td>HRQoL (12 months): not reported</td>
</tr>
<tr>
<td>TUR syndrome: (A) = 0 (n = 72), (B) = 2 (n = 76)</td>
</tr>
</tbody>
</table>

**Secondary outcomes:**
Blood transfusion: not reported
Urinary incontinence (12 months): reported only at 6 months
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**
IPSS at 3 months (data for 6/12 months available only in graphical format with no specific data)
QoL at 3 months
$Q_{\text{max}}$ (mL/s)
Urinary incontinence at 6 months
Urethral stricture
Bladder neck contracture
Mean duration of operation (minutes)
Mean duration of catheterisation (days)
Mean duration of hospital stay (days)
Mean change in postoperative serum sodium (Na+) (mEq/L)
Mean reduction in postoperative haemoglobin (Hb) (g/dL)

**Source of funding**
None reported

**Notes**
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports that all participants (n = 76 in monopolar and n = 72 in bipolar arms) were included in the analysis for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Wu 2005

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

**Participants**
- **Total participants enrolled:** 400; (A) = 200, (B) = 200
- **Inclusion criteria:** symptomatic BPH that required surgery owing to urinary retention or failed medical therapy
- **Exclusion criteria:** prostate cancer

**Baseline characteristics:**
No significant differences between arms reported
Mean age, years (range): (A) = 74.1 (58 to 91), (B) = 73.8 (56 to 90)
Mean preoperative prostate volume, grams (SD): (A) = 56.3 (40.2), (B) = 49.3 (36.6)
Preoperative catheterisation state: not reported

**Interventions**

- **Intervention A:** bipolar TURP (Gyrus 27F Stoze Electrosurgical System)
- **Intervention B:** monopolar TURP (WOLF Electrosurgical System, irrigation fluid = 5% glucose)

**Outcomes**

**Primary outcomes:**
Mean IPSS (12 months): not reported (only 6 months)
Mean QoL (12 months): not reported (only 6 months)
TUR syndrome: (A) = 0 (n = 200), (B) = 5 (n = 200)

**Secondary outcomes:**
Blood transfusion: (A) = 0 (n = 200), (B) = 18 (n = 200)
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5, 12 months): not reported explicitly at 12 months
Need for re-TURP: not reported

**Other reported outcomes:**
Mean duration of operation
Mean change in postoperative serum sodium
Mean change in postoperative haemoglobin

**Source of funding**
None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
### Wu 2005 (Continued)

**syndrome, Urinary Incontinence**

<table>
<thead>
<tr>
<th>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</th>
<th>Low risk</th>
<th>Not reported but objective outcomes unlikely to have been affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports that all participants (n = 200 in both arms) were included in analyses for these perioperative outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/ IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Xie 2012

**Methods**
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

**Participants**
- **Total number enrolled:** 220; (A) = 110, (B) = 110
- **Inclusion criteria:** BPO, maximal flow rate ($Q_{max}$) < 15 mL/s, > 45 years of age, prostate volume on transrectal ultrasound > 20 g, medication (5α-reductase inhibitors or α-blockers) failure
- **Exclusion criteria:** renal impairment, neurovesical dysfunction, bladder calculus, prostate carcinoma, previous history of prostatic or urethral surgery, urethral stricture, hydronephrosis

**Baseline characteristics:**
- No significant difference between arms reported
  - Mean age, years (SD): (A) = 69.95 (11.54), (B) = 64.91 (10.92)
  - Mean preoperative prostate volume, mL (SD): (A) = 65.86 (17.32), (B) = 67.00 (18.93)
  - Preoperative catheterisation state: not reported

**Interventions**
- **Intervention A:** bipolar TURP (Gyrus), irrigation fluid = saline
- **Intervention B:** monopolar (Olympus), irrigation fluid = glycine 1.5%

**Outcomes**
- **Primary outcomes:**
  - IPSS (12 months): (A) = 6.50 ± 2.03* (n = nr), (B) = 6.79 ± 2.59* (n = nr)
  - HRQoL (12 months): (A) = 2.15 ± 0.58* (n = nr), (B) = 2.56 ± 0.97* (n = nr)
  - TUR syndrome: (A) = 0 (n = 110), (B) = 2 (n = 110)

**Secondary outcomes:**
- Blood transfusion: (A) = 0 (n = 110), (B) = 2 (n = 110)
Urinary incontinence (12 months): reported only at 6 months
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): (A) = 3 (n = nr), (B) = 3 (n = nr)

**Other reported outcomes:**

IPSS at 24, 36, 48, 60 months (n = unclear except for 60 months)
HRQoL at 24, 36, 48, 60 months
Q\text{max} at 12, 24, 36, 48, 60 months
Clot retention
Urethral stricture
Bladder neck stenosis
UTI
Acute urinary retention
Mean drop in sodium (mmol/L)
Mean drop in haemoglobin (g/dL)
Mean operative time (minutes)
Postoperative irrigation time (hours)
Mean catheterisation duration (days)
Mean hospital stay (days)

**Source of funding**
None reported

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Low risk</td>
<td>&quot;Randomization was performed using the opaque envelope method&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Low risk</td>
<td>Study states: &quot;opaque envelopes were used as method of allocation concealment&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Study states: &quot;neither the patient nor the surgeon was blinded to the type of the procedure performed&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>High risk</td>
<td>Study reports that patients were not blinded to allocated arm</td>
</tr>
</tbody>
</table>

Study states: "one independent investigator, who was blinded to the type of surgery, performed the 1-, 6-, 12-, 24-, 36-, 48-, and 60-month follow-ups"
Study authors considered that IPSS, HRQoL, IIEF-5, and urinary incontinence are primarily patient-reported symptoms
Xie 2012 (Continued)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</th>
<th>Low risk</th>
<th>&quot;One independent investigator, who was blinded to the type of surgery, performed the 1-, 6-, 12-, 24-, 36-, 48-, and 60-month follow-ups&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports that all participants (n = 110 in each arm) were included in analyses for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Low risk</td>
<td>Study does not specifically report on completeness of outcome data nor loss to follow-up at 1 year for these outcomes - only at 5 years</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>

Xin 2007

Methods

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

Participants

- **Total participants enrolled:** 130; (A) = 65, (B) = 65
- **Inclusion criteria:** not reported
- **Exclusion criteria:** not reported

**Baseline characteristics:**

Not clear if significant differences reported between arms

Mean age (SD): not reported

Mean preoperative prostate volume (mL) (SD): not reported

Preoperative catheterisation status: not reported

Interventions

- **Intervention A:** bipolar TURP (Plasmakinetic TURP, Gyrus device)
- **Intervention B:** monopolar TURP, irrigation fluid = not reported

Outcomes

**Primary outcomes:**

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 65), (B) = 3 (n = 65)

**Secondary outcomes:**

- Blood transfusion: not reported
- Urinary incontinence (12 months): not reported
- Erectile dysfunction (IIEF-5) (12 months): not reported
**Need for repeat TURP (i.e. re-TURP):** not reported

**Other reported outcomes:**
- Mean decrease in postoperative serum sodium (mmol/L)
- Mean decrease in postoperative Hb (gram/L)

<table>
<thead>
<tr>
<th>Source of funding</th>
<th>None reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notes</td>
<td>This is a conference abstract with limited information</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>
### Xin 2009

#### Methods
- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

<table>
<thead>
<tr>
<th>Participants</th>
<th>Study type: single-centre randomised controlled trial (1:1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total participants enrolled:</strong> 160; (A) = 80, (B) = 80</td>
<td>Study type: single-centre randomised controlled trial (1:1)</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
<td>Study type: single-centre randomised controlled trial (1:1)</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong> neurogenic bladder dysfunction, prostate cancer, bladder cancer, severe medical disease, detrusor weakness</td>
<td>Study type: single-centre randomised controlled trial (1:1)</td>
</tr>
</tbody>
</table>

**Baseline characteristics:**

No significant differences between arms reported

- Mean age, years (SD): (A) = 69.0 (6.6), (B) = 66.0 (7.2)
- Mean preoperative prostate volume, mL (SD): (A) = 51.4 (19.5), (B) = 53.0 (19.2)
- Preoperative catheterisation state: not reported

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Intervention A: bipolar TURP (Gyrus Electrosurgical System)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention B:</strong> monopolar TURP (WOLF F26 Storz Electrosurgical System), irrigation fluid = 1.5% glycine</td>
<td>Intervention A: bipolar TURP (Gyrus Electrosurgical System)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Primary outcomes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPSS (12 months): reported only at 6 months</td>
<td>Primary outcomes:</td>
</tr>
<tr>
<td>HRQoL (12 months): reported only at 6 months</td>
<td>Primary outcomes:</td>
</tr>
<tr>
<td>TUR syndrome: (A) = 0 (n = 76), (B) = 5 (n = 77)</td>
<td>Primary outcomes:</td>
</tr>
</tbody>
</table>

**Secondary outcomes:**

- Blood transfusion: (A) = 2 (n = 76), (B) = 13 (n = 77)
- Urinary incontinence (12 months): reported only at 6 months
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

**Other reported outcomes:**

- Mean Q\(_{\text{max}}\) (mL/s) (6 months)
- Urethral stricture
- Mean duration of catheterisation (days)
- Mean duration of hospital stay (days)

#### Source of funding
- None reported

#### Notes

---

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

---

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Methods

- **Study type:** single-centre randomised controlled trial (1:1)
- **Setting:** China

### Participants

- **Total participants enrolled:** 64; (A) = 32, (B) = 32
- **Inclusion criteria:** symptomatic BPH that required surgery owing to urinary retention or failed medical therapy
- **Exclusion criteria:** neurogenic bladder dysfunction, prostate cancer

#### Baseline characteristics:

No significant differences between arms reported

- Mean age, years (range): (A) = 69.5 (55 to 84), (B) = 68.2 (53 to 84)
- Mean preoperative prostate volume, mL (range): (A) = 54.4 (30 to 102), (B) = 53.6 (36 to 92)
Preoperative catheterisation state: 2 in group A were catheterised for retention

Interventions
- **Intervention A**: bipolar TURP (Gyrus Electrosurgical System)
- **Intervention B**: monopolar TURP (WOLF Electrosurgical System), irrigation fluid = 1.5% glycine

Outcomes

### Primary outcomes:
- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 32), (B) = 1 (n = 32)

### Secondary outcomes:
- Blood transfusion: (A) = 0 (n = 32), (B) = 3 (n = 32)
- Urinary incontinence (12 months): reported only at 6 months
- Erectile dysfunction (IIEF-5) (12 months): not reported
- Need for repeat TURP (i.e. re-TURP): not reported

### Other reported outcomes:
- IPSS: reported at 3 months, results for 6 and 12 months only reported in graphical format
- QoL reported at 3 months only
- Mean $Q_{\text{max}}$ (mL/s)
- Mean duration of operation (minutes)
- Mean duration of catheterisation (days)
- Mean duration of hospital stay (days)
- Mean change in postoperative serum sodium (Na$^+$) (mEq/L)
- Mean reduction in postoperative haemoglobin (Hb) (g/dL)

Source of funding
None reported

Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias):</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
### Xue 2008 (Continued)

Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence)

<table>
<thead>
<tr>
<th>Outcome Assessment</th>
<th>Risk Assessment</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</td>
<td>Low risk</td>
<td>Not reported but objective outcomes unlikely to have been affected</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Objective outcomes (TUR syndrome, Blood transfusion)</td>
<td>Low risk</td>
<td>Study reports that all participants (n = 32 in bipolar and n = 32 in monopolar arm) have been included in analyses for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

### Yang 2004

Methods

- **Study type**: single-centre randomised controlled trial (1:1)
- **Setting**: Taiwan

Participants

- **Total number enrolled**: 117; (A) = 58, (B) = 59
- **Inclusion criteria**: confirmed bladder outlet obstruction caused by BPH and about to undergo surgical management (TURP); high PSA but with significant comorbid disease or old age not suitable or unwilling to undergo radical surgery
- **Exclusion criteria**: medical history suggesting little or no improvement in voiding symptoms after surgical management

**Baseline characteristics:**

- No significant differences between arms reported
- Mean age, years (SD): not reported
- Mean preoperative prostate volume, mL (SD): (A) = 45.8 (n = 58), (B) = 48.9 (n = 59)
- Preoperative catheterisation state: not reported

Interventions

- **Intervention A**: bipolar TURP (Gyrus Plasmasect), irrigation fluid = normal saline
- **Intervention B**: monopolar TURP, irrigation fluid = distilled water

Outcomes

**Primary outcomes:**

- IPSS (12 months): not reported
- HRQoL (12 months): not reported
- TUR syndrome: (A) = 0 (n = 58), (B) = 1 (n = 59)
Secondary outcomes:

Blood transfusion: (A) = 1 (n = 58), (B) = 1 (n = 59)

Urinary incontinence (12 months): not reported specifically at 12 months

Erectile dysfunction (IIEF-5) (12 months): not reported specifically at 12 months

Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:

IPSS at 3 months
QoL at 3 months
Qmax (mL/s)

IIEF-5 at 3 months

Urethral stricture

Acute urinary retention

Mean drop in postoperative haemoglobin (g/dL)

Mean drop in postoperative Na (mEq/L)

Frequency of retrograde ejaculation

Mean duration of operation (minutes)

Mean duration of irrigation (hours)

Mean duration of catheterisation (days)

Mean duration of hospital stay (days)

Source of funding

None reported

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias): All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): All outcomes</td>
<td>High risk</td>
<td>Not reported but considered unlikely that operating surgeon(s) were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
Yang 2004 (Continued)

syndrome, Urinary Incontinence)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment: Objective outcomes (Blood transfusion, Re-TURP)</th>
<th>Low risk</th>
<th>Not reported but objective outcomes unlikely to have been affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</td>
<td>Unclear risk</td>
<td>This study does not explicitly report on attrition, exclusion of participants from analyses, or the presence of incomplete outcome data for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol could not be identified to allow for full assessment</td>
</tr>
</tbody>
</table>

Yousef 2010

Methods

- Study type: single-centre, single-blinded RCT (1:1:1)
- Setting: Tanta, Egypt

Participants

- Total number enrolled: 360; (A) = 120, (B) = 120, (C) = 120
- Inclusion criteria: symptomatic BPH
- Exclusion criteria: bleeding disorders or existing coagulopathy, diabetes mellitus, metabolic acidosis, apparent cardiac disease with ECG evidence of ischaemia, history of myocardial infarction/congestive cardiac failure, renal insufficiency, contraindication to spinal anaesthesia

Baseline characteristics:

No significant differences between arms reported
Mean age, years (SD): (A) = 62 (6.5), (B) = 60.7 (5.1), (C) = 60.9 (4.9)
Mean preoperative prostate volume, grams (SD): not reported
Preoperative catheterisation state: not reported

Interventions

- Intervention A: bipolar TURP (Storez, Tottling, Germany), irrigation fluid = normal saline
- Intervention B: monopolar TURP (Storez, Tottling, Germany), irrigation fluid = glycine 1.5%
- Intervention C: monopolar TURP (Storez, Tottling, Germany), irrigation fluid = glucose 5%

Outcomes

Primary outcomes:

IPSS (12 months): not reported
HRQoL (12 months): not reported
TUR syndrome: (A) = 0 (n = 120) (B) = 17 (n = 240)

Secondary outcomes:
Blood transfusion: (A) = 0 (n = 120), (B) = 4 (n = 240)
Urinary incontinence (12 months): not reported
Erectile dysfunction (IIEF-5) (12 months): not reported
Need for repeat TURP (i.e. re-TURP): not reported

Other reported outcomes:
- Clot retention
- Acute urinary retention
- Mean duration of operation
- Mean duration of postoperative catheterisation
- Mean duration of hospital stay
- Serum sodium level change
- Haemoglobin level change

Source of funding
None reported

Notes
Protocol is available at http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry?_nfp-b=true&_windowLabel=BasicSearchUpdateController_1&BasicSearchUpdateController_1_actionOverride=%2Fpageflows%2Ftrial%2FbasicSearchUpdate%2FviewTrail&BasicSearchUpdateController_1id=179

"A Randomized Comparison Between Three Types of Irrigating Fluids During Transurethral Resection in Benign Prostatic Hyperplasia" (PACT Registry ID: ATMR201001001793131)

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias): All outcomes | Low risk | "Simple randomisation using a randomisation table created by a computer software program" (as stated in the protocol)
"Randomization was performed by computer-generated random allocations sequence by simple randomization" (Yousef 2010) |
| Allocation concealment (selection bias): All outcomes | Unclear risk | Steps taken to ensure allocation concealment are not reported explicitly |
| Blinding of participants and personnel (performance bias): All outcomes | High risk | Not reported but considered unlikely that operating surgeon(s) were blinded |
| Blinding of outcome assessment (detection bias): Subjective outcomes (IPSS, HRQoL, IIEF-5, TUR syndrome, Urinary Incontinence) | Unclear risk | Study states: "the medical and nursing stuff involved in patients care, monitoring in the post-operative period and assessment of the complications and the incidence and the severity of TUR syndrome were completely blinded to the patient’s group assignment and the type irrigating fluid used" (Yousef 2010)
However, not reported whether patients were blinded to interventions |
| Blinding of outcome assessment: Objective outcomes | Low risk | Not reported but objective outcomes unlikely to have been affected |
Yousef 2010 *(Continued)*

comes (Blood transfusion, Re-TURP)

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias): Immediate postoperative outcomes (TUR syndrome, Blood transfusion)</th>
<th>Low risk</th>
<th>Study reports that all participants (n = 120 in each trial arm) were included in analyses for these outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias): Long-term outcomes (IPSS/HRQoL/IIEF-5/urinary incontinence at 12 months, and re-TURP)</td>
<td>Unclear risk</td>
<td>These outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias): All outcomes</td>
<td>Unclear risk</td>
<td>RCT protocol not available to allow for full assessment</td>
</tr>
</tbody>
</table>

ASA: American Society of Anesthesiology.
AUASS: AUA Symptom Score.
BEP: benign enlargement of the prostate.
BOO: bladder outlet obstruction.
BPE: benign prostatic enlargement.
BPH: benign prostatic hyperplasia.
BTURP: bipolar transurethral resection of the prostate.
DRE: digital rectal examination.
HRQoL: health-related quality of life.
IIEF-5: International Index of Erectile Function.
IPSS: International Prostate Symptoms Score.
LUTS: lower urinary tract symptoms.
MTURP: monopolar transurethral resection of the prostate.
PMR: postmicturition residual.
PSA: prostate-specific antigen.
PVR: postvoid residual.
Qmax: maximum urinary flow rate.
QoL: quality of life.
RCT: randomised controlled trial.
SD: standard deviation.
TRUS: transrectal ultrasound.
TUR: transurethral resection.
TURP: transurethral resection of the prostate.
UTI: urinary tract infection.

**Characteristics of excluded studies [ordered by study ID]**

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demir 2015</td>
<td>Quasi-randomisation process used</td>
</tr>
<tr>
<td>El Saied Hafez 2013</td>
<td>Quasi-randomisation process used</td>
</tr>
<tr>
<td>Engeler 2010</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Fung 2005</td>
<td>This study is an RCT that compares MTURP vs bipolar vaporesection instead of BTURP alone</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Inzuna 2017</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Kwon 2011</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Liangyu 2006</td>
<td>No evidence of randomisation (article translated in English from Chinese language using Google translator [<a href="https://translate.google.com/">https://translate.google.com/</a>] after appropriate conversion of pdf into word file [<a href="http://www.onlineocr.net">http://www.onlineocr.net</a>])</td>
</tr>
<tr>
<td>Lv 2012</td>
<td>No evidence of randomisation</td>
</tr>
<tr>
<td>Michielsen 2010b</td>
<td>No evidence of randomisation</td>
</tr>
<tr>
<td>Michielsen 2011</td>
<td>No evidence of randomisation</td>
</tr>
<tr>
<td>Muslimanoglu 2012</td>
<td>This is an extension of Tefekli 2005. This study is an RCT that compares MTURP with a combination of bipolar transurethral vapourisation and BTURP (hybrid technique) instead of BTURP alone (see below)</td>
</tr>
<tr>
<td>Neyer 2011</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Tefekli 2005</td>
<td>This study is an RCT that compares MTURP with a combination of bipolar transurethral vapourisation and BTURP (hybrid technique) instead of BTURP alone</td>
</tr>
<tr>
<td>Treharne 2018</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Valdivia Uría 2005</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Vasudeva 2019</td>
<td>Not an RCT</td>
</tr>
<tr>
<td>Yoon 2006</td>
<td>No evidence of randomisation</td>
</tr>
<tr>
<td>Zhang 2013</td>
<td>Not an RCT</td>
</tr>
</tbody>
</table>

BTURP: bipolar transurethral resection of the prostate.
MTURP: monopolar transurethral resection of the prostate.
RCT: randomised controlled trial.

DATA AND ANALYSES

Comparison 1. BTURP versus MTURP

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Urological symptoms (IPSS at 12 months)</td>
<td>16</td>
<td>2531</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.24 [-0.39, -0.09]</td>
</tr>
<tr>
<td>2 Bother (HRQoL at 12 months)</td>
<td>11</td>
<td>2004</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.12 [-0.25, 0.02]</td>
</tr>
<tr>
<td>3 TUR syndrome</td>
<td>44</td>
<td>6745</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.17 [0.09, 0.30]</td>
</tr>
<tr>
<td>Outcome or subgroup title</td>
<td>No. of studies</td>
<td>No. of participants</td>
<td>Statistical method</td>
<td>Effect size</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>-----------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>4 Urinary incontinence at 12 months</td>
<td>4</td>
<td>751</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.20 [0.01, 4.06]</td>
</tr>
<tr>
<td>5 Blood transfusion</td>
<td>38</td>
<td>5727</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.42 [0.30, 0.59]</td>
</tr>
<tr>
<td>6 Re-TURP</td>
<td>6</td>
<td>652</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.02 [0.44, 2.40]</td>
</tr>
<tr>
<td>7 Erectile function (IIEF-5 score at 12 months)</td>
<td>3</td>
<td>321</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.88 [-0.56, 2.32]</td>
</tr>
</tbody>
</table>

**Analysis 1.1. Comparison 1 BTURP versus MTURP, Outcome 1 Urological symptoms (IPSS at 12 months).**

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Sio 2006</td>
<td>35</td>
<td>35</td>
<td>0.92%</td>
<td>0.1</td>
<td>-1.45, 1.65</td>
</tr>
<tr>
<td>Nuhoglu 2006</td>
<td>24</td>
<td>26</td>
<td>6.6%</td>
<td>0.2</td>
<td>0.72, 2.12</td>
</tr>
<tr>
<td>Seckiner 2006</td>
<td>23</td>
<td>21</td>
<td>0.51%</td>
<td>0.4</td>
<td>1.68, 2.48</td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>120</td>
<td>120</td>
<td>8.67%</td>
<td>0</td>
<td>0.51, 0.51</td>
</tr>
<tr>
<td>Iori 2008</td>
<td>27</td>
<td>26</td>
<td>0.8%</td>
<td>0.3</td>
<td>1.37, 1.97</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>50</td>
<td>50</td>
<td>2.4%</td>
<td>0.1</td>
<td>0.86, 1.06</td>
</tr>
<tr>
<td>Singhania 2010</td>
<td>30</td>
<td>30</td>
<td>9.81%</td>
<td>0.2</td>
<td>0.58, 0.38</td>
</tr>
<tr>
<td>Geavlete 2011</td>
<td>170</td>
<td>170</td>
<td>8.89%</td>
<td>0.1</td>
<td>-0.51, -0.01</td>
</tr>
<tr>
<td>Xie 2012</td>
<td>110</td>
<td>110</td>
<td>5.87%</td>
<td>0.2</td>
<td>-0.9, 0.32</td>
</tr>
<tr>
<td>Mamoulakis 2013</td>
<td>88</td>
<td>73</td>
<td>1.16%</td>
<td>0.2</td>
<td>-1.18, 1.58</td>
</tr>
<tr>
<td>Akman 2013</td>
<td>127</td>
<td>130</td>
<td>4.26%</td>
<td>0.5</td>
<td>-1.22, 0.22</td>
</tr>
<tr>
<td>Giulianelli 2013</td>
<td>80</td>
<td>80</td>
<td>4.18%</td>
<td>0.8</td>
<td>-1.53, 0.07</td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>52</td>
<td>57</td>
<td>10.56%</td>
<td>0.1</td>
<td>-0.59, 0.33</td>
</tr>
<tr>
<td>Ghozzi 2014</td>
<td>31</td>
<td>29</td>
<td>11.56%</td>
<td>0.5</td>
<td>-0.94, 0.06</td>
</tr>
<tr>
<td>Komura 2015</td>
<td>52</td>
<td>58</td>
<td>1.77%</td>
<td>0.7</td>
<td>-1.82, 0.42</td>
</tr>
<tr>
<td>Al-Rawashdah 2017</td>
<td>251</td>
<td>246</td>
<td>28.04%</td>
<td>0.4</td>
<td>-0.42, 0.14</td>
</tr>
</tbody>
</table>

Total ***: 1270

Heterogeneity: Tau²=0; Chi²=9.76, df=15(P=0.83); I²=0%

Test for overall effect: Z=3.13(P=0)

Favours B-TURP: 2 -1 0 1 2
Favours M-TURP: 1 -0 1 0 -2

**Analysis 1.2. Comparison 1 BTURP versus MTURP, Outcome 2 Bother (HRQoL at 12 months).**

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Sio 2006</td>
<td>35</td>
<td>35</td>
<td>10.56%</td>
<td>0.1</td>
<td>-0.59, 0.33</td>
</tr>
<tr>
<td>Nuhoglu 2006</td>
<td>24</td>
<td>26</td>
<td>11.56%</td>
<td>0.5</td>
<td>-0.94, 0.06</td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>120</td>
<td>120</td>
<td>12.73%</td>
<td>0</td>
<td>0.25, 0.25</td>
</tr>
<tr>
<td>Iori 2008</td>
<td>27</td>
<td>26</td>
<td>4.86%</td>
<td>0</td>
<td>0.54, 0.54</td>
</tr>
<tr>
<td>Geavlete 2011</td>
<td>170</td>
<td>170</td>
<td>11.18%</td>
<td>0.1</td>
<td>-0.39, 0.19</td>
</tr>
<tr>
<td>Xie 2012</td>
<td>110</td>
<td>110</td>
<td>14.79%</td>
<td>0.4</td>
<td>-0.41, 0.62</td>
</tr>
</tbody>
</table>

Favours B-TURP: -0.5 -0.25 0 0.25 0.5
Favours M-TURP: 1 -0 1 0 -2
### Analysis 1.3. Comparison 1 BTURP versus MTURP, Outcome 3 TUR syndrome.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td></td>
<td>M-H, Random, 95% CI</td>
</tr>
<tr>
<td>Yang 2004</td>
<td>0/58</td>
<td>1/59</td>
<td>3.3% [0.01, 8.15]</td>
<td>0.34</td>
<td>[0.01, 18.15]</td>
</tr>
<tr>
<td>Wu 2005</td>
<td>0/200</td>
<td>5/200</td>
<td>4% [0.01, 16.63]</td>
<td>0.09</td>
<td>[0.01, 16.63]</td>
</tr>
<tr>
<td>Singh 2005</td>
<td>0/30</td>
<td>0/30</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>De Sio 2006</td>
<td>0/35</td>
<td>0/35</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Nuhoglu 2006</td>
<td>0/27</td>
<td>0/30</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Akçayoz 2006</td>
<td>0/21</td>
<td>0/21</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Abascal Junquera 2006</td>
<td>0/24</td>
<td>0/21</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Seckiner 2006</td>
<td>0/24</td>
<td>0/24</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Patankar 2006</td>
<td>0/52</td>
<td>2/51</td>
<td>3.68% [0.01, 3.99]</td>
<td>0.20</td>
<td>[0.01, 3.99]</td>
</tr>
<tr>
<td>Kim 2006</td>
<td>0/25</td>
<td>0/25</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Bertoletto 2007</td>
<td>0/48</td>
<td>0/52</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Xin 2007</td>
<td>0/65</td>
<td>0/65</td>
<td>3.85% [0.01, 7.89]</td>
<td>0.14</td>
<td>[0.01, 7.89]</td>
</tr>
<tr>
<td>Rose 2007</td>
<td>0/38</td>
<td>0/34</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Michielsen 2007</td>
<td>0/285</td>
<td>2/265</td>
<td>3.63% [0.01, 3.86]</td>
<td>0.19</td>
<td>[0.01, 3.86]</td>
</tr>
<tr>
<td>Wang 2007</td>
<td>0/72</td>
<td>2/76</td>
<td>3.66% [0.01, 4.32]</td>
<td>0.21</td>
<td>[0.01, 4.32]</td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>0/120</td>
<td>2/120</td>
<td>3.65% [0.01, 4.12]</td>
<td>0.20</td>
<td>[0.01, 4.12]</td>
</tr>
<tr>
<td>Ho 2007</td>
<td>0/48</td>
<td>2/52</td>
<td>3.68% [0.01, 4.39]</td>
<td>0.22</td>
<td>[0.01, 4.39]</td>
</tr>
<tr>
<td>Xue 2008</td>
<td>0/32</td>
<td>1/32</td>
<td>3.34% [0.01, 7.89]</td>
<td>0.33</td>
<td>[0.01, 7.89]</td>
</tr>
<tr>
<td>Iori 2008</td>
<td>0/27</td>
<td>0/26</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>0/50</td>
<td>0/50</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Goh 2009</td>
<td>0/110</td>
<td>3/100</td>
<td>3.84% [0.01, 2.49]</td>
<td>0.13</td>
<td>[0.01, 2.49]</td>
</tr>
<tr>
<td>Xin 2009</td>
<td>0/76</td>
<td>5/77</td>
<td>4.03% [0.01, 1.64]</td>
<td>0.09</td>
<td>[0.01, 1.64]</td>
</tr>
<tr>
<td>Chen 2009</td>
<td>0/21</td>
<td>1/19</td>
<td>3.38% [0.01, 7.02]</td>
<td>0.30</td>
<td>[0.01, 7.02]</td>
</tr>
<tr>
<td>Kong 2009</td>
<td>0/51</td>
<td>0/51</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Bhansali 2009</td>
<td>0/34</td>
<td>4/33</td>
<td>4.02% [0.01, 1.93]</td>
<td>0.11</td>
<td>[0.01, 1.93]</td>
</tr>
<tr>
<td>Acuña Lopez 2010</td>
<td>0/15</td>
<td>0/15</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Singhania 2010</td>
<td>0/30</td>
<td>0/30</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Yousif 2010</td>
<td>0/120</td>
<td>17/240</td>
<td>4.25% [0.01, 0.94]</td>
<td>0.06</td>
<td>[0.01, 0.94]</td>
</tr>
<tr>
<td>He 2010</td>
<td>0/140</td>
<td>5/139</td>
<td>4.01% [0.01, 1.62]</td>
<td>0.09</td>
<td>[0.01, 1.62]</td>
</tr>
<tr>
<td>Mei 2010</td>
<td>0/73</td>
<td>2/73</td>
<td>3.66% [0.01, 4.1]</td>
<td>0.20</td>
<td>[0.01, 4.1]</td>
</tr>
<tr>
<td>Gevleter 2011</td>
<td>0/170</td>
<td>3/170</td>
<td>3.82% [0.01, 2.74]</td>
<td>0.14</td>
<td>[0.01, 2.74]</td>
</tr>
<tr>
<td>Fagerström 2011</td>
<td>0/98</td>
<td>3/87</td>
<td>3.84% [0.01, 2.42]</td>
<td>0.13</td>
<td>[0.01, 2.42]</td>
</tr>
<tr>
<td>Méndez-Probst 2011</td>
<td>0/22</td>
<td>0/21</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td>Mamoulakis 2013</td>
<td>0/141</td>
<td>1/138</td>
<td>3.28% [0.03, 7.94]</td>
<td>0.33</td>
<td>[0.03, 7.94]</td>
</tr>
</tbody>
</table>

Total *** 1008 996 100% -0.12[-0.25, 0.02]

Heterogeneity: Tau²=0.02; Chi²=18.63, df=10(P=0.05); I²=46.33%

Test for overall effect: Z=1.7(P=0.09)
<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td></td>
<td>M-H, Random, 95% CI</td>
</tr>
<tr>
<td>Xie 2012</td>
<td>0/110</td>
<td>2/110</td>
<td></td>
<td>3.65%</td>
<td>0.2[0.01,4.12]</td>
</tr>
<tr>
<td>Akman 2013</td>
<td>0/143</td>
<td>2/143</td>
<td></td>
<td>3.64%</td>
<td>0.2[0.01,4.13]</td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>0/57</td>
<td>1/60</td>
<td></td>
<td>3.3%</td>
<td>0.35[0.01,8.43]</td>
</tr>
<tr>
<td>Giulianelli 2013</td>
<td>0/80</td>
<td>2/80</td>
<td></td>
<td>3.66%</td>
<td>0.2[0.01,4.1]</td>
</tr>
<tr>
<td>Komura 2015</td>
<td>0/63</td>
<td>0/61</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Stucki 2014</td>
<td>0/70</td>
<td>1/67</td>
<td></td>
<td>3.3%</td>
<td>0.32[0.01,7.7]</td>
</tr>
<tr>
<td>Ghossi 2014</td>
<td>0/31</td>
<td>2/29</td>
<td></td>
<td>3.72%</td>
<td>0.19[0.01,3.75]</td>
</tr>
<tr>
<td>Ahmad 2016</td>
<td>0/110</td>
<td>0/110</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Demirdag 2016</td>
<td>0/36</td>
<td>2/45</td>
<td></td>
<td>3.7%</td>
<td>0.25[0.01,5.02]</td>
</tr>
<tr>
<td>Al-Rawashdah 2017</td>
<td>0/251</td>
<td>7/246</td>
<td></td>
<td>4.09%</td>
<td>0.07[0.1,1.14]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>3333</td>
<td>3412</td>
<td></td>
<td>100%</td>
<td>0.17[0.09,0.3]</td>
</tr>
</tbody>
</table>

Total events: 0 (B-TURP), 83 (M-TURP)
Heterogeneity: Tau²=0; Chi²=3.07, df=26(P=1); I²=0%
Test for overall effect: Z=6.04(P<0.0001)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td></td>
<td>M-H, Random, 95% CI</td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>0/120</td>
<td>0/120</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Chen 2010</td>
<td>0/50</td>
<td>2/50</td>
<td></td>
<td>100%</td>
<td>0.2[0.01,4.06]</td>
</tr>
<tr>
<td>Akman 2013</td>
<td>0/127</td>
<td>0/130</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Giulianelli 2013</td>
<td>0/79</td>
<td>0/75</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>376</td>
<td>375</td>
<td></td>
<td>100%</td>
<td>0.2[0.01,4.06]</td>
</tr>
</tbody>
</table>

Total events: 0 (B-TURP), 2 (M-TURP)
Heterogeneity: Not applicable
Test for overall effect: Z=1.05(P=0.29)

Analysis 1.5. Comparison 1 BTURP versus MTURP, Outcome 5 Blood transfusion.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td></td>
<td>M-H, Random, 95% CI</td>
</tr>
<tr>
<td>Yang 2004</td>
<td>1/58</td>
<td>1/59</td>
<td></td>
<td>1.53%</td>
<td>1.02[0.07,15.88]</td>
</tr>
<tr>
<td>Singh 2005</td>
<td>0/30</td>
<td>1/30</td>
<td></td>
<td>1.16%</td>
<td>0.33[0.01,7.87]</td>
</tr>
<tr>
<td>Wu 2005</td>
<td>0/200</td>
<td>18/200</td>
<td></td>
<td>1.47%</td>
<td>0.03[0.05,0.43]</td>
</tr>
<tr>
<td>Nuhoglu 2006</td>
<td>1/27</td>
<td>2/30</td>
<td></td>
<td>2.11%</td>
<td>0.56[0.05,5.79]</td>
</tr>
<tr>
<td>Patankar 2006</td>
<td>0/52</td>
<td>1/51</td>
<td></td>
<td>1.15%</td>
<td>0.33[0.01,7.85]</td>
</tr>
<tr>
<td>Akçayoz 2006</td>
<td>0/21</td>
<td>0/21</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>DeSio 2006</td>
<td>1/35</td>
<td>0/35</td>
<td></td>
<td>1.15%</td>
<td>3[0.13,71.22]</td>
</tr>
<tr>
<td>Kim 2006</td>
<td>0/25</td>
<td>2/25</td>
<td></td>
<td>1.3%</td>
<td>0.2[0.01,3.97]</td>
</tr>
<tr>
<td>Abascal Junquera 2006</td>
<td>0/24</td>
<td>0/21</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Michielsen 2007</td>
<td>4/118</td>
<td>1/120</td>
<td></td>
<td>2.44%</td>
<td>4.07[0.46,35.86]</td>
</tr>
<tr>
<td>Ho 2007</td>
<td>1/48</td>
<td>1/52</td>
<td></td>
<td>1.54%</td>
<td>1.08[0.07,16.84]</td>
</tr>
</tbody>
</table>

Favours B-TURP 0.001 0.1 1 10 1000 Favours M-TURP

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td>M-H, Random, 95% CI</td>
<td></td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>1/120</td>
<td>7/120</td>
<td>2.68%</td>
<td>0.14[0.02,1.14]</td>
<td></td>
</tr>
<tr>
<td>Iori 2008</td>
<td>0/27</td>
<td>0/26</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Xue 2008</td>
<td>0/32</td>
<td>3/32</td>
<td>1.35%</td>
<td>0.14[0.01,2.66]</td>
<td></td>
</tr>
<tr>
<td>Bhansali 2009</td>
<td>2/34</td>
<td>7/33</td>
<td>5.17%</td>
<td>0.28[0.06,1.24]</td>
<td></td>
</tr>
<tr>
<td>Chen 2010</td>
<td>1/50</td>
<td>3/50</td>
<td>2.33%</td>
<td>0.33[0.04,3.1]</td>
<td></td>
</tr>
<tr>
<td>Chen 2009</td>
<td>1/21</td>
<td>3/19</td>
<td>2.44%</td>
<td>0.3[0.03,2.66]</td>
<td></td>
</tr>
<tr>
<td>Kong 2009</td>
<td>0/51</td>
<td>2/51</td>
<td>1.28%</td>
<td>0.2[0.01,4.07]</td>
<td></td>
</tr>
<tr>
<td>Xin 2009</td>
<td>2/76</td>
<td>13/77</td>
<td>5.47%</td>
<td>0.16[0.04,0.67]</td>
<td></td>
</tr>
<tr>
<td>Singhania 2010</td>
<td>0/30</td>
<td>0/30</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>He 2010</td>
<td>1/142</td>
<td>3/139</td>
<td>2.29%</td>
<td>0.33[0.03,3.1]</td>
<td></td>
</tr>
<tr>
<td>Yousef 2010</td>
<td>0/120</td>
<td>4/240</td>
<td>1.36%</td>
<td>0.22[0.01,4.08]</td>
<td></td>
</tr>
<tr>
<td>Acuña Lopez 2010</td>
<td>0/15</td>
<td>0/15</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Mei 2010</td>
<td>1/73</td>
<td>4/73</td>
<td>2.47%</td>
<td>0.25[0.03,2.18]</td>
<td></td>
</tr>
<tr>
<td>Méndez-Probst 2011</td>
<td>0/22</td>
<td>0/21</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Fagerström 2011</td>
<td>4/98</td>
<td>10/87</td>
<td>9.18%</td>
<td>0.36[0.12,1.09]</td>
<td></td>
</tr>
<tr>
<td>Gevlete 2011</td>
<td>3/170</td>
<td>11/170</td>
<td>7.31%</td>
<td>0.27[0.08,0.96]</td>
<td></td>
</tr>
<tr>
<td>Mamoulakis 2013</td>
<td>9/141</td>
<td>4/138</td>
<td>8.69%</td>
<td>2.2[0.69,6.98]</td>
<td></td>
</tr>
<tr>
<td>Xie 2012</td>
<td>0/110</td>
<td>2/110</td>
<td>1.27%</td>
<td>0.2[0.01,4.12]</td>
<td></td>
</tr>
<tr>
<td>Akman 2013</td>
<td>3/143</td>
<td>8/143</td>
<td>6.78%</td>
<td>0.38[0.11,3.38]</td>
<td></td>
</tr>
<tr>
<td>Giulianelli 2013</td>
<td>0/80</td>
<td>3/80</td>
<td>1.33%</td>
<td>0.14[0.01,2.72]</td>
<td></td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>3/57</td>
<td>7/60</td>
<td>6.82%</td>
<td>0.45[0.12,6.66]</td>
<td></td>
</tr>
<tr>
<td>Komura 2015</td>
<td>1/63</td>
<td>4/61</td>
<td>2.48%</td>
<td>0.24[0.03,2.1]</td>
<td></td>
</tr>
<tr>
<td>Ghezzi 2014</td>
<td>1/31</td>
<td>2/29</td>
<td>2.1%</td>
<td>0.47[0.04,4.89]</td>
<td></td>
</tr>
<tr>
<td>Stock 2014</td>
<td>1/70</td>
<td>1/67</td>
<td>1.53%</td>
<td>0.96[0.06,14.99]</td>
<td></td>
</tr>
<tr>
<td>Demirdag 2016</td>
<td>4/36</td>
<td>8/45</td>
<td>9.28%</td>
<td>0.63[0.2,2.91]</td>
<td></td>
</tr>
<tr>
<td>Ahmad 2016</td>
<td>1/110</td>
<td>0/110</td>
<td>1.14%</td>
<td>3[0.12,72.85]</td>
<td></td>
</tr>
<tr>
<td>Al-Rawashdah 2017</td>
<td>0/251</td>
<td>5/246</td>
<td>1.39%</td>
<td>0.09[0.1,6]</td>
<td></td>
</tr>
</tbody>
</table>

**Total (95% CI)**

2811 [2916] = 100% [0.42[0.3,0.59]]

**Test for overall effect:** Z=5.02 (P<0.0001)

**Heterogeneity:** Tau²=0; Chi²=28.46, df=31 (P=0.6); I²=0%

---

**Analysis 1.6. Comparison 1 BTURP versus MTURP, Outcome 6 Re-TURP.**

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td>M-H, Random, 95% CI</td>
<td></td>
</tr>
<tr>
<td>De Sio 2006</td>
<td>1/32</td>
<td>1/31</td>
<td>9.74%</td>
<td>0.97[0.06,14.82]</td>
<td></td>
</tr>
<tr>
<td>Nuhoglu 2006</td>
<td>0/27</td>
<td>0/30</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Singhania 2010</td>
<td>0/30</td>
<td>0/30</td>
<td>Not estimable</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Fagerström 2011</td>
<td>0/98</td>
<td>3/87</td>
<td>8.33%</td>
<td>0.13[0.01,2.42]</td>
<td></td>
</tr>
<tr>
<td>Xie 2012</td>
<td>3/110</td>
<td>3/110</td>
<td>29.09%</td>
<td>1[0.21,4.85]</td>
<td></td>
</tr>
<tr>
<td>Akman 2013</td>
<td>6/34</td>
<td>4/33</td>
<td>52.84%</td>
<td>1.46[0.45,4.7]</td>
<td></td>
</tr>
</tbody>
</table>

**Total (95% CI)**

331 [321] = 100% [1.02[0.44,2.4]]

**Test for overall effect:** Z=0.05 (P=0.96)

**Heterogeneity:** Tau²=2.4, Chi²=3 (P=0.49); I²=0%

---

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
## Analysis 1.7. Comparison 1 BTURP versus MTURP, Outcome 7 Erectile function (IIEF-5 score at 12 months).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>B-TURP</th>
<th>M-TURP</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>Random, 95% CI</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>24</td>
<td>19.5 (6.1)</td>
<td>28</td>
<td>19.3 (4)</td>
<td>17.23%</td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>52</td>
<td>16.3 (2.6)</td>
<td>57</td>
<td>16.2 (2.4)</td>
<td>43.48%</td>
</tr>
<tr>
<td>Giulianelli 2013</td>
<td>80</td>
<td>24 (4.3)</td>
<td>80</td>
<td>22 (3.2)</td>
<td>39.29%</td>
</tr>
<tr>
<td>**Total *****</td>
<td>156</td>
<td>165</td>
<td>100%</td>
<td>0.88 (-0.56, 2.32)</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau²=1.02; Chi²=6.16, df=2(P=0.05); I²=67.52%

Test for overall effect: Z=1.19(P=0.23)

### ADDITIONAL TABLES
### Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>Intervention(s) and comparator(s)</th>
<th>Duration of intervention (duration of follow-up) [days, months, years...]</th>
<th>Description of participants</th>
<th>Trial period [year to year]</th>
<th>Country</th>
<th>Setting</th>
<th>Ethnic groups [%]</th>
<th>Duration of disease [mean/range years (SD), or as reported]</th>
</tr>
</thead>
<tbody>
<tr>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Refractory BPH (no response to oral treatment), acute urine retention, repetitive urinary tract infections</td>
<td>2014 to 2016</td>
<td>Spain</td>
<td>Hospital</td>
<td>Data not reported</td>
<td>Data not collected</td>
</tr>
<tr>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>El-Assmy 2018</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Patients presenting for BPH surgery; patients 50 years or older at the time of intervention who were married, sexually interested, and having a continuous relationship with the same partner</td>
<td>2013 to 2014</td>
<td>Egypt</td>
<td>Hospital</td>
<td>Data not reported</td>
</tr>
<tr>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasution 2017</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Patients with BPH and urinary retention who planned for surgery</td>
<td>Data not reported</td>
<td>Indonesia</td>
<td>Hospital</td>
<td>Data not reported</td>
</tr>
<tr>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaik 2017</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Inclusion/exclusion criteria not reported (abstract only)</td>
<td>2015 to 2016</td>
<td>India</td>
<td>Hospital</td>
<td>Data not reported</td>
</tr>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Comparators</th>
<th>Data collected</th>
<th>Inclusion/exclusion criteria</th>
<th>Timeframe</th>
<th>Country</th>
<th>Setting</th>
<th>Data reported</th>
<th>Data collected</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Egui Rojo 2017</strong></td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Inclusion/exclusion criteria not reported (abstract only)</td>
<td>2014 to 2016</td>
<td>Spain</td>
<td>Hospital</td>
<td>Data not reported</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Al-Rawashdah 2017</strong></td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>BPH scheduled to undergo TURP</td>
<td>2007 to 2014</td>
<td>Italy</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ahmad 2016</strong></td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Symptomatic enlarged prostate based on IPSS</td>
<td>2013 to 2014</td>
<td>Pakistan</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Demirdag 2016</strong></td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Patients with prostate glands larger than 60 mL, moderate to severe lower urinary tract symptoms, significant post-micturition residual (PMR) urine volume (&gt; 100 mL) in spite of medical treatment with alpha-blockers and 5-alpha reductase inhibitors</td>
<td>2013 to 2015</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Demir 2015</strong></td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Maximum urinary flow rate &lt; 10 mL/s or obstructive pressure flow, severe LUTS requiring surgical treatment based on IPSS, recurrent haematuria or UTIs; patients who were suspected to have</td>
<td>2013 to 2014</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Komura 2015</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td>Age &gt; 50 years, Eastern Cooperative Oncology Group performance status ≤ 2; acute urinary retention if catheter removal failed after therapy with alpha-blockers, chronic urinary retention unresponsive to medical therapies; IPSS ≥ 15</td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td>Started in 2008 (year of closure not reported)</td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td>Japan Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
<tr>
<td>Ghossi 2014</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td>Benign prostatic hyperplasia, indication for TURP, age over 50 years, PSA &lt; 4 ng/mL, no suspicious finding on DRE</td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td>2010 to 2011</td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td>France Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
<tr>
<td>Kadyan 2014</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td>&gt; 50 years, DRE benign gland, gland volume &gt; 50 mL, PSA &lt; 4 ng/mL, LUTS with BEP, urine culture -ve</td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td>India Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
<tr>
<td>Qian 2014</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td>Symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td>Data not available from translation</td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td>China Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not available from translation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Group 1: Bipolar TURP</th>
<th>Group 2: Monopolar TURP</th>
<th>Baseline characteristics</th>
<th>Data collection status</th>
<th>Country</th>
<th>Hospital</th>
<th>Ref.</th>
<th>Date of inclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stucki 2014</td>
<td>Data not collected</td>
<td></td>
<td>Moderate or severe LUTS (IPSS &gt; 16) who failed medical therapy (≥ 2 weeks), recurrent urinary retention, able to give fully informed consent</td>
<td>Data not collected</td>
<td>Switzerland</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Akman 2013</td>
<td>Data not collected</td>
<td></td>
<td>Diagnosis of benign enlargement of the prostate undergoing TURP, ASA II or III</td>
<td>Data not collected</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>El Saied Hafez 2013</td>
<td>Data not collected</td>
<td></td>
<td>LUTS of BPH</td>
<td>Data not collected</td>
<td>Italy</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>Data not collected</td>
<td></td>
<td>LUTS secondary to BPE, age ≥ 50, IPSS &gt; 7, prostate volume measured by transrectal ultrasound (TRUS): &gt; 20 and &lt; 80 mL, Qmax &lt; 15 mL/s</td>
<td>Data not collected</td>
<td>India</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Study</td>
<td>Treatment 1</td>
<td>Treatment 2</td>
<td>Eligibility Criteria</td>
<td>Country(s)</td>
<td>Hospital</td>
<td>Data Collection Status</td>
<td>Data Source</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>----------</td>
<td>------------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Mamoulakis 2013</td>
<td>I1: bipolar TURP</td>
<td>I2: monopolar TURP</td>
<td>Benign prostatic obstruction, $Q_{\text{max}} &lt; 15$, IPSS &gt; 13, voided volume &gt; 125 mL, indwelling/intermittent catheterisation</td>
<td>Netherlands, Greece, Italy, Germany</td>
<td>Hospital</td>
<td>Data not reported</td>
<td>Data not collected</td>
<td></td>
</tr>
<tr>
<td>Huang 2012</td>
<td>I1: bipolar TURP</td>
<td>I2: monopolar TURP</td>
<td>Symptomatic BPH, &gt; 50 years, medication failure, International Prostate Symptom Score (IPSS) &gt; 16, maximum flow rate ($Q_{\text{max}}$) &lt; 15 mL/s, prostate volume 30 to 80 mL estimated on transrectal ultrasound (TRUS)</td>
<td>China</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
<td></td>
</tr>
<tr>
<td>Xie 2012</td>
<td>I1: bipolar TURP</td>
<td>I2: monopolar TURP</td>
<td>Patients with BPO, maximal flow rate ($Q_{\text{max}}$) &lt; 15 mL/s, &gt; 45 years, prostate volume on transrectal ultrasound &gt; 20 g, medication failure (5α-reductase inhibitors or α-blockers)</td>
<td>China</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
<td></td>
</tr>
<tr>
<td>Fagerstrom 2011</td>
<td>I1: bipolar TURP</td>
<td>I2: monopolar TURP</td>
<td>Symptomatic BPH requiring surgery due to failed medical therapy or urinary retention, TRUS estimated prostatic volume 30 to 100 mL</td>
<td>Sweden</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
<td></td>
</tr>
<tr>
<td>Geavlete 2011</td>
<td>I1: bipolar TURP</td>
<td>I2: monopolar TURP</td>
<td>BPH and severe LUTS; inclusion criteria consisted of $Q_{\text{max}} &lt; 10$ mL/s, IPSS &gt; 19, prostate volume between 30 and 80 mL</td>
<td>Romania</td>
<td>Hospital</td>
<td>Data not reported explicitly</td>
<td>Data not collected</td>
<td></td>
</tr>
</tbody>
</table>
### Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mendez-Probst 2011</td>
<td>Bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LUTS suggestive of BPH, peak urinary flow rates &lt; 12 mL/s, American Urological Association (AUA) symptom scores &gt; 12, acute urinary retention</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not reported explicitly</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
<tr>
<td>Acuna-Lopez 2010</td>
<td>Bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diagnosis of BPH, presented with ultrasound prostate volume between 20 and 80 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2008 to 2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mexico</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>Bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Failure of medical therapy; all indications for surgical treatment of BPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2005 to 2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
<tr>
<td>He 2010</td>
<td>Bipolar TURP</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not available</td>
</tr>
<tr>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not available</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data not collected</td>
</tr>
</tbody>
</table>
### Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>I1: bipolar TURP</th>
<th>I2:</th>
<th>C1: monopolar TURP</th>
<th>C2:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mei 2010</td>
<td>Data not collected</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singhania 2010</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Failed medical therapy, acute urinary retention with failed voiding trial</td>
<td>Not reported explicitly</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yousef 2010</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Symptomatic BPH</td>
<td>Not reported explicitly by trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C1: monopolar TURP with 1.5% glycine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C2: monopolar TURP with 5% glucose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhansali 2009</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>BPH-related LUTS requiring surgical intervention, prostate gland &gt; 60 grams on 3D transrectal US</td>
<td>2004 to 2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen 2009</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Age &gt; 55 years and fit for anaesthesia, symptomatic BPH, prostate volume &gt; 50 mL, IPSS ≥ 18, Qmax &lt; 15 mL/s. Failed medical therapy with alpha blockers or 5-alpha reductase inhibitors</td>
<td>2005 to 2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Table continues on the next page...*
<table>
<thead>
<tr>
<th>Study</th>
<th>I1: bipolar TURP</th>
<th>Data not collected</th>
<th>Symptomatic BPH, age ≥ 50 years, good performance status, acute urinary retention if catheter removal failed after therapy with alpha-blockers, chronic urinary retention unresponsive to medical treatment, IPSS ≥ 18, maximal flow rate ($Q_{\text{max}}$) &lt; 15 mL/s</th>
<th>Not reported explicitly</th>
<th>Italy</th>
<th>Hospital</th>
<th>Data not reported by trial</th>
<th>Data not collected</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Sio 2009</td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goh 2009</td>
<td>I2:</td>
<td></td>
<td>Inclusion/exclusion criteria not reported (abstracts only)</td>
<td>2005 to 2008</td>
<td>UK</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Kong 2009</td>
<td>I2:</td>
<td></td>
<td>Moderate to severe LUTS that failed medical treatment, complications of BOO or catheter dependency</td>
<td>2007 to 2008</td>
<td>Malaysia</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Xin 2009</td>
<td>I2:</td>
<td></td>
<td>Symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
<td>Data not available from translation</td>
<td>China</td>
<td>Hospital</td>
<td>Data not available from translation</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Iori 2008</td>
<td>I2:</td>
<td></td>
<td>LUTS secondary to BPO</td>
<td>2002 to 2005</td>
<td>Italy</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td>Study, Year</td>
<td>Comparator</td>
<td>Comparator Description</td>
<td>Comparator Data</td>
<td>Comparator Country</td>
<td>Comparator Hospital</td>
<td>Comparator Data Avail.</td>
<td>Comparator Data from Translation</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>-----------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>Xue 2008</td>
<td>Bipolar TURP</td>
<td>Symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
<td>Data not collected</td>
<td>China</td>
<td>Hospital</td>
<td>Data not available from translation</td>
<td>No data from translation</td>
<td></td>
</tr>
<tr>
<td>Bertolotto 2007</td>
<td>Bipolar TURP</td>
<td>Candidates for surgery for obstructive symptoms, prostate estimated volume &lt; 100 mL, Qmax ≤ 15 mL/s, IPSS ≥ 13, PSA ≤ 4 ng/L</td>
<td>Data not collected</td>
<td>Italy</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>No data from translation</td>
<td></td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>Bipolar TURP</td>
<td>BPE with moderate or severe LUTS (IPSS ≥ 18) or significant postvoid residual volume (&gt; 50 mL)</td>
<td>Data not collected</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>No data from translation</td>
<td></td>
</tr>
<tr>
<td>Ho 2007</td>
<td>Bipolar TURP</td>
<td>&gt; 50 years of age, fit for anaesthesia, failed medical therapy with alpha-blockers or 5-alpha reductase inhibitors, IPSS &gt; 18, Qmax &lt; 15 mL/s, acute urinary retention, failed trial of void without urinary catheter</td>
<td>Data not collected</td>
<td>Singapore</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>No data from translation</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Inclusion criteria</th>
<th>Time Frame</th>
<th>Country</th>
<th>Hospital</th>
<th>Data Collection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michielsen 2007</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Bladder obstruction due to BPH, IPSS ≥ 13, QoL ≥ 3, Qmax &lt; 15 mL/s</td>
<td>2005 to 2009</td>
<td>Belgium</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rose 2007</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Inclusion criteria not available from translation</td>
<td>2004 to 2005</td>
<td>Germany</td>
<td>Hospital</td>
<td>Data not available from translation</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang 2007</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Symptomatic BPH that required surgery owing to urinary retention or failed medical therapy</td>
<td>Data not available from translation</td>
<td>China</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xin 2007</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Inclusion criteria not reported by trial (abstract only)</td>
<td>2004 to 2006</td>
<td>China</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abascal 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Clinical diagnosis of symptomatic BPH with USS prostate volume between 30 and 70 mL</td>
<td>2005 (March) to 2005 (December)</td>
<td>Spain</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Data collected</th>
<th>Comparator</th>
<th>Follow-up</th>
<th>Country</th>
<th>Setting</th>
<th>Data reported by trial</th>
<th>Data collected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akcayoz 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Clinical BPH</td>
<td>2003 to 2004</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bahadzor 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Benign prostatic hyperplasia (BPH)</td>
<td>Data not reported by trial</td>
<td>Malaysia</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choi 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>BPH patients</td>
<td>2003 to 2005</td>
<td>South Korea</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Aged ≥ 50 with IPSS score &gt; 8, ( Q_{\text{max}} &lt; 15 ) mL/s, prostate volume 30 to 120 mL was on the basis of the TRUS test</td>
<td>2003 to 2004</td>
<td>South Korea</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>LUTS due to BPH</td>
<td>2003 (April) to 2003 (October)</td>
<td>Taiwan</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
<td>Data not collected</td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Diagnosis</th>
<th>Time Period</th>
<th>Location</th>
<th>Reporting</th>
<th>Type of Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuhoglu 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Diagnosis of BPH, LUTS, IPSS &gt; 15, Qmax &lt; 10 mL/s</td>
<td>2001 to 2003</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td>Patankar 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Men older than 45 years, AUA score ≥ 18, prostate volume 35 to 70 mL, Qmax ≤ 10 mL/s</td>
<td>2004 (January) to 2004 (March)</td>
<td>India</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td>Seckiner 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>IPSS &gt; 8, Qmax &lt; 15 mL/s, prostate volume 30 to 70 g on transrectal ultrasonography</td>
<td>2003 (January) to 2003 (October)</td>
<td>Turkey</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td>Terrone 2006</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Bothersome LUTS</td>
<td>Not reported explicitly</td>
<td>Italy</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td>Singh 2005</td>
<td>I1: bipolar TURP</td>
<td>Data not collected</td>
<td>Symptomatic benign prostatic hyperplasia (BPH) requiring surgical intervention,</td>
<td>2003 to 2004</td>
<td>India</td>
<td>Hospital</td>
<td>Data not reported by trial</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Group 1</td>
<td>Group 2</td>
<td>Group 3</td>
<td>Group 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wu 2005</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D'Elia 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eaton 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eaton 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D'Elia 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang 2004</td>
<td></td>
<td>monopolar TURP</td>
<td>bipolar TURP</td>
<td>Data not collected</td>
<td>Data not collected</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Baseline characteristics (Continued)
Table 1. Baseline characteristics (Continued)

<table>
<thead>
<tr>
<th>Symons</th>
<th>I1: bipolar TURP</th>
<th>Data not collected</th>
<th>Clinical diagnosis of BPH with bladder outflow obstruction</th>
<th>Not reported explicitly</th>
<th>UK</th>
<th>Hospital</th>
<th>Data not reported by trial</th>
<th>Data not collected</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C1: monopolar TURP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- denotes not reported

ASA: American Society of Anesthesiologists.
BOO: bladder outlet obstruction.
BPE: benign prostatic enlargement.
BPH: benign prostatic hyperplasia.
BPO: benign prostatic obstruction.
C: comparator.
DRE: digital rectal examination.
I: intervention.
IPSS: International Prostate Symptoms Score.
LUTS: lower urinary tract symptoms.
PMR: postmicturition residual.
PSA: prostate-specific antigen.
PVP: photoselective vaporisation of the prostate.
Q\textsubscript{max}: maximum urinary flow rate.
SD: standard deviation.
TRUS: transurethral ultrasound.
TURP: transurethral resection of the prostate.
TWOC: trial without catheter.
US: ultrasound.
USS: XXX.
UTI: urinary tract infection.
### Table 2. Description of interventions

<table>
<thead>
<tr>
<th>Study, Year</th>
<th>Intervention(s) [route, frequency, total dose/d]</th>
<th>Intervention(s) appropriate as applied in a clinical practice setting[a] [description]</th>
<th>Comparator(s)</th>
<th>Comparator(s) appropriate as applied in a clinical practice setting[b] [description]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rojo 2018</td>
<td>I1: bipolar TURP</td>
<td>Specific technology not reported</td>
<td>C1: monopolar TURP</td>
<td>Specific technology not reported, irrigation fluid = glycine</td>
</tr>
<tr>
<td>El-Assmy 2018</td>
<td>I1: bipolar TURP</td>
<td>TUR in Saline-TURis, Olympus SurgMaster UES-40 Bipolar Generator</td>
<td>C1: monopolar TURP</td>
<td>ValleyLab Force FX electrosurgical unit, irrigation fluid = glycine</td>
</tr>
<tr>
<td>Nasution 2017</td>
<td>I1: bipolar TURP</td>
<td>Specific technology not reported</td>
<td>C1: monopolar TURP</td>
<td>Specific technology/irrigation fluid not reported</td>
</tr>
<tr>
<td>Shaik 2017</td>
<td>I1: bipolar TURP</td>
<td>Specific technology not reported</td>
<td>C1: monopolar TURP</td>
<td>Specific technology/irrigation fluid not reported</td>
</tr>
<tr>
<td>Egui Rojo 2017</td>
<td>I1: bipolar TURP</td>
<td>Specific technology not reported</td>
<td>C1: monopolar TURP</td>
<td>Specific technology/irrigation fluid not reported</td>
</tr>
<tr>
<td>Al-Rawashdah 2017</td>
<td>I1: bipolar TURP</td>
<td>Gyrus PK Super-Pulse Olympus</td>
<td>C1: monopolar TURP</td>
<td>Karl Storz and ERBE Generator, irrigation fluid = sorbitol/mannitol irrigation fluid</td>
</tr>
<tr>
<td>Ahmad 2016</td>
<td>I1: bipolar TURP</td>
<td>Specific technology not reported</td>
<td>C1: monopolar TURP</td>
<td>Specific technology not reported, irrigation fluid = mannitol 1.5%</td>
</tr>
<tr>
<td>Demirdag 2016</td>
<td>I1: bipolar TURP</td>
<td>Olympus Gyrus PK SuperPulse Generator</td>
<td>C1: monopolar TURP</td>
<td>ValleyLab Force FX Electrocautery, irrigation fluid = glycine 5%</td>
</tr>
<tr>
<td>Komura 2015</td>
<td>I1: bipolar TURP</td>
<td>Olympus TURis</td>
<td>C1: monopolar TURP</td>
<td>Specific technology not reported, irrigation fluid = mannitol 4%</td>
</tr>
<tr>
<td>Ghozzi 2014</td>
<td>I1: bipolar TURP</td>
<td>Olympus TURis</td>
<td>C1: monopolar TURP</td>
<td>Olympus, irrigation fluid = 1.5% glycine</td>
</tr>
</tbody>
</table>

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Study Year</th>
<th>Intervention 1</th>
<th>Intervention 2</th>
<th>Intervention 3</th>
<th>Intervention 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kadayan 2014</td>
<td>I1: bipolar TURP</td>
<td>ERBE technology</td>
<td>C1: monopolar TURP</td>
<td>Technology/irrigation fluid not reported</td>
</tr>
<tr>
<td>Qian 2014</td>
<td>I1: bipolar TURP</td>
<td>Specific technology not reported (study in Chinese)</td>
<td>C1: monopolar TURP</td>
<td>Specific technology/irrigation fluid not reported</td>
</tr>
<tr>
<td>Stucki 2014</td>
<td>I1: bipolar TURP</td>
<td>Gyrus PK SuperPulse</td>
<td>C1: monopolar TURP</td>
<td>Karl Storz, ERBE Generator, irrigation fluid = sorbitol/mannitol</td>
</tr>
<tr>
<td>Akman 2013</td>
<td>I1: bipolar TURP</td>
<td>Olympus UES 40 Surg MasterSystem</td>
<td>C1: monopolar TURP</td>
<td>Gebruder Martine ME 411, irrigation fluid = glycine</td>
</tr>
<tr>
<td>El Saied Hafez 2013</td>
<td>I1: bipolar TURP</td>
<td>Gyrus Plasmakinetic, PK</td>
<td>C1: monopolar TURP</td>
<td>Erbee Resection System, irrigation fluid = 1.5% glycine</td>
</tr>
<tr>
<td>Giulianelli 2013</td>
<td>I1: bipolar TURP</td>
<td>Gyrus Plasmakinetic (PK-TURP)</td>
<td>C1: monopolar TURP</td>
<td>Karl Storz, irrigation fluid = mannitol-sorbitol</td>
</tr>
<tr>
<td>Kumar 2013</td>
<td>I1: bipolar TURP</td>
<td>Gyrus ACM Plasmakinetic System</td>
<td>C1: monopolar TURP</td>
<td>Specific technology not reported; irrigation fluid = 1.5% glycine</td>
</tr>
<tr>
<td>Mamoulakis 2013</td>
<td>I1: bipolar TURP</td>
<td>Autocon II 400 ESU Karl Storz</td>
<td>C1: monopolar TURP</td>
<td>Karl Storz, irrigation fluid = sorbitol 5%, sorbitol-mannitol, water for injection, glycine (multi-centre)</td>
</tr>
<tr>
<td>Huang 2012</td>
<td>I1: bipolar TURP</td>
<td>PlasmaKinetic (Gyrus ACM)</td>
<td>C1: monopolar TURP</td>
<td>Karl Storz, irrigation fluid = mannitol 5%</td>
</tr>
<tr>
<td>Xie 2012</td>
<td>I1: bipolar TURP</td>
<td>Gyrus Plasmakinetic</td>
<td>C1: monopolar TURP</td>
<td>Olympus, irrigation fluid = glycine 1.5%</td>
</tr>
<tr>
<td>Fagerstrom 2011</td>
<td>I1: bipolar TURP</td>
<td>Olympus TURis</td>
<td>C1: monopolar TURP</td>
<td>Karl Storz ERBE, irrigation fluid = mannitol 3% and ethanol 1%</td>
</tr>
</tbody>
</table>
Table 2. Description of interventions (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geavlete 2011</td>
<td>I1: bipolar TURP, TURis Olympus SurgMaster C1: monopolar TURP Storz, irrigation fluid = sterile water</td>
</tr>
<tr>
<td></td>
<td>I2: C2: plasmakinetic vaporisation of the prostate, Olympus Vaporesection</td>
</tr>
<tr>
<td>Acuna-Lopez 2010</td>
<td>I1: bipolar TURP, Gyrus ACMI C1: monopolar TURP Specific technology not reported, irrigation fluid = glycine solution</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>I1: bipolar TURP, TURis Olympus SurgMasterSystem C1: monopolar TURP Olympus, irrigation fluid = 4% mannitol, 1% ethanol</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>He 2010</td>
<td>I1: bipolar TURP, Gyrus Electrosurgical System C1: monopolar TURP Storz Electrosurgical Generator, irrigation fluid = 5% mannitol</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>Mei 2010</td>
<td>I1: bipolar TURP, Gyrus Electrosurgical System C1: monopolar TURP WOLF Electrosurgical System, irrigation fluid = 5% mannitol</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>Singhania 2010</td>
<td>I1: bipolar TURP, Gyrus PK System C1: monopolar TURP Specific technology not specified, irrigation fluid = 1.5% glycine</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>Yousef 2010</td>
<td>I1: bipolar TURP, &quot;Storez&quot; technology, unclear if this refers to Karl Storz AUTOCON technology C1: monopolar TURP with 1.5% glycine Storez technology</td>
</tr>
<tr>
<td></td>
<td>I2: C2: monopolar TURP with 5% glucose Storez technology</td>
</tr>
<tr>
<td>Bhansali 2009</td>
<td>I1: bipolar TURP, Plasmakinetic Superpulse System – 24 Gyrus C1: monopolar TURP ValleyLab, irrigation fluid = glycine</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>Chen 2009</td>
<td>I1: bipolar TURP, TURIS, Olympus C1: monopolar TURP Olympus, irrigation fluid = mannitol 4%</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
<tr>
<td>De Sio 2009</td>
<td>I1: bipolar TURP, Gyrus Plasmakinetic System C1: monopolar TURP ValleyLab Force FX, specific irrigation fluid not reported</td>
</tr>
<tr>
<td></td>
<td>I2: C2:</td>
</tr>
</tbody>
</table>
Table 2. Description of interventions (Continued)

<table>
<thead>
<tr>
<th>Study Year</th>
<th>Type 1</th>
<th>Type 2</th>
<th>Type 3</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goh 2009</td>
<td>bipolar TURP</td>
<td>Olympus SurgMaster TURis</td>
<td>monopolar TURP</td>
<td>Olympus, irrigation fluid = glycine</td>
</tr>
<tr>
<td>Kong 2009</td>
<td>bipolar TURP</td>
<td>Gyrus Plasmakinetic Re-section (PKRP)</td>
<td>monopolar TURP</td>
<td>Pfizer Electrosurgical Instrument System, irrigation fluid = glycine</td>
</tr>
<tr>
<td>Mendez-Probst 2009</td>
<td>bipolar TURP</td>
<td>VISTA, ACMI</td>
<td>monopolar TURP</td>
<td>ERBE, irrigation fluid = not reported explicitly</td>
</tr>
<tr>
<td>Xin 2009</td>
<td>bipolar TURP</td>
<td>Gyrus Electrosurgical System (PKRP)</td>
<td>monopolar TURP</td>
<td>WOLF Storz Electrosurgical System, irrigation fluid = 1.5% glycine</td>
</tr>
<tr>
<td>Iori 2008</td>
<td>bipolar TURP</td>
<td>Gyrus PlasmaKinetic</td>
<td>monopolar TURP</td>
<td>Storz Resectoscope, irrigation fluid = mannitol</td>
</tr>
<tr>
<td>Xue 2008</td>
<td>bipolar TURP</td>
<td>Gyrus Electrosurgical System (PKRP)</td>
<td>monopolar TURP</td>
<td>WOLF Electrosurgical System, irrigation fluid = 1.5% glycine</td>
</tr>
<tr>
<td>Bertolotto 2007</td>
<td>bipolar TURP</td>
<td>TURis Olympus SurgMaster</td>
<td>monopolar TURP</td>
<td>Specific monopolar technology not reported, irrigation fluid = glycine</td>
</tr>
<tr>
<td>Erturhan 2007</td>
<td>bipolar TURP</td>
<td>Gyrus Plasmakinetic Re-section</td>
<td>monopolar TURP</td>
<td>ValleyLab Force EX, irrigation fluid = glycine 5%</td>
</tr>
<tr>
<td>Ho 2007</td>
<td>bipolar TURP</td>
<td>Olympus TURIS System SurgMaster</td>
<td>monopolar TURP</td>
<td>Olympus, irrigation fluid = glycine 5%</td>
</tr>
<tr>
<td>Michelson 2007</td>
<td>bipolar TURP</td>
<td>Olympus SurgMaster TURIS</td>
<td>monopolar TURP</td>
<td>Olympus, irrigation fluid = glycine 1.5%</td>
</tr>
<tr>
<td>Rose 2007</td>
<td>bipolar TURP</td>
<td>Olympus TURIS</td>
<td>monopolar TURP</td>
<td>Olympus, irrigation fluid = mannitol</td>
</tr>
<tr>
<td>Wang 2007</td>
<td>bipolar TURP</td>
<td>Gyrus F27 Electrosurgical System (PKRP)</td>
<td>monopolar TURP</td>
<td>WOLF Electrosurgical System, irrigation fluid = 5% mannitol</td>
</tr>
</tbody>
</table>
Table 2. Description of interventions (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>I1: Bipolar TURP</th>
<th>C1: Monopolar TURP</th>
<th>Specific monopolar technology/irrigation fluid</th>
<th>I2:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xin 2007</td>
<td>Plasmakinetic TURP, Gyrus device</td>
<td>Specific monopolar technology not reported</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Abascal 2006</td>
<td>Olympus SurgMaster</td>
<td>Storz, irrigation fluid = glycine</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Akcayoz 2006</td>
<td>Gyrus Plasmakinetic (PKRP)</td>
<td>Specific monopolar technology not reported, irrigation fluid = 1.5% glycine</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Bahadzor 2006</td>
<td>Plasma Kinetic Resection of Prostate (PKRP)</td>
<td>Specific monopolar technology/irrigation fluid not reported</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Choi 2006</td>
<td>Plasmakinetic (PK) Tissue Management System (Gyrus)</td>
<td>Specific monopolar technology/irrigation fluid not reported</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Kim 2006</td>
<td>Gyrus Plasma Kinetic Resectoscope</td>
<td>Specific monopolar technology not available from translation, irrigating fluid = Urion liquid</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Lin 2006</td>
<td>Vista CTR</td>
<td>Vista CTR, irrigation fluid = distilled water</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Nuhoglu 2006</td>
<td>Gyrus Plasmakinetic (PKRP)</td>
<td>Storz, irrigation fluid = glycine</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Patankar 2006</td>
<td>Plasmakinetic Superpulse</td>
<td>Specific monopolar technology not reported, irrigation fluid = glycine</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Seckiner 2006</td>
<td>Gyrus Plasmakinetic Tissue Management System</td>
<td>Karl Storz, irrigation fluid = glycine</td>
<td></td>
<td>C2:</td>
</tr>
<tr>
<td>Terrone 2006</td>
<td>Vista CTR Bipolar Resection System, ACMI</td>
<td>Specific monopolar technology/irrigation fluid not reported</td>
<td></td>
<td>C2:</td>
</tr>
</tbody>
</table>
### Table 2. Description of interventions (Continued)

<table>
<thead>
<tr>
<th>Singer 2005</th>
<th>I1: bipolar TURP</th>
<th>Vista CTR ACMI</th>
<th>C1: monopolar TURP</th>
<th>Wolf Resectoscope, irrigation fluid = not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wu 2005</th>
<th>I1: bipolar TURP</th>
<th>Gyrus 27F Stoze Electrosurgical System</th>
<th>C1: monopolar TURP</th>
<th>WOLF Electrosurgical System, irrigation fluid = 5% glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D'Elia 2004</th>
<th>I1: bipolar TURP</th>
<th>Gyrus technology</th>
<th>C1: monopolar TURP</th>
<th>Specific monopolar technology/irrigation fluid not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eaton 2004</th>
<th>I1: bipolar TURP</th>
<th>Use of both Plasmakinetic Resection (PKRP) and Karl Storz reported</th>
<th>C1: monopolar TURP</th>
<th>Specific monopolar technology/irrigation fluid not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yang 2004</th>
<th>I1: bipolar TURP</th>
<th>Gyrus Plasmaset</th>
<th>C1: monopolar TURP</th>
<th>Specific monopolar technology not reported, irrigation fluid = distilled water</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symons 2002</th>
<th>I1: bipolar TURP</th>
<th>Gyrus Plasmakinetic Electrosurgical System</th>
<th>C1: monopolar TURP</th>
<th>Specific monopolar technology not reported, irrigation fluid =1.5% glycine</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- denotes not reported.

*aThe term 'clinical practice setting' refers to the specification of the intervention/comparator as used in the course of a standard medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications, and other important features).

C: comparator; I: intervention; N/CPS: no specification of clinical practice setting possible.

### APPENDICES

#### Appendix 1. The Cochrane Library search strategy

(Ovid Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews 2005 to Present>)

1 exp Prostatic Hyperplasia/

2 exp Urinary Bladder Neck Obstruction/

3 (benign and prostat* and (obstruction* or enlargement*)).tw,kw.
4 (bladder adj5 (obstruction* or sclerosis or neck strangulation or obstructed voiding or stenosis or stenoses or scleroses or contracture or stricture or narrowing or fistula*)).tw,kw.

5 (BPH or BPO or BPE or BOO).tw.

6 (prostat* adj3 (adenoma* or hyperplas* or hypertroph*)).tw.

7 or/1-6

8 exp "Transurethral Resection of Prostate"/

9 ((transurethra* or trans-urethra*) and prostat* and (prostatectom* or resect* or electroresection* or ablation* or vapo resection* or electrovaporization* or thermotherap*)).tw,kw.

10 (TUR or TURP or TURPs or Vlap or TUNA or TUVP).tw,kw.

11 or/8-10

12 7 and 11

13 (monopolar or bipolar or mono polar or bi polar or "Gyrus" or "TURIs" or "M-TURP" or "B-TURP").tw,kw.

14 (ablation* or coblation* or saline resectoscope or Tekno Tom or AUTOCON ).tw,kw.

15 13 or 14

16 12 and 15

Appendix 2. MEDLINE search strategy

(Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>)

1 exp Prostatic Hyperplasia/

2 exp Urinary Bladder Neck Obstruction/

3 (benign and prostat* and (obstruction* or enlargement*)).tw,kw.

4 (bladder adj5 (obstruction* or sclerosis or neck strangulation or obstructed voiding or stenosis or stenoses or scleroses or contracture or stricture or narrowing or fistula*)).tw,kw.

5 (BPH or BPO or BPE or BOO).tw.

6 (prostat* adj3 (adenoma* or hyperplas* or hypertroph*)).tw.

7 or/1-6

8 exp "Transurethral Resection of Prostate"/

9 ((transurethra* or trans-urethra*) and prostat* and (prostatectom* or resect* or electroresection* or ablation* or vapo resection* or electrovaporization* or thermotherap*)).tw,kw.

10 (TUR or TURP or TURPs or Vlap or TUNA or TUVP).tw,kw.

11 or/8-10

12 7 and 11

13 (monopolar or bipolar or mono polar or bi polar or "Gyrus" or "TURIs" or "M-TURP" or "B-TURP").tw,kw.

14 (ablation* or coblation* or saline resectoscope or Tekno Tom or AUTOCON ).tw,kw.

15 13 or 14

16 12 and 15

17 randomized controlled trial.pt.

18 controlled clinical trial.pt.
19 random*.ab.
20 trial.ab.
21 groups.ab.
22 or/16-21
23 exp animals/ not humans.sh.
24 22 not 23
25 16 and 24

Note:
1. As suggested by the Cochrane handbook (http://handbook.cochrane.org/), we will use the RCT filter as suggested in "Box 6.4.c: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid format".
2. A minor revision is made: we use “random*” instead of “randomized.ab” or “randomly.ab.” to capture other word variations such as “randomised, randomization”.
3. We removed the lines “drug therapy.fs.” and “placebo” because this review is not about drugs. Searching drug therapy trials will reduce the search specificity without increasing any sensitivity.

Appendix 3. Embase search strategy
(Database: Ovid Embase <1974 to present>
1 exp prostate hypertrophy/
2 exp bladder neck stenosis/
3 exp bladder obstruction/
4 exp prostate adenoma/
5 (benign and prostat* and (obstruction* or enlargement*)).tw,kw.
6 (bladder adj5 (obstruction* or sclerosis or neck stranulation or obstructed voiding or stenosis or stenoses or scleroses or contracture or stricture or narrowing or fistula* ) ).tw,kw.
7 (BPH or BP O or BO O ).tw.
8 (prostat* adj3 (adenoma* or hyperplasia or hypertroph*)).tw.
9 or/1-8
10 exp transurethral resection/
11 ((transurethra* or trans-urethra*) and prostat* and (prostatectom* or resect* or electroresection* or ablation* or vaporization* or electrosurgical* or thermodissection* or percutaneous* and laser* or microwave* or recanalization* or needle* or pump* or power probe* or laser probe* or "TURPs" or "TURSi" or "M-TURP" or "B-TURP").tw,kw.
12 (TUR or TURP or TURPs or Vlap or TUNA or TVUP).tw.
13 or/10-12
14 9 and 13
15 (monopolar or bipolar or mono polar or bi polar or "Gyrus" or "TURIs" or "M-TURP" or "B-TURP").tw,kw.
16 (ablation* or coblation* or saline resectoscope or Tekno Tom or AUTOCON ).tw,kw.
17 15 or 16
18 14 and 17
19 random:.tw.
20 clinical trial:.mp.
21 exp health care quality/
22 double-blind:.tw.
23 or/19-22
24 exp animal/ not human.sh.
25 23 not 24
26 18 and 25

Note:
As suggested by the Cochrane Handbook for Systematic Reviews of Interventions (6.4.11.2 "Search filters for identifying randomized trials in EMBASE", http://handbook.cochrane.org/), we use the Wong 2006 method. “The search filter designed by Wong and colleagues for identifying what they define as “clinically sound treatment studies” in EMBASE may be used (Wong 2006) " (Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. Journal of the Medical Library Association 2006;94:41-47.) The Wong 2006 filter is also well known as Hedge, and is available online as: http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspx

We combined the strings that are suggested under maximises sensitivity and maximises specificity in the filter for therapy. We removed the line “placebo:mp.”, because this review is not about drugs and no placebo is possible.

CONTRIBUTIONS OF AUTHORS
Review and update of existing protocol: all review authors.
Electronic search: Y Yuan.
Abstract and full-text screening: C Alexander, M Scullion, C Chen.
Development of DE form: C Alexander, M Scullion.
Data extraction, risk of bias assessment: C Alexander, M Scullion, C Chen.
Input of data into Review Manager and meta-analysis: C Alexander, M Scullion.
Interpretation of data: all review authors.
Drafting the review: C Alexander and M Scullion; C. Mamoulakis and T Lam wrote the discussion section; all review authors made comments on various revisions.

DECLARATIONS OF INTEREST
Cameron Edwin Alexander: none known.
Malo MF Scullion: none known.
Muhammad Imran Omar: none known.
Yuhong Yuan: none known.
Charalampos Mamoulakis: none known.
James MO N'Dow: none known.
Changhao Chen: none known.
Thomas BL Lam: none known.
SOURCES OF SUPPORT

Internal sources
- none, Other.

External sources
- none, Other.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

- Review objective: altered to specifically focus on comparing clinical effectiveness between BTURP and MTURP. Comparing methods of TURP in terms of adverse effects or safety profile was removed as a primary objective because of associated limitations of RCTs in assessing this. However, a number of outcomes are recorded, which will be related to adverse effects.

- Review outcomes: these have been re-arranged to include a smaller number of primary outcomes, most specifically related to the primary objective of clinical effectiveness, and a larger number of secondary outcomes. Those outcomes selected as primary and secondary outcomes and those to be used for GRADE certainty of evidence were included on the basis of re-assessment following discussion with clinical experts regarding those outcomes (i) of greatest clinical significance, and (ii) most related to answering the review objectives. Specifically, drop in sodium level, drop in haemoglobin level, meatal stenosis, retrograde ejaculation, operation time, duration of bladder irrigation, and catheterisation time were considered to be surrogate outcomes or of reduced clinical importance relative to other clinical outcomes.

- Electronic search: updated to meet outlined Cochrane requirements. A more focused search for non-published trial data and ongoing trials was performed using ClinicalTrials.gov and WHO ICTR.

- Assessment of risk of bias was updated to meet those requirements outlined in the Cochrane Handbook for Systematic Reviews of Interventions, and the Cochrane RoB tool was primarily used to include blinding of participants and outcome assessors, which was not previously mentioned in the protocol.

- Measure of treatment effect: updated according to guidance in the Cochrane Handbook for Systematic Reviews of Interventions and provided by the statistician. Number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNHB) were not included as they are not considered necessary in addition to other descriptive and statistical analyses.

- Review authors: following publication of the protocol, the following authors were not involved in development of the review and as such did not remain as co-authors: Frank Sofras, Jean de la Rosette, and Dirk T Ubbink. The review was taken on by an updated team who had sufficient expertise in Cochrane Review methods. The following co-authors were involved since publication of the protocol: Cameron E Alexander, Malo MF Scullion, Yuhong Yuan, and Changhao Chen.